var title_f30_49_31504="Mitral valve prolapse M-mode echocardiogram";
var content_f30_49_31504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65945/mmodemvp_conv.mp4?title=Mitral+valve+prolapse+M-mode+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral valve prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 161px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram shows significant prolapse of the posterior leaflet during systole. There are multiple echos of the mitral valve suggesting redundancy of the leaflets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31504=[""].join("\n");
var outline_f30_49_31504=null;
var title_f30_49_31505="Parainfluenza gene maps";
var content_f30_49_31505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Parainfluenza gene maps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gene maps of parainfluenza viruses (PIV), not to exact scale. Each negative-sense genome is drawn 3' to 5', which is the direction of gene transcription. Each encoded messenger RNA (mRNA) is shown as a rectangle; those encoding the envelope-associated proteins are shaded gray. The letter(s) within each rectangle identify the encoded protein(s); for the P gene, the protein encoded by the unedited mRNA is listed first. Nucleotide lengths are under each diagram; those representing extragenic leader (le), trailer (tr), and intergenic regions are underlined. Amino acid lengths are shown above the line.",
"    <div class=\"footnotes\">",
"     N: nucleocapsid protein; P: phosphoprotein; C: C protein; D: D protein; M: matrix protein; F: fusion glycoprotein; HN: hemagglutinin-neuraminidase glycoprotein; L: polymerase protein.",
"     <br>",
"      * PIV-3 also encodes a V protein, possibly using ribosome frameshifting.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Karron RA, Collins PL. Parainfluenza Viruses. In: Fields Virology, 5th Edition, Knipe D, Howley P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31505=[""].join("\n");
var outline_f30_49_31505=null;
var title_f30_49_31506="Acute tinea pedis 2";
var content_f30_49_31506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesicles and bullae are present on the plantar foot in this patient with acute tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31506=[""].join("\n");
var outline_f30_49_31506=null;
var title_f30_49_31507="Skull PI";
var content_f30_49_31507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F62443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F62443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Skull bones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31507=[""].join("\n");
var outline_f30_49_31507=null;
var title_f30_49_31508="Flow cytometry DLBCL";
var content_f30_49_31508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Flow cytometry diffuse large B-cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow cytometry histograms show positive CD19, CD20, K, and FMC-7 but negative CD5, CD23, and lambda reactions.",
"    <div class=\"footnotes\">",
"     SS: side scatter; PC5: phycoerythrin-cyanin 5; FITC: fluorescein isothiocyanate; ECD: phycoerythrin-Texas Red; PE: phycoerythrin.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31508=[""].join("\n");
var outline_f30_49_31508=null;
var title_f30_49_31509="Occipital neuralgia";
var content_f30_49_31509=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occipital neuralgia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31509/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31509/contributors\">",
"     Ivan Garza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31509/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31509/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31509/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31509/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/49/31509/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuralgia is a form of neuropathic pain that is characterized by the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal, brief (seconds to a few minutes), shock-like or lightning-like pain that follows a peripheral or cranial nerve distribution and can spread to adjacent areas in the course of the attack.",
"     </li>",
"     <li>",
"      By definition, no objective neurologic deficits are found in the distribution of the affected nerve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link\">",
"       \"Overview of craniofacial pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attacks can be provoked by nonpainful stimulation (allodynia) of trigger points or zones.",
"     </li>",
"     <li>",
"      A refractory period follows attacks; the duration of the refractory period shortens as the disease progresses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occipital neuralgia can be a cause of headache in the occipital region. It is described as a paroxysmal jabbing pain in the greater, lesser,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    third occipital nerve distribution, sometimes accompanied by diminished sensation or dysesthesia in the affected area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review clinical aspects of occipital neuralgia. Other cranial neuralgias and central causes of facial pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link\">",
"     \"Overview of craniofacial pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32904?source=see_link\">",
"     \"Central craniofacial pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31090?source=see_link\">",
"     \"Cold stimulus headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6917?source=see_link\">",
"     \"Nervus intermedius (geniculate) neuralgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16243?source=see_link\">",
"     \"Nummular headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensation in the posterior neck is supplied by medial branches of dorsal primary rami of cervical nerve roots C2, C3, C4, and occasionally C5 (",
"    <a class=\"graphic graphic_figure graphicRef70877 \" href=\"mobipreview.htm?12/32/12802\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The greater occipital nerve originates from the second cervical nerve, perforates the semispinalis capitis and trapezius muscles, and supplies sensation to the uppermost neck and posterior head from the suboccipital area to the vertex.",
"   </p>",
"   <p>",
"    The third occipital nerve originates from the third cervical spinal nerve, perforates the trapezius muscle, and supplies sensation to the upper posterior neck and lower occipital region of the scalp.",
"   </p>",
"   <p>",
"    The lesser occipital nerve is formed by divisions of the second and third cervical nerves, ascends along the posterior margin of the sternocleidomastoid muscle, and provides sensory fibers to the area of the scalp lateral to the greater occipital nerve, behind and superior to the auricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of occipital neuralgia is uncertain. One hypothesis is that occipital neuralgia results from injury to the C2-C3 nerve roots",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occipital nerves through different mechanisms (chronic instability, entrapment, trauma, inflammation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/9\">",
"     9",
"    </a>",
"    ]. Some have proposed vascular compression of the nerve by the occipital artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The currently accepted view is that this disorder results from the chronic entrapment of the occipital nerves by the posterior neck and scalp muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. However, there is no compelling evidence to support the concept of irritation of the occipital nerves as the cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, there is no indisputable evidence from surgical studies to support entrapment of the occipital nerves as the etiology.",
"   </p>",
"   <p>",
"    Most often, occipital neuralgia develops spontaneously.",
"   </p>",
"   <p>",
"    The classification and pathophysiology of neuropathic pain is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of craniofacial pain\", section on 'Neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occipital neuralgia is thought by many nonspecialists to be common, but it is a relatively rare encounter in clinical practice among headache specialists. The literature on occipital neuralgia is conflicting, and the actual incidence and prevalence are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/16\">",
"     16",
"    </a>",
"    ]. This situation reflects a lack of consensus regarding the definition and diagnostic criteria for occipital neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/13\">",
"     13",
"    </a>",
"    ]. Quite often, the diagnosis is arbitrarily given to any pain in the occipital region.",
"   </p>",
"   <p>",
"    Injuries such as whiplash during motor vehicle accidents may be a risk factor for occipital neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain of occipital neuralgia has a sudden onset. It is described as severe, stabbing, electric, shock-like, sharp, or shooting. It originates in the nuchal region and immediately spreads towards the vertex. The bouts of pain may start spontaneously or be provoked by specific maneuvers such as brushing the hair, exposing to cold, or moving the neck. The pain is usually unilateral, but bilateral cases occur as well. A dull occipital discomfort may be present during periods between the painful paroxysms.",
"   </p>",
"   <p>",
"    On examination, pressure, palpation, or percussion over the occipital nerve trunks may reveal local tenderness, trigger painful paroxysms, worsen the background discomfort, or elicit paresthesias along the distribution of the affected nerve. Percussion of the nerve often reproduces the distribution of pain (Tinel's sign).",
"   </p>",
"   <p>",
"    Cervical range of motion may be restricted and local posterior neck muscle spasms may be found.",
"   </p>",
"   <p>",
"    Although somewhat contradictory to the strict definition of neuralgia, occipital neuralgia is sometimes accompanied by diminished sensation or dysesthesia in the affected area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/5\">",
"     5",
"    </a>",
"    ]. The remainder of the neurologic exam is typically normal. An abnormal neurologic exam is an alert for potential alternative or underlying causes of the symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is considered when typical clinical features are present and can be confirmed when pain is transiently relieved by a local occipital anesthetic block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a local block is a nonspecific intervention, so symptomatic relief does not indicate a specific etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current International Classification of Headache Disorders-2 (ICHD-2) classification requires the presence of all the following diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal stabbing pain, with or without persistent aching between paroxysms, in the distribution(s) of the greater, lesser,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      third occipital nerves",
"     </li>",
"     <li>",
"      Tenderness over the affected nerve",
"     </li>",
"     <li>",
"      Pain is eased temporarily by local anesthetic block of the nerve",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The current ICHD-2 classification also requires distinguishing occipital neuralgia from occipital referral of pain from the atlantoaxial or upper zygapophyseal joints or from tender trigger points in neck muscles or other insertions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of cervical spine pain referred to the head is broad. Possible sources of such pain include structures innervated by the upper three cervical spinal nerves, including the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Median atlantoaxial, atlanto-occipital, and lateral atlantoaxial joints",
"     </li>",
"     <li>",
"      C2-3 zygapophyseal joint",
"     </li>",
"     <li>",
"      Suboccipital and upper posterior neck muscles",
"     </li>",
"     <li>",
"      Upper prevertebral muscles",
"     </li>",
"     <li>",
"      Spinal and posterior cranial fossa dura mater",
"     </li>",
"     <li>",
"      Vertebral arteries",
"     </li>",
"     <li>",
"      C2-3 intervertebral disc",
"     </li>",
"     <li>",
"      Trapezius and sternocleidomastoid muscles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, occipital neuralgia must be differentiated from referred occipital pain that originates in any of these structures. Multiple structural and infiltrative lesions have been identified as causes of occipital neuralgia, including meningioma, schwannoma, arteriovenous fistula, vascular compression, pyomyositis, multiple myeloma, and myelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/18-24\">",
"     18-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cervicogenic headache is thought to be caused by referred pain from the upper cervical joints, and is another consideration in the differential diagnosis. The pathophysiology, true source of pain, and even the existence of cervicogenic headache as a distinct clinical entity have been debated and remain somewhat controversial. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26568?source=see_link\">",
"     \"Cervicogenic headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful evaluation of the upper cervical spine and posterior fossa is imperative for patients with suspected occipital neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/17\">",
"     17",
"    </a>",
"    ]. There are no clear guidelines regarding the utility of neuroimaging studies for the evaluation of occipital neuralgia. However, because structural and infiltrative lesions may cause occipital neuralgia (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential'",
"    </a>",
"    above), we suggest obtaining MRI of the head and cervical spine for new cases of suspected occipital neuralgia, and we recommend imaging if the pain is atypical or if the neurologic examination is abnormal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of continuous (rather than intermittent) occipital pain and the absence of impaired sensation suggest the pain is referred from some of the structures in the cervical region mentioned above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cervical medial branch blocks can provide the means to detect whether or not the neck pain is originating in one or more of the upper zygapophyseal joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative management with the application of local moist heat may alleviate muscle spasm and pain. Other patients might get some relief by applying cold locally one to three times daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a local occipital nerve block (usually a mixture of a local anesthetic plus a glucocorticoid) is usually the treatment of choice among practitioners experienced with this procedure, since it has the potential of being both diagnostic and therapeutic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/15,27\">",
"     15,27",
"    </a>",
"    ]. The nerve blocks should be performed by physicians who are properly trained in the procedure.",
"   </p>",
"   <p>",
"    Following occipital nerve block, pain relief is typically prompt and may last several weeks or even months. The procedure can be repeated when pain recurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. The procedure is generally safe, with few complications, as long as the",
"    <span class=\"nowrap\">",
"     anesthetic/glucocorticoid",
"    </span>",
"    injection is not inadvertently injected intravascularly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/28\">",
"     28",
"    </a>",
"    ]. Rarely, a patient may become cushingoid secondary to serial glucocorticoid-containing blocks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/27,29\">",
"     27,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By definition and diagnostic criteria, the diagnosis is not occipital neuralgia if the pain does not resolve after occipital nerve block. Thus, other causes for the neuralgiform pain should be explored if occipital nerve block fails. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    may relieve the pain if it is paroxysmal in nature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Variable benefit has also been observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/8\">",
"     8",
"    </a>",
"    ]. In the setting of acute occipital neuralgia secondary to traumatic cervical",
"    <span class=\"nowrap\">",
"     strain/sprain",
"    </span>",
"    injury, immobilization using a neck collar for two to three weeks may provide relief of painful paroxysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/8,30\">",
"     8,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occipital nerve stimulation has been employed in selected cases of severe occipital neuralgia unresponsive to less invasive measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31509/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], but at present is not a routine therapeutic measure and should be reserved for use in a pain center with expertise in neuromodulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occipital neuralgia can be a cause of headache in the occipital region. It is characterized by paroxysmal jabbing pain in the greater, lesser,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      third occipital nerve distribution. In most cases, the condition develops spontaneously. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occipital neuralgia is a relatively rare encounter in clinical practice. The actual incidence and prevalence are unknown. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pain of occipital neuralgia is sudden in onset and described as stabbing, electric, shock-like, sharp, or shooting. It originates in the nuchal region and immediately spreads towards the vertex. Attacks may begin spontaneously or may be provoked by specific maneuvers. A dull occipital discomfort can be present during periods between the painful paroxysms. Examination may reveal local tenderness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypesthesia in the territory of the affected nerve. Percussion may elicit paresthesias along the distribution of the affected nerve. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of occipital neuralgia is considered when typical clinical features are present. The diagnosis can be confirmed when pain is transiently relieved by a local occipital anesthetic block. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occipital neuralgia must be distinguished from referred occipital pain originating from atlantoaxial or upper zygapophyseal joints, tender trigger points in neck muscles, or other structures innervated by the upper three cervical spinal nerves. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful evaluation of the upper cervical spine and posterior fossa is imperative for patients with suspected occipital neuralgia. For patients with newly diagnosed occipital neuralgia, we suggest imaging with MRI of the head and cervical spine to exclude structural or infiltrative lesions, and we recommend imaging for patients who have atypical pain or an abnormal neurologic examination. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected occipital neuralgia who have moderate to severe pain or debilitating symptoms, we suggest a local occipital nerve block (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This method can be both diagnostic and therapeutic. Pain relief is typically prompt and may last several weeks or even months. The procedure is generally safe and can be repeated when pain recurs. Other causes for the neuralgiform pain should be explored if occipital nerve block fails. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/1\">",
"      Bruyn GW. Nervus intermedius neuralgia (Hunt). Cephalalgia 1984; 4:71.",
"     </a>",
"    </li>",
"    <li>",
"     Peter C, Watson N. Trigeminal neuropathy and neuralgia. In: Neurological therapeutics: Principles and practice, Noseworthy JH.  (Ed), Martin Dunitz, London, New York 2003. p.1849.",
"    </li>",
"    <li>",
"     Goodwin JG, Bajwa ZH. Understanding the patient with chronic pain. In: Principles and practice of pain medicine, Warfield CA, Bajwa ZH.  (Eds), McGraw Hill, USA 2004. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/4\">",
"      Bogduk N. The anatomy of occipital neuralgia. Clin Exp Neurol 1981; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/5\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     Hiat JL, Gartner LP. Neck. In: Head and neck anatomy, Lippincott Williams and Wilkins, Philadelphia, PA 2001. p.109.",
"    </li>",
"    <li>",
"     Lang J. Musculature. In: Clinical anatomy of the cervical spine, Thieme Medical Publishers, New York 1993. p.127.",
"    </li>",
"    <li>",
"     Handel TE, Kaplan RJ. Occipital Neuralgia. In: Essentials of physical medicine and rehabilitation, Frontera WR, Silver JK.  (Eds), Lippincott Williams and Wilkins, Philadelphia, PA 2002. p.38.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/9\">",
"      Elias WJ, Burchiel KJ. Trigeminal neuralgia and other neuropathic pain syndromes of the head and face. Curr Pain Headache Rep 2002; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/10\">",
"      White JB, Atkinson PP, Cloft HJ, Atkinson JL. Vascular compression as a potential cause of occipital neuralgia: a case report. Cephalalgia 2008; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/11\">",
"      Shimizu S, Oka H, Osawa S, et al. Can proximity of the occipital artery to the greater occipital nerve act as a cause of idiopathic greater occipital neuralgia? An anatomical and histological evaluation of the artery-nerve relationship. Plast Reconstr Surg 2007; 119:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/12\">",
"      Sharma RR, Parekh HC, Prabhu S, et al. Compression of the C-2 root by a rare anomalous ectatic vertebral artery. Case report. J Neurosurg 1993; 78:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/13\">",
"      Bogduk N. The neck and headaches. Neurol Clin 2004; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     Boes, CJ, Copobianco, DJ, Cutrer, FM, et al. Headache and other craniofacial pain. In: Neurology in clinical practice, Bradley, WG, Daroff, RB, Fenichel, GM, et al (Eds), Butterworth Heinemann, Philadelphia, PA 2004. p.2055.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/15\">",
"      Ashkenazi A, Levin M. Three common neuralgias. How to manage trigeminal, occipital, and postherpetic pain. Postgrad Med 2004; 116:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/16\">",
"      Manzoni GC, Torelli P. Epidemiology of typical and atypical craniofacial neuralgias. Neurol Sci 2005; 26 Suppl 2:s65.",
"     </a>",
"    </li>",
"    <li>",
"     Facial pain and the neuralgias. In: Handbook of headache management: A practical guide to diagnosis and treatment of head, neck, and facial pain. Saper, JR, Silberstein, S, Gordon, CD, et al (Eds), Lippincott Williams and Wilkins, Baltimore, Maryland 1999. p.249.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/18\">",
"      Garza I. Craniocervical junction schwannoma mimicking occipital neuralgia. Headache 2007; 47:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/19\">",
"      Cornely C, Fischer M, Ingianni G, Isenmann S. Greater occipital nerve neuralgia caused by pathological arterial contact: treatment by surgical decompression. Headache 2011; 51:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/20\">",
"      Kim NH, Yang SY, Koo JB, Jeong SW. Occipital neuralgia as the only presenting symptom of foramen magnum meningioma. J Clin Neurol 2009; 5:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/21\">",
"      Peltier J, Baroncini M, Thines L, et al. Subacute involvement of the medulla oblongata and occipital neuralgia revealing an intracranial dural arteriovenous fistula of the craniocervical junction. Neurol India 2011; 59:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/22\">",
"      Sierra-Hidalgo F, Ru&iacute;z J, Morales-Cartagena A, et al. Infiltrative cervical lesions causing symptomatic occipital neuralgia. Cephalalgia 2011; 31:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/23\">",
"      Boes CJ. C2 myelitis presenting with neuralgiform occipital pain. Neurology 2005; 64:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/24\">",
"      Lucchesi C, Puglioli M, Gori S. Occipital neuralgia: a symptomatic case caused by an abnormal left vertebral artery. Neurol Sci 2013; 34:243.",
"     </a>",
"    </li>",
"    <li>",
"     Cranial neuralgias and central causes of facial pain. In: Mechanism and management of headache, Lance, JW, Goadsby, PJ (Eds), Elsevier Butterworth Heinemann, Philadelphia, PA 2005. p.333.",
"    </li>",
"    <li>",
"     Bogduk, N, Karasek, M. Precision diagnosis and treatment of back and neck pain. In: Continuum: Pain and palliative care, Miller, AE (Ed), Lippincott Williams and Wilkins, Philadelphia, PA 2005. p.94.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/27\">",
"      Ward JB. Greater occipital nerve block. Semin Neurol 2003; 23:59.",
"     </a>",
"    </li>",
"    <li>",
"     Lehmann, LJ. Peripheral nerve blocks. In: Principles and practice of pain medicine, Warfield, CA, Bajwa, ZH (Eds), McGraw-Hill, USA 2004. p.684.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/29\">",
"      Lavin PJ, Workman R. Cushing syndrome induced by serial occipital nerve blocks containing corticosteroids. Headache 2001; 41:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/30\">",
"      Evans RW. Some observations on whiplash injuries. Neurol Clin 1992; 10:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/31\">",
"      Skaribas I, Calvillo O, Delikanaki-Skaribas E. Occipital peripheral nerve stimulation in the management of chronic intractable occipital neuralgia in a patient with neurofibromatosis type 1: a case report. J Med Case Rep 2011; 5:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31509/abstract/32\">",
"      Eldrige JS, Obray JB, Pingree MJ, Hoelzer BC. Occipital neuromodulation: ultrasound guidance for peripheral nerve stimulator implantation. Pain Pract 2010; 10:580.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3330 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31509=[""].join("\n");
var outline_f30_49_31509=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3330|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/32/12802\" title=\"figure 1\">",
"      Cutaneous fields head neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32904?source=related_link\">",
"      Central craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26568?source=related_link\">",
"      Cervicogenic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31090?source=related_link\">",
"      Cold stimulus headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6917?source=related_link\">",
"      Nervus intermedius (geniculate) neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/55/16243?source=related_link\">",
"      Nummular headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_49_31510="Overview of cardiac pacing in heart failure";
var content_f30_49_31510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of cardiac pacing in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31510/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31510/contributors\">",
"     Leslie A Saxon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31510/contributors\">",
"     Michael Cao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31510/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31510/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31510/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31510/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/49/31510/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapies, such as angiotensin converting enzyme inhibitors, beta blockers, angiotensin II receptor blockers, and mineralocorticoid receptor antagonists have led to improvements in both symptom control and overall survival in patients with heart failure (HF) due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Implanted devices, such as cardiac pacemakers and implantable cardioverter-defibrillators (ICDs), have also become an increasingly used component of the management of HF patients. The impact of these devices on the incidence and progression of HF is complex, and depends upon both the nature of the device (eg, single chamber, dual chamber, or biventricular pacemaker, or an ICD), and device programming. The following observations illustrate the range of issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one time, dual chamber (right atrial and right ventricular) cardiac pacing was proposed as a possible therapy for HF. However, data from both retrospective analyses and a randomized trial demonstrate that right ventricular (RV) pacing can exacerbate HF. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'DAVID trial'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cardiac resynchronization therapy (CRT) with biventricular (left and right ventricular) pacing can improve cardiac function, symptoms, and survival in selected HF patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ICDs are recommended for the primary prevention of sudden cardiac death (SCD) in selected patients with ischemic and nonischemic cardiomyopathy. By reducing the incidence of arrhythmic death, ICDs may result in more patients surviving to advanced stages of HF. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link&amp;anchor=H28#H28\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H9\">",
"       'Implantable cardioverter-defibrillators'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contemporary ICDs also function as pacemakers, if necessary, and some ICDs are capable of biventricular pacing. Thus, issues related to the impact of various pacing modalities also apply to ICDs with similar capabilities.",
"   </p>",
"   <p>",
"    The role of implantable cardiac devices in patients with HF will be reviewed here. The general indications for permanent pacemakers and the various modes of cardiac pacing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DUAL-CHAMBER PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The idea that a dual-chamber pacemaker might improve cardiac function in patients with HF was based upon the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pacing permits more aggressive beta blocker therapy, which is often limited by symptomatic bradycardia.",
"     </li>",
"     <li>",
"      Dual chamber pacing allows optimization of the AV interval, thereby improving coordination between atria and ventricles, optimizing valve closure, and minimizing mitral regurgitation (MR). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of MR and AV delay optimization'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Atrial pacing has been reported to reduce the frequency of atrial fibrillation in some studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5367?source=see_link\">",
"       \"The role of pacemakers in the prevention of atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential benefit of dual-chamber pacing was suggested in an initial uncontrolled study of 17 patients with idiopathic dilated cardiomyopathy who had medically refractory HF and severe symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These findings provided the rationale for performing a randomized trial, DAVID, which did not confirm any benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     DAVID trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DAVID trial was designed to test the hypothesis that dual-chamber pacing would improve outcomes in HF patients who do not otherwise meet standard criteria for pacing (eg, sick sinus syndrome or conduction abnormalities). The trial enrolled 506 patients with a left ventricular ejection fraction (LVEF) &le;40 percent and an indication for ICD implantation but no indication for antibradycardia pacing. The patients were randomly assigned to VVI pacing with a lower rate limit of 40 beats per minute (VVI-40) or to DDDR pacing with a lower rate limit of 70 beats per minute (DDDR-70) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/4\">",
"     4",
"    </a>",
"    ]. The primary end point was the combination of death or hospitalization for HF.",
"   </p>",
"   <p>",
"    Although the threshold LVEF in the DAVID trial was &le;40 percent, the mean for the population was only 27 percent. Despite the low mean LVEF, approximately 50 percent of the patients were in NYHA functional class I and only 12 percent were in class III-IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The frequency of right ventricular (RV) pacing was substantially higher in the DDDR-70 compared to the VVI-40 group (60 versus 1 percent). Thus, this was effectively a trial comparing DDDR pacing with sinus rhythm.",
"   </p>",
"   <p>",
"    At one year follow-up, there was an unexpected",
"    <strong>",
"     detrimental",
"    </strong>",
"    effect of DDDR-70 pacing, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival free of the primary composite end point was significantly lower in the DDDR-70 group (73 versus 84 percent with VVI-40 group).",
"     </li>",
"     <li>",
"      There were nonstatistically significant increased rates of both components of the primary endpoint: mortality (10.1 versus 6.4 percent; HR=1.61, [CI] 0.84 to 3.09) and HF hospitalization (22.6 versus 13.3 percent; HR=1.54, [CI] 0.97 to 2.46).",
"     </li>",
"     <li>",
"      Among patients in the DDDR-70 group, there was a nonsignificant trend toward a higher rate of event-free survival among those pacing less than 40 percent of the time (87 versus 76 percent who were paced more frequently).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RV pacing and dyssynchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the DAVID trial showed that DDDR pacing increased HF admissions and mortality compared to sinus rhythm, it is likely that the RV component of dual chamber pacing was primarily responsible for the detrimental effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/5\">",
"     5",
"    </a>",
"    ]. The following sequence is thought to explain the mechanism of the adverse effect of RV pacing",
"   </p>",
"   <p>",
"    When the native conduction system is normal, the QRS duration is &le;120 msec, and ventricular contraction is well-coordinated, or synchronous. Synchronous ventricular contraction optimizes cardiac pump function.",
"   </p>",
"   <p>",
"    Standard RV pacing causes the RV to contract before the left ventricle (interventricular dyssynchrony). In addition, pacing the RV simulates the effect of left bundle branch block (LBBB), causing the septum to contract before the lateral wall (intraventricular dyssynchrony).",
"   </p>",
"   <p>",
"    The loss of ventricular synchrony can reduce the overall efficiency of cardiac pump function. Although such an impairment may be clinically imperceptible in patients without an underlying cardiomyopathy, it can be important in the setting of a failing ventricle, resulting in increased HF symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/6\">",
"     6",
"    </a>",
"    ]. The relationships between ventricular dyssynchrony, HF, and resynchronization therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     MOST trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Support for the deleterious effect of RV pacing was provided by a post hoc analysis of data from the MOST trial of pacing modes in patients with sinus node dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37576?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of the sick sinus syndrome\", section on 'Meta-analysis and clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of the 2010 patients enrolled in the MOST trial, this analysis was restricted to the 1339 participants who had a baseline QRS duration &lt;120 msec. Among these patients, 707 were assigned to DDDR and 632 to VVIR pacing. Regardless of pacing mode, patients with a higher cumulative percentage of ventricular paced beats had a significantly higher rates of subsequent HF hospitalization and atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Baseline dyssynchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a post-hoc analysis from the DAVID trial, the detrimental effects of DDDR-70 pacing were more prominent in patients with a baseline QRS &ge;110 msec [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with baseline QRS prolongation were more likely than those with a normal QRS to have other markers of poor outcome (eg, worse systolic function and a history of HF). Thus, it is not clear if baseline conduction abnormalities themselves or associated cardiac abnormalities predispose patients to intolerance of RV pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment of MR and AV delay optimization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have evaluated the impact of dual chamber pacing with optimal AV delay on hemodynamic and clinical parameters in patients with significant MR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial observational series provided conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a series of nine patients with sinus rhythm and complete heart block, reductions in AV delay across a range from 200 to 50 did not result in significant changes in MR, systolic or diastolic ventricular function, or invasive hemodynamic data such as cardiac index, stroke volume index, or left ventricular stroke work index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More promising results were generated from a prospective series of 20 patients with symptomatic complete AV block and dual chamber pacemakers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/9\">",
"     9",
"    </a>",
"    ]. Optimal AV delay was determined by echocardiographic parameters. The mean optimal AV delay was 98 msec, which reduced the severity of MR. Additionally, the cardiac output and systolic blood pressure improved.",
"   </p>",
"   <p>",
"    Further insight into the impact of dual chamber pacing with optimized AV delay came from a small randomized trial. This study enrolled 38 patients in sinus rhythm with HF and randomly assigned them to optimal medical therapy or optimal medical therapy with dual chamber pacing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/11\">",
"     11",
"    </a>",
"    ]. AV delay was optimized according to echocardiographic parameters and generally ranged between 100 to 120 msec (in 14 of 19 patients). There was no difference between the two arms in most clinical endpoints, although the degree of MR and systolic left ventricular diameter were both reduced in patients assigned to dual chamber pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RESYNCHRONIZATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;RV pacing induces ventricular dyssynchrony. Ventricular dyssynchrony can also be present in patients with conduction disease and QRS prolongation, particularly LBBB. Among patients with systolic dysfunction, dyssynchrony due to either mechanism can exacerbate HF. In such patients, cardiac resynchronization therapy (CRT) can improve cardiac function, HF symptoms, and survival. CRT is performed with a pacemaker (or ICD) that simultaneously paces the right and left ventricles (biventricular pacing). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/983?source=see_link\">",
"     \"Cardiac resynchronization therapy in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICDs are increasingly used for the primary prevention of SCD in patients with cardiomyopathy and HF. The indications for ICD implantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link&amp;anchor=H28#H28\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ICDs can influence the incidence and progression of HF by two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contemporary ICDs also function as cardiac pacemakers, and the DAVID trial, discussed above, involved dual chamber ICDs. Thus, the detrimental impact of RV pacing also applies to ICDs. Because many patients with an ICD do not have a standard indication for pacing, efforts to minimize ventricular pacing are particularly important in these patients. The programming and device selection options discussed below are also available in ICDs. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      By aborting arrhythmic deaths, ICDs prolong survival in patients with substantial cardiac disease. Such patients may later progress to more advanced HF. This phenomenon was illustrated in a post-hoc analysis from the MADIT II trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/12\">",
"       12",
"      </a>",
"      ]. In this trial, 1218 patients with a prior myocardial infarction and an LVEF &le;30 percent were randomly assigned to ICD implantation or conventional medical therapy. The patients assigned to ICD therapy had a significant reduction in mortality. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=see_link&amp;anchor=H5#H5\">",
"       \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'MADIT II trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At a mean follow-up of 20 months, patients assigned to an ICD were significantly more likely to be hospitalized for HF than those assigned to conventional therapy (23 versus 17 percent). Among patients assigned to ICD therapy, the incidence of HF was significantly greater after appropriate ICD therapy compared to before such therapy (23 versus 16 events per 100 person years). Both the incidence of initial HF admissions and the intensity of recurrent admissions increased after appropriate ICD therapies. In contrast, there was no change in the incidence of HF after inappropriate device therapies.",
"   </p>",
"   <p>",
"    In combination, these data suggest that appropriate ICD therapies are more common in patients who have or will soon experience worsening HF. Thus, life-prolonging ICD therapies may transform SCD risk to subsequent HF risk, although short-term mortality is improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who do not have a standard indication (eg, sick sinus syndrome or AV block), single or dual chamber cardiac pacing is not indicated for the purpose of treating HF. In contrast, CRT with biventricular pacing is appropriate for some HF patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many patients with HF will require a single or dual chamber pacemaker or an ICD for standard indications. In such patients, the impact of RV pacing can be minimized by appropriate device selection and programming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Device selection and programming",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HF and systolic dysfunction who require a pacemaker or an ICD, devices with the following capabilities can reduce the impact ventricular dyssynchrony, either by minimizing RV pacing or by utilizing CRT with biventricular pacing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Managed ventricular pacing &mdash; Devices with this capability allow native conduction to occur, even in the setting of substantial PR prolongation or second degree atrioventricular (AV) block. If high grade AV block develops, the device will switch to dual chamber pacing. These devices are appropriate for patients with first or second degree AV block in whom they can substantially reduce the frequency of ventricular pacing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link&amp;anchor=H13#H13\">",
"       \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Modes to minimize ventricular pacing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac resynchronization therapy &mdash; CRT involves simultaneous pacing of the left and right ventricles to restore ventricular synchrony. These devices are appropriate for selected HF patients with systolic dysfunction and dyssynchrony. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Resynchronization therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with HF and systolic dysfunction have a pacemaker or an ICD that does not have the capabilities of managed ventricular pacing or an ICD. However, in patients with intact AV conduction, the following device programming options can reduce the frequency of ventricular pacing (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged programmed AV intervals",
"     </li>",
"     <li>",
"      Eliminating rate responsive AV delay",
"     </li>",
"     <li>",
"      DDI or DDIR pacing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these programming options have limitations, and in many patients it is difficult to minimize ventricular pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/34/37410?source=see_link\">",
"       \"Patient information: Cardiac resynchronization therapy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the role of cardiac pacemakers and ICDs in patients with HF. These recommendations are in general agreement with the 2009 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/13\">",
"     13",
"    </a>",
"    ], the 2010 Heart Failure Society of America (HFSA) practice guidelines for use of devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/14\">",
"     14",
"    </a>",
"    ], 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device based therapy for cardiac rhythm abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/15\">",
"     15",
"    </a>",
"    ], and 2011 HFSA CRT Guideline Update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31510/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with HF be treated with a single or dual chamber pacemaker",
"      <strong>",
"       only",
"      </strong>",
"      if there is a standard bradycardic indication for pacing (ie, cardiac pacing, other than CRT, is not indicated for the purpose of treating HF) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Dual-chamber pacing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"       \"Indications for permanent cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with HF and systolic dysfunction who have a standard indication for a pacemaker or ICD, including CRT devices, we recommend that device selection and programming should maintain or restore ventricular synchrony (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'RV pacing and dyssynchrony'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Options for maintaining or restoring ventricular synchrony include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Devices with managed ventricular pacing capability. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard dual chamber devices programmed to minimize RV pacing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with sinus node dysfunction, normal AV conduction, and no indication for an ICD, single chamber AAI pacemakers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37576?source=see_link\">",
"       \"Treatment of the sick sinus syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who have dyssynchrony prior to device implantation or in whom ventricular pacing is unavoidable (ie, complete heart block), CRT with biventricular pacing can restore ventricular synchrony. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15300442\">",
"    <span class=\"h2\">",
"     Acknowledgment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Drs. Kumar and DeMarco for contributing as authors to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/1\">",
"      Auricchio A, Salo RW. Acute hemodynamic improvement by pacing in patients with severe congestive heart failure. Pacing Clin Electrophysiol 1997; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/2\">",
"      Hochleitner M, H&ouml;rtnagl H, Ng CK, et al. Usefulness of physiologic dual-chamber pacing in drug-resistant idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 66:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/3\">",
"      Hochleitner M, H&ouml;rtnagl H, H&ouml;rtnagl H, et al. Long-term efficacy of physiologic dual-chamber pacing in the treatment of end-stage idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 70:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/4\">",
"      Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/5\">",
"      Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol 2006; 47:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/6\">",
"      Saxon LA, Stevenson WG, Middlekauff HR, Stevenson LW. Increased risk of progressive hemodynamic deterioration in advanced heart failure patients requiring permanent pacemakers. Am Heart J 1993; 125:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/7\">",
"      Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/8\">",
"      Hayes JJ, Sharma AD, Love JC, et al. Abnormal conduction increases risk of adverse outcomes from right ventricular pacing. J Am Coll Cardiol 2006; 48:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/9\">",
"      Rossi R, Muia N Jr, Turco V, et al. Short atrioventricular delay reduces the degree of mitral regurgitation in patients with a sequential dual-chamber pacemaker. Am J Cardiol 1997; 80:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/10\">",
"      Shinbane JS, Chu E, DeMarco T, et al. Evaluation of acute dual-chamber pacing with a range of atrioventricular delays on cardiac performance in refractory heart failure. J Am Coll Cardiol 1997; 30:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/11\">",
"      Capucci A, Romano S, Puglisi A, et al. Dual chamber pacing with optimal AV delay in congestive heart failure: a randomized study. Europace 1999; 1:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/12\">",
"      Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation 2006; 113:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/13\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.heartfailureguideline.org/guideline_sections/41 (Accessed on May 29, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/15\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31510/abstract/16\">",
"      Stevenson WG, Hernandez AF, Carson PE, et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail 2012; 18:94.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3493 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31510=[""].join("\n");
var outline_f30_49_31510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DUAL-CHAMBER PACING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DAVID trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RV pacing and dyssynchrony",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - MOST trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Baseline dyssynchrony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment of MR and AV delay optimization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RESYNCHRONIZATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Device selection and programming",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15300442\">",
"      Acknowledgment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/983?source=related_link\">",
"      Cardiac resynchronization therapy in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/34/37410?source=related_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5367?source=related_link\">",
"      The role of pacemakers in the prevention of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_49_31511="Overview of neonatal respiratory distress: Disorders of transition";
var content_f30_49_31511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of neonatal respiratory distress: Disorders of transition",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31511/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31511/contributors\">",
"     Richard Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31511/contributors\">",
"     Firas Saker, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31511/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31511/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31511/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/49/31511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress is common immediately after birth, typically caused by abnormal respiratory function during the transition from fetal to neonatal life. It is manifested by tachypnea, nasal flaring, intercostal or subcostal retractions, audible grunting, and cyanosis. Neonatal respiratory distress may be transient; however, persistent distress requires a rational diagnostic and therapeutic approach to optimize outcome and minimize morbidity.",
"   </p>",
"   <p>",
"    This topic review provides an overview of the pathogenesis, clinical features, and approach to initial management of three common respiratory disorders of perinatal transition: transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), and persistent pulmonary hypertension of the newborn (PPHN). These disorders, including their specific management, are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32804?source=see_link\">",
"     \"Transient tachypnea of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TRANSITION FROM FETAL LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The successful transition from fetal to neonatal life at delivery requires a series of rapid physiologic changes of the cardiorespiratory system. These changes result in redirection of gas exchange from the placenta to the lung and comprise:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Replacement of alveolar fluid with air",
"     </li>",
"     <li>",
"      Onset of regular breathing",
"     </li>",
"     <li>",
"      Increase in pulmonary blood flow as a result of increased systemic vascular resistance and decreased pulmonary vascular resistance (PVR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These processes result in an increase in neonatal arterial oxygen tension (PaO2) from 25 to a range of 60 to 80 mmHg during the first minutes of life. This increase in PaO2 reverses hypoxic respiratory depression and contributes to a regular breathing pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most neonates successfully transition between intrauterine and extrauterine life, about 10 percent will have difficulty and require resuscitative efforts at birth. This difficulty may be a consequence of impaired lung function due to fluid retention, airway obstruction associated with congenital anomalies, persistent pulmonary hypertension, or apnea associated with lack of respiratory effort. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43223?source=see_link\">",
"     \"Management of apnea of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physiologic transition from intrauterine to extrauterine life, including its difficulties, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=see_link\">",
"     \"Physiologic transition from intrauterine to extrauterine life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the common causes of neonatal respiratory distress is reviewed briefly here. A more detailed discussion for each disorder is found separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transient tachypnea of the newborn (TTN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient tachypnea of the newborn (TTN) is caused by failure of adequate lung fluid clearance at birth, resulting in excess lung liquid. The liquid fills the air spaces and moves into the extra-alveolar interstitium where it pools in perivascular tissues and interlobar fissures until it is cleared by the lymphatic or vascular circulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32804?source=see_link\">",
"     \"Transient tachypnea of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the precise pathogenesis of TTN remains unknown, it is proposed that TTN is caused by",
"    <strong>",
"     impairment",
"    </strong>",
"    of the following mechanisms that normally clear fetal alveolar fluid:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of amiloride-sensitive sodium channels, which increases sodium reabsorption, thereby creating an osmotic gradient for water uptake across the pulmonary epithelium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/2\">",
"       2",
"      </a>",
"      ]. The ability to reabsorb sodium appears relatively late in fetal life. Low pulmonary expression or activity of airway epithelial sodium channels may delay lung fluid clearance, especially in premature infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lung inflation that generates a transepithelial hydrostatic pressure gradient, which promotes fluid movement of liquid from the airway. This is consistent with the finding that positive end-expiratory pressure (PEEP) facilitates airway liquid clearance and lung aeration in animal models mechanically ventilated from birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The excess lung water in TTN causes decreased pulmonary compliance, and possibly increased airway resistance due to extrinsic compression of small airways by fluid in the extra-alveolar interstitium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Respiratory distress syndrome (RDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress syndrome (RDS) is caused by deficiency of surfactant, the phospholipid mixture (predominantly desaturated palmitoyl phosphatidyl choline) that reduces alveolar surface tension, which decreases the pressure needed to keep the alveoli inflated, and maintains alveolar stability. When surfactant is deficient, the infant may not be able to generate the increased inspiratory pressure needed to inflate alveolar units, resulting in the development of progressive and diffuse atelectasis. Surfactant deficiency also leads to an inability to maintain open alveoli at low lung volume, for example, during end expiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffuse atelectasis leads to low compliance and low functional residual capacity. Hypoxemia results primarily from mismatching of ventilation and perfusion as blood bypasses atelectatic air spaces (intrapulmonary shunting). Right-to-left shunting that occurs through the ductus arteriosus and foramen ovale, because of increased pulmonary vascular resistance (PVR), also contributes to decreased oxygenation. Hypoxemia is often accompanied by respiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although surfactant deficiency plays the major etiologic role for neonatal RDS, the inability to clear lung fluid from air spaces may also contribute to RDS in the preterm infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, data from a twin cohort study demonstrate a significant genetic susceptibility to RDS, although the underlying genetic component(s) remains to be elucidated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Persistent pulmonary hypertension (PPHN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension (PPHN) is caused by the abnormal persistence of elevated PVR that leads to right-to-left shunting of deoxygenated blood through the foramen ovale and the ductus arteriosus, resulting in hypoxemia.",
"   </p>",
"   <p>",
"    The normal transition from fetal life must include a dramatic decrease in PVR. This is mediated by mechanical factors that result in the opening of air spaces and improved oxygenation, and decrease pulmonary vasoconstriction. The balance of vascular mediators (ie, endothelin and nitric oxide, which induce vasoconstriction and vasorelaxation, respectively) also plays a key role in changing pulmonary vascular tone.",
"   </p>",
"   <p>",
"    It has been proposed that PPHN is caused by a combination of underdevelopment, maldevelopment, or maladaptation of the pulmonary vascular bed. PPHN is also often associated with nonacute conditions due to a structural abnormality (eg, congenital diaphragmatic hernia) or chronic in utero stress (eg, meconium aspiration syndrome). These concurrent findings suggest that a structural etiology (eg, increased musculature of pulmonary vessels), rather than simply a functional change in pulmonary vascular reactivity at birth, contributes to PPHN in many cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link&amp;anchor=H4#H4\">",
"     \"Persistent pulmonary hypertension of the newborn\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic clinical features help distinguish among the disorders that result in respiratory distress immediately after birth, although there can be considerable overlap among these conditions (",
"    <a class=\"graphic graphic_algorithm graphicRef74233 \" href=\"mobipreview.htm?19/34/20000\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transient tachypnea of the newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient tachypnea of the newborn (TTN) is most frequently seen in late preterm infants born at a gestational age between 34 and 37 weeks, many of whom are delivered by elective caesarean section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/7\">",
"     7",
"    </a>",
"    ]. Term and postterm babies are also at risk for TTN.",
"   </p>",
"   <p>",
"    The onset of TTN usually occurs within two hours after delivery. Tachypnea (respiratory rate &ge;60 breaths per minute) is the most prominent feature. Affected infants also may have increased work of breathing manifested by nasal flaring, mild intercostal and subcostal retractions, and expiratory grunting (the sound produced by expiration through partially closed vocal cords). These signs of respiratory distress are generally mild and often resolve more quickly than tachypnea. Cyanosis may be present and is usually corrected with low concentrations of supplemental oxygen. Respiratory acidosis, if present, is mild. While TTN frequently resolves within 24 hours, a persistent course of up to 72 hours is not uncommon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32804?source=see_link\">",
"     \"Transient tachypnea of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Respiratory distress syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with respiratory distress syndrome (RDS) are nearly always premature. Respiratory distress (ie, tachypnea and labored breathing) and cyanosis occur at or soon after birth. Typical signs include grunting (which prevents end-expiratory alveolar collapse), nasal flaring (which reduces nasal resistance and reflects increased use of accessory muscles of respiration), and intercostal and subcostal retractions (due to decreased lung compliance and the highly compliant chest wall). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic clinical course of RDS is observed less frequently because of interventions that reduce the risk of RDS. These include the use of antenatal glucocorticoid therapy, early intubation for surfactant therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    administration of continuous positive air pressure (CPAP) or positive end expiratory pressure (PEEP) in the delivery room to provide adequate lung volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/8\">",
"     8",
"    </a>",
"    ]. As a result of these measures, many extremely low birth weight (birth weight &lt;1000 g) infants do not exhibit the clinical features of RDS, even though they are at considerable risk for later development of bronchopulmonary dysplasia (BPD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Persistent pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension (PPHN) usually occurs in term infants, although it may also present in late preterm or postterm infants. Although the diagnosis is rare in very low birth weight (VLBW) infants (birth weight &lt;1500 g), PPHN may dominate the clinical picture of respiratory distress in a small number of VLBW infants.",
"   </p>",
"   <p>",
"    PPHN is characterized by tachypnea and cyanosis. Differential pre- and postductal saturation is a common finding. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Cardiac evaluation'",
"    </a>",
"    below.) It may also be accompanied by a systolic murmur of tricuspid insufficiency. Sepsis, hypoxia-ischemia, meconium aspiration syndrome, and congenital diaphragmatic hernia are associated with PPHN. In these cases, metabolic acidosis may be present due to lactic acidosis from poor perfusion or severe hypoxemia in addition to the respiratory acidosis that accompanies respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14199103\">",
"    <span class=\"h2\">",
"     Other etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders that can result in neonatal respiratory distress include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumonia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=see_link&amp;anchor=H20#H20\">",
"       \"Neonatal pneumonia\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital heart disease (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=see_link&amp;anchor=H12#H12\">",
"       \"Cardiac causes of cyanosis in the newborn\", section on 'Cardiac causes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link&amp;anchor=H1146178#H1146178\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Tachypnea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumothorax and other pulmonary air leak disorders (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=see_link\">",
"       \"Pulmonary air leak in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital diaphragmatic hernia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28026?source=see_link&amp;anchor=H2#H2\">",
"       \"Congenital diaphragmatic hernia in the neonate\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other pulmonary congenital defects (eg, tracheoesophageal fistula and cystic adenomatous malformation). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/810?source=see_link\">",
"       \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical diagnosis of newborns with respiratory distress is based primarily upon the history and radiographic findings, as the physical findings are often similar. The evolving course also helps define the specific disorder (",
"    <a class=\"graphic graphic_algorithm graphicRef74233 \" href=\"mobipreview.htm?19/34/20000\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about the gestational age, method of delivery, risk of infection, and associated complications will assist in the diagnosis as demonstrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TTN is a frequent cause of respiratory distress in the late preterm infant after caesarean delivery without labor because of the failure to initiate the normal physiologic mechanisms that contribute to lung fluid clearance. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transient tachypnea of the newborn (TTN)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preterm infants are at increased risk of RDS and the risk rises as gestational age decreases. In addition, RDS occurs more frequently in infants of diabetic mothers compared with infants of nondiabetic mothers at similar gestational age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link\">",
"       \"Infant of a diabetic mother\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants born through meconium-stained amniotic fluid and those who have perinatal depression are at increased risk for PPHN. PPHN also is more likely in infants with a history of bacterial infection, and poor intrauterine growth and nonreassuring fetal heart rate patterns, suggesting poor placental function and chronic fetal hypoxemia. Although the presence of respiratory distress and precipitating factor(s) are clinical findings that help distinguish PPHN from structural cyanotic heart disease in term infants with severe cyanosis, the diagnosis should be confirmed by echocardiography. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cardiac evaluation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link&amp;anchor=H9#H9\">",
"       \"Persistent pulmonary hypertension of the newborn\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographic findings may be useful in differentiating among the disorders of neonatal respiratory distress:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The chest radiograph in TTN usually exhibits characteristic bilateral perihilar linear streaking secondary to engorged lymphatic or blood vessels. Patchy infiltrates that clear within 24 to 48 hours may also reflect the fluid retention of TTN but make initial differentiation from pneumonia problematic. Lung ultrasound has been proposed as an imaging technique for reliable early diagnosis and differentiation of TTN (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64045 \" href=\"mobipreview.htm?30/36/31298\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In RDS, atelectasis results in the classical radiographic findings of a diffuse, reticulogranular, ground glass appearance with air bronchograms, and low lung volume (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52323 \" href=\"mobipreview.htm?36/11/37040\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The appearance of the chest radiograph in PPHN depends upon the presence of associated lung disease. In infants without lung disease, the lung fields may appear clear with decreased pulmonary vascularity. The heart size may be normal or increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiac evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography should be performed in infants with severe hypoxemia to exclude structural heart disease. In particular, because of the possible paucity of chest radiographic findings in infants with PPHN, echocardiography is an important diagnostic tool to differentiate this disorder from cyanotic heart disease.",
"   </p>",
"   <p>",
"    In infants with PPHN, echocardiography will show a structurally normal heart with signs of elevated right ventricular pressure and right-to-left shunting through the foramen ovale",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the ductus arteriosus. In the presence of atrial right-to-left shunting, there will be poor oxygenation measured in all extremities. If right-to-left shunting is limited to the ductus, simultaneous measurements of oxygenation will reveal lower levels in the postductally perfused regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our initial approach to an infant with respiratory distress, regardless of etiology, consists of the following (",
"    <a class=\"graphic graphic_algorithm graphicRef74233 \" href=\"mobipreview.htm?19/34/20000\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of supplemental oxygen to relieve respiratory distress or cyanosis. For ongoing management of preterm infants with respiratory distress, oxygenation saturation based upon pulse oximetry (SpO2) is typically targeted between 90 and 95 percent, however, the optimal SpO2 range for infants based upon gestational age remains an area of investigation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31511/abstract/8\">",
"       8",
"      </a>",
"      ]. If PPHN is suspected, targeted oxygen saturation should be kept at or above the high end of this range. Noninvasive measurement of oxygenation should be complemented by a blood gas to evaluate presence of respiratory or metabolic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29656?source=see_link&amp;anchor=H18#H18\">",
"       \"Oxygen monitoring and therapy in the newborn\", section on 'Oxygen target levels'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assisted ventilation via CPAP, or intubation with mechanical ventilation, may be needed for infants with respiratory failure (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4729?source=see_link&amp;anchor=H3#H3\">",
"       \"Mechanical ventilation in neonates\", section on 'Indications for ventilation'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      As discussed above, a chest radiograph should be obtained to assist in diagnosis and to identify complications, such as pneumothorax, that may require urgent treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=see_link\">",
"       \"Pulmonary air leak in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appropriate fluid and metabolic management and provision of a neutral thermal environment reduce the infant's energy and oxygen consumption. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27591?source=see_link\">",
"       \"Fluid and electrolyte therapy in newborns\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the majority of infants, initial laboratory evaluation includes a blood gas, complete blood count and blood culture, possibly followed-up by C-reactive protein (CRP). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Laboratory evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Empiric antibiotics, typically",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      , should be considered if there is delayed transitioning, progressive respiratory distress, or if sepsis risk factors are present. The results of blood culture, chest radiography, and clinical course will guide the duration of antibiotic therapy. The dosing regimen of antibiotics is dependent upon the gestational age of the infant. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26200?source=see_link\">",
"       \"Treatment and outcome of sepsis in term and late preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific therapy for the three main causes of neonatal therapy is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient tachypnea of the newborn (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32804?source=see_link&amp;anchor=H7#H7\">",
"       \"Transient tachypnea of the newborn\", section on 'Management'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The prevention and management of an infant with RDS (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43561?source=see_link\">",
"       \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Persistent pulmonary hypertension (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link&amp;anchor=H15#H15\">",
"       \"Persistent pulmonary hypertension of the newborn\", section on 'Management'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/20/26945?source=see_link\">",
"       \"Patient information: Transient tachypnea of the newborn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress is common immediately after birth. Clinical findings include tachypnea, nasal flaring, intercostal or subcostal retractions, audible grunting, and cyanosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal respiratory distress commonly occurs because of a poor transition from fetal to neonatal life due to impaired lung function, persistent pulmonary hypertension, airway obstruction, or lack of respiratory effort. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Transition from fetal life'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three most common causes of respiratory distress are transient tachypnea of the newborn (TTN), respiratory distress syndrome (RDS), and persistent pulmonary hypertension of the newborn (PPHN). Clinical and radiographic findings, and disease course are used to differentiate the three and make an initial diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       TTN",
"      </strong>",
"      is typically seen in late preterm infants, although term and postterm infants are also at risk. It is caused by inadequate lung fluid clearance at birth that results in excess lung fluid, which leads to decreased pulmonary compliance and possibly increased airway resistance. TTN is characterized by the onset of tachypnea usually within two hours after delivery. Symptoms generally resolve after 12- to 24-hours but may persist as long as 72 hours in severe cases. The chest radiograph typically exhibits bilateral perihilar linear streaking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32804?source=see_link\">",
"       \"Transient tachypnea of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       RDS",
"      </strong>",
"      typically occurs in preterm infants, and its incidence increases with decreasing gestational age. It is caused by surfactant deficiency that leads to alveolar collapse and diffuse atelectasis. Hypoxemia results from the mismatch of ventilation and perfusion as blood bypasses the atelectatic air spaces. Respiratory distress and cyanosis occur at or soon after birth. The chest radiograph is characterized by low lung volumes and the classical findings of a diffuse, reticulogranular, ground glass appearance with air bronchograms (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64045 \" href=\"mobipreview.htm?30/36/31298\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       PPHN",
"      </strong>",
"      usually occurs in term infants, although it may also present in late preterm or postterm infants. It is caused by the abnormal persistence of elevated pulmonary vascular resistance (PVR) that leads to right-to-left shunting of deoxygenated blood through the foramen ovale and the ductus arteriosus, resulting in hypoxemia. PPHN is characterized by severe cyanosis and tachypnea, and may be accompanied by a systolic murmur of tricuspid insufficiency. The appearance of the chest radiograph in PPHN depends upon the presence of associated lung disease. In infants without lung disease, the lung fields may appear clear with decreased pulmonary vascularity, and the heart size may be normal or increased. Echocardiography is required to confirm the diagnosis of PPHN and differentiate it from structural cyanotic heart disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link\">",
"       \"Persistent pulmonary hypertension of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the following initial management of neonatal respiratory distress regardless of the etiology (",
"      <a class=\"graphic graphic_algorithm graphicRef74233 \" href=\"mobipreview.htm?19/34/20000\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Supplemental oxygen for respiratory distress or cyanosis",
"     </li>",
"     <li>",
"      Assisted ventilation in infants with respiratory failure",
"     </li>",
"     <li>",
"      Diagnostic chest radiography",
"     </li>",
"     <li>",
"      Fluid and electrolyte management and a neutral thermal environment to minimize energy and oxygen consumption",
"     </li>",
"     <li>",
"      Laboratory evaluation, including blood gas, complete blood count, C-reactive protein, and blood culture",
"     </li>",
"     <li>",
"      Empiricl antibiotic therapy of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      should be considered if there is delayed transitioning, progressive respiratory distress, or if sepsis risk factors are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific therapy for TTN, RDS, and PPHN is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32804?source=see_link&amp;anchor=H7#H7\">",
"       \"Transient tachypnea of the newborn\", section on 'Management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43561?source=see_link\">",
"       \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link&amp;anchor=H15#H15\">",
"       \"Persistent pulmonary hypertension of the newborn\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Stephen Welty, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/1\">",
"      Mariani G, Dik PB, Ezquer A, et al. Pre-ductal and post-ductal O2 saturation in healthy term neonates after birth. J Pediatr 2007; 150:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/2\">",
"      Jain L, Eaton DC. Physiology of fetal lung fluid clearance and the effect of labor. Semin Perinatol 2006; 30:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/3\">",
"      Helve O, Pitk&auml;nen O, Jan&eacute;r C, Andersson S. Pulmonary fluid balance in the human newborn infant. Neonatology 2009; 95:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/4\">",
"      Siew ML, Te Pas AB, Wallace MJ, et al. Positive end-expiratory pressure enhances development of a functional residual capacity in preterm rabbits ventilated from birth. J Appl Physiol 2009; 106:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/5\">",
"      Avery ME. Surfactant deficiency in hyaline membrane disease: the story of discovery. Am J Respir Crit Care Med 2000; 161:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/6\">",
"      Levit O, Jiang Y, Bizzarro MJ, et al. The genetic susceptibility to respiratory distress syndrome. Pediatr Res 2009; 66:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/7\">",
"      Tita AT, Landon MB, Spong CY, et al. Timing of elective repeat cesarean delivery at term and neonatal outcomes. N Engl J Med 2009; 360:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/8\">",
"      Finer N, Leone T. Oxygen saturation monitoring for the preterm infant: the evidence basis for current practice. Pediatr Res 2009; 65:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31511/abstract/9\">",
"      Copetti R, Cattarossi L. The 'double lung point': an ultrasound sign diagnostic of transient tachypnea of the newborn. Neonatology 2007; 91:203.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4964 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-190.81.197.98-24A80F9498-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31511=[""].join("\n");
var outline_f30_49_31511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TRANSITION FROM FETAL LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transient tachypnea of the newborn (TTN)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Respiratory distress syndrome (RDS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Persistent pulmonary hypertension (PPHN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Persistent pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14199103\">",
"      Other etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiac evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4964|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/34/20000\" title=\"algorithm 1\">",
"      Eval neonatal resp distress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4964|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/36/31298\" title=\"diagnostic image 1\">",
"      Chest radiograph TTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/11/37040\" title=\"diagnostic image 2\">",
"      Chest radiograph RDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28026?source=related_link\">",
"      Congenital diaphragmatic hernia in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/50/810?source=related_link\">",
"      Congenital pulmonary airway (cystic adenomatoid) malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27591?source=related_link\">",
"      Fluid and electrolyte therapy in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/39/4729?source=related_link\">",
"      Mechanical ventilation in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/20/26945?source=related_link\">",
"      Patient information: Transient tachypnea of the newborn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/19/8502?source=related_link\">",
"      Physiologic transition from intrauterine to extrauterine life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4631?source=related_link\">",
"      Pulmonary air leak in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26200?source=related_link\">",
"      Treatment and outcome of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_49_31512="Molecular genetics of chronic myeloid leukemia";
var content_f30_49_31512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular genetics of chronic myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31512/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31512/contributors\">",
"     Richard A Van Etten, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31512/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31512/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/49/31512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML, also known as chronic myelocytic, myelogenous, or granulocytic leukemia) is classified as one of the myeloproliferative neoplasms, along with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This group of diseases shares several distinct features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are clonal disorders of hematopoiesis that arise in a hematopoietic stem or early progenitor cell.",
"     </li>",
"     <li>",
"      They are characterized by the dysregulated production of a particular lineage of mature myeloid cells with fairly normal differentiation.",
"     </li>",
"     <li>",
"      They exhibit a variable tendency to progress to acute leukemia.",
"     </li>",
"     <li>",
"      They share abnormalities of hemostasis and thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The individual myeloproliferative neoplasms predominantly affect a single myeloid cell type, resulting in an excess of neutrophils in CML, erythrocytes in PV, and platelets in ET. However, there is considerable overlap between the clinical features as patients with CML, for example, often have thrombocytosis.",
"   </p>",
"   <p>",
"    CML is almost invariably associated with an abnormal chromosome 22 known as the Philadelphia chromosome, often abbreviated as Ph, Ph(1), or Ph",
"    <sup>",
"     1",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The Philadelphia chromosome t(9;22)(q34;q11) results in the formation of a unique gene product (BCR-ABL1), which is a constitutively active tyrosine kinase. This deregulated tyrosine kinase is implicated in the development of CML and has become a primary target for the treatment of this disorder.",
"   </p>",
"   <p>",
"    The molecular genetics of the Philadelphia chromosome will be reviewed here. How the BCR-ABL1 fusion protein product of the Philadelphia chromosome promotes leukemogenesis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE PHILADELPHIA CHROMOSOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Philadelphia (Ph) chromosome was originally detected by workers in Philadelphia as an abnormally short G-group chromosome in analysis of bone marrow metaphases from CML patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/3\">",
"     3",
"    </a>",
"    ]; it has the distinction of being the first genetic abnormality to be associated with a human cancer. Subsequently, advances in chromosome banding techniques demonstrated that the Ph chromosome was the result of a balanced translocation between chromosomes 9 and 22, denoted t(9;22) (q34.1;q11.21), where the derivative chromosome 22 is significantly smaller (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"mobipreview.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/4\">",
"     4",
"    </a>",
"    ]. The Ph chromosome is present in hematopoietic cells from patients with CML but not in nonhematopoietic tissues, including bone marrow fibroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/5\">",
"     5",
"    </a>",
"    ]; thus, the Ph chromosome is acquired and not inherited through the germline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nomenclature",
"    </span>",
"    &nbsp;&mdash;&nbsp;A generally accepted nomenclature is used to distinguish translocated genes and the gene products. Human genes are designated by capitalized italics (as in BCR-ABL1 gene with BCR-ABL in italics), while human proteins are designated by having the letters capitalized, without the use of italics (as in BCR-ABL1 protein without italics). Proteins may also be designated by the prefix \"p\" followed by the molecular weight in kilodaltons followed by the gene name added as a superscript (as in p210",
"    <sup>",
"     BCR-ABL",
"    </sup>",
"    protein). Due to technical constraints, italics will not be used in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Structure of the Philadelphia chromosome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The structure of the Ph chromosome was established by initial studies demonstrating translocation of the ABL1 gene (also known as c-ABL) on chromosome 9q34 to the Ph chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/6\">",
"     6",
"    </a>",
"    ], and the subsequent discovery of breakpoints near the 5' end of the ABL1 gene in leukemic cells from patients with CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/7\">",
"     7",
"    </a>",
"    ]. The ABL1 gene had been previously identified as the cellular homologue of the transforming gene of Abelson murine leukemia virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/8\">",
"     8",
"    </a>",
"    ], an acutely transforming retrovirus that induces B-lymphoid leukemia in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/9\">",
"     9",
"    </a>",
"    ]. The ABL1 gene on chromosome 9 has 11 exons with 2 alternative 5' first exons, and a very large first intron of over 250 kilobases (kb). The ABL1 gene encodes a non-receptor protein-tyrosine kinase, c-ABL (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H11#H11\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'c-ABL1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DNA sequences immediately 5' to the ABL1 gene on the Ph chromosome were derived from chromosome 22 sequences, and DNA probes from a small region on chromosome 22 detected genomic rearrangements by Southern analysis of genomic DNA in virtually all CML samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/10\">",
"     10",
"    </a>",
"    ]. This locus on chromosome 22 was named the",
"    <strong>",
"     b",
"    </strong>",
"    reakpoint",
"    <strong>",
"     c",
"    </strong>",
"    luster",
"    <strong>",
"     r",
"    </strong>",
"    egion, or bcr. Subsequent characterization of this locus demonstrated that the bcr region was in the middle of a large protein-coding gene of 25 exons now called the BCR gene (also called PHL in some early reports). Five small exons were initially identified in the bcr region and denoted exons b1 through b5; they are now known to be exons 12 through 16 of the major breakpoint cluster region (M-BCR). The BCR gene product is a 160 kilodalton cytoplasmic phosphoprotein denoted BCR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H10#H10\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'BCR'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the location of the breakpoint within the major BCR region, the consequence of the t(9;22) translocation in CML is to fuse the first 13 or 14 exons of the BCR gene upstream of the second exon of the ABL1 gene, with the breakpoint on chromosome 9 falling in the large first intron region. The two alternative fusion genes are traditionally described according to the original bcr exon nomenclature as b2a2 and b3a2 fusions or by the subsequent nomenclature as e13a2 or e14a2, respectively. Transcription of the fusion gene followed by RNA splicing leads to the generation of a novel 8.5 kb fusion BCR-ABL1 mRNA that encodes a fusion protein of 210 kilodaltons designated p210 BCR-ABL1 or p210",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/11\">",
"     11",
"    </a>",
"    ]. The protein product of the b3a2 fusion is 25 amino acids longer than the b2a2 product due to the inclusion of the b3 exon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H12#H12\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'BCR-ABL1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4596194\">",
"    <span class=\"h3\">",
"     Distinct forms of BCR-ABL1 from alternative chromosome 22 breakpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several years after the description of BCR-ABL1 in patients with CML, it was discovered that the majority of pediatric and adult patients with Ph-positive B-ALL had chromosome 22 breakpoints within the large first intron of the BCR gene rather than the classic bcr region, leading to formation of a smaller BCR-ABL1 fusion gene consisting of the first exon of BCR fused upstream of ABL1 exon 2 (e1a2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The bcr region in CML was renamed the major or M-bcr, while the first intron breakpoints were designated the minor or m-bcr. This fusion generates a protein of 190 kD in size, p190",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    (also referred to as p185 in some references) that contains BCR first exon-encoded sequence fused to the same amount of ABL1 found in p210 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/14\">",
"     14",
"    </a>",
"    ]. A third minor BCR region (mu-BCR) on chromosome 22 resulting in fusion of BCR exon 19 to ABL1 exon 2 (e19a2) has been described in several patients, leading to generation of a p230 form of BCR-ABL1 (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As such, there are three common variants of BCR-ABL1 (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      p210",
"      <sup>",
"       BCR-ABL1",
"      </sup>",
"      &mdash; Created by the fusion of the ABL1 gene at a2 with a breakpoint in the major BCR region at either e13 or e14 to produce an e13a2 or e14a2 transcript which is translated into a 210 kilodalton protein. This variant is present in most patients with CML and one-third of those with Ph-positive B cell acute lymphoblastic leukemia (Ph+ B-cell ALL).",
"     </li>",
"     <li>",
"      p190",
"      <sup>",
"       BCR-ABL1",
"      </sup>",
"      &mdash; Created by the fusion of the ABL1 gene at a2 with a breakpoint in the minor BCR region at e1 to produce an e1a2 transcript which is translated into a 190 kilodalton protein. This variant is present in two-thirds of those with Ph+ B-cell ALL and a minority of patients with CML.",
"     </li>",
"     <li>",
"      p230",
"      <sup>",
"       BCR-ABL1",
"      </sup>",
"      &mdash; Created by the fusion of the ABL1 gene at a2 with a breakpoint in the mu BCR region at e19 to produce an e19a2 transcript which is translated into a 230 kilodalton protein. This variant is seen in some patients with chronic neutrophilic leukemia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'p190 and p230 fusion proteins'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these more common variant forms, rare patients with fusion of BCR exon 1 or exon b2 to ABL exon 3 (e1a3 and b2a3) and BCR exon 6 to ABL1 exon 2 (e6a2) have been described, where both fusion mRNAs are predicted to have an intact translational reading frame [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Reciprocal translocation product",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reciprocal translocation product on the derivative chromosome 9, notated as der(9), is an ABL1-BCR fusion gene that could generate an ABL1-BCR fusion protein. However, the inconsistent expression of the ABL1-BCR gene in patients with CML, along with survival data in ABL1-BCR negative patients, suggest that this product does not play a major role in the pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Some studies have suggested that der(9) deletions may confer a worse prognosis in patients with CML marked by lower response rates and a shorter progression-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. However, deletion of der(9) may no longer be a marker of poor prognosis among patients treated with tyrosine kinase inhibitors. As an example, combined data from 521 patients enrolled in three prospective with a median follow-up of 42 months demonstrated that der(9) deletions detected by FISH did not confer a worse prognosis for patients with early chronic phase CML treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4596364\">",
"    <span class=\"h2\">",
"     Leukemogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of chronic phase CML appears to be a direct result of BCR-ABL1 activity, which promotes its development by allowing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncontrolled proliferation of transformed cells",
"     </li>",
"     <li>",
"      Discordant maturation",
"     </li>",
"     <li>",
"      Escape from apoptosis",
"     </li>",
"     <li>",
"      Altered interaction with the cellular matrix",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The progression of CML from chronic phase to accelerated phase or blast crisis is a complex, multistep process, but also appears to involve the constitutive expression of the BCR-ABL1 tyrosine kinase. The role of BCR-ABL in the pathogenesis of CML is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Detecting the Philadelphia chromosome or its products",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) diagnostic criteria for CML require the detection of the Ph chromosome or its products, the BCR-ABL1 fusion mRNA and the BCR-ABL1 protein. This can be accomplished through conventional cytogenetic analysis (karyotyping), fluorescence in situ hybridization (FISH) analysis, or by reverse transcription polymerase chain reaction (RT-PCR). Southern blot techniques to identify BCR-ABL1 gene rearrangements were used in the past, but are time consuming and no longer employed as a routine diagnostic test. Evaluating for BCR-ABL1 protein by Western blot analysis is also not commonly used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4596973\">",
"    <span class=\"h2\">",
"     Cytogenetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ph chromosome was initially discovered by cytogenetic analysis using May-Gr&uuml;nwald-Giemsa (MGG) banded metaphase chromosomes from marrow or peripheral blood. However, this technique requires in vitro culture, is time- and labor-intensive, has a sensitivity limit of detection of about 5 percent Ph positive cells in a population of normal cells, and can give false negative results in cells with complex chromosomal rearrangements. For these reasons, traditional cytogenetic analysis is being supplanted by newer methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     FISH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluorescence in situ hybridization (FISH) employs large DNA probes linked to fluorophores; it permits direct detection of the chromosomal position of the BCR and ABL1 genes when employed with metaphase chromosome preparations. It can also be utilized on interphase cells from bone marrow or peripheral blood, in which physical colocalization of BCR and ABL probes is indicative of the presence of the BCR-ABL fusion gene (",
"    <a class=\"graphic graphic_figure graphicRef73543 \" href=\"mobipreview.htm?8/58/9134\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/23\">",
"     23",
"    </a>",
"    ]. The specificity of metaphase FISH is somewhat higher than MGG banding for detection of the Ph chromosome, and allows easy identification of complex chromosomal rearrangements that mask the t(9;22) translocation. The specificity of interphase FISH is lower, by approximately 10 percent, due to false positive results from coincidental colocalization of non-fused BCR and ABL1 genes in interphase nuclei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/23\">",
"     23",
"    </a>",
"    ]. The use of double-color, dual-fusion probes for interphase FISH may improve the specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most FISH techniques cannot distinguish among different chromosome 22 breakpoints, some commercially available probes allow detection of a range of chromosome 9 breakpoints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Preliminary results using these additional FISH probes suggest that the presence of 5'-ABL1 deletions on the derivative chromosome 9 in 10 to 15 percent of patients with CML may indicate a subset having a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], independent of the Sokal and",
"    <span class=\"nowrap\">",
"     Hasford/Euro",
"    </span>",
"    prognostic scoring systems. However, this must be confirmed in a prospective study. The poor outcome of these patients cannot be attributed to the loss of reciprocal ABL1-BCR expression and is not fully reversed by therapy with tyrosine kinase inhibitors or allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4597093\">",
"    <span class=\"h3\">",
"     RT-PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse-transcription polymerase chain reaction (RT-PCR) is a highly sensitive technique that employs specific primers to amplify a DNA fragment from BCR-ABL1 mRNA transcripts. Depending upon the combination of primers used, the method can detect the e1a2, e13a2 (b2a2), e14a2 (b3a2) and e19a2 fusion genes. The use of nested primers and sequential PCR reactions makes the technique extremely sensitive, capable of routine detection of one Ph positive cell in 10(5) to 10(6) normal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4596194\">",
"     'Distinct forms of BCR-ABL1 from alternative chromosome 22 breakpoints'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because RT-PCR is low-cost, sensitive, rapid, and not labor intensive, it is becoming the diagnostic test of choice for Ph-positive leukemia. The data can be quantitated by including a competitive standard RNA in the reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/30\">",
"     30",
"    </a>",
"    ] or by monitoring the accumulation of product in real time using fluorescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/31\">",
"     31",
"    </a>",
"    ]. This technique can be used to monitor response to treatment as well as to detect minimal residual disease following allogeneic bone marrow transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/29,32,33\">",
"     29,32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Monitoring response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several features must be considered in the interpretation of RT-PCR data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are many variables in the RT-PCR assay, including which internal standard to use, and how to compare results obtained in different laboratories. While initial efforts to create an international standardized scale for quantitative PCR for BCR-ABL measurements look promising [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/34\">",
"       34",
"      </a>",
"      ], it is preferable to obtain serial samples from individual patients at the same laboratory, if possible [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with rare fusions, such as e6a2 or b2a3, may not be detected with standard primer sets.",
"     </li>",
"     <li>",
"      Patients with 5' m-bcr breakpoints can sometimes exhibit both e13a2 (b2a2) and e14a2 (b3a2) transcripts, while M-bcr breakpoints can also produce e1a2 transcripts at lower levels, probably due to alternative splicing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      BCR-ABL1 fusion transcripts (M-bcr or m-bcr) can be detected at very low level [one cell in 10",
"      <sup>",
"       8",
"      </sup>",
"      to 10",
"      <sup>",
"       9",
"      </sup>",
"      ] in hematopoietic cells from some normal individuals; this defines the limits of useful sensitivity of RT-PCR for diagnosis of leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4597105\">",
"    <span class=\"h3\">",
"     Southern blotting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Southern blotting uses DNA probes from the three bcr regions (M-, m- and &micro;-bcr) to detect rearrangements in genomic DNA from leukemic samples. This method can distinguish the three different principal BCR-ABL1 gene fusions, but is labor-intensive and has a sensitivity similar to cytogenetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Western blotting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Western blotting permits direct detection of the Bcr-Abl protein using a specific monoclonal antibody against Bcr or Abl [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/38\">",
"     38",
"    </a>",
"    ]. This technique allows unequivocal identification of the specific form of Bcr-Abl protein present, but has a low sensitivity, is labor intensive, and is not commonly available in clinical laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Type of BCR-ABL1 fusion may influence the clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various types of BCR-ABL1 fusion may be associated with distinct leukemia phenotypes; this is most apparent with p190",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/16\">",
"     16",
"    </a>",
"    ]. Determining whether different forms of BCR-ABL1 are associated with distinct leukemic phenotypes and clinical outcomes is important, since it is plausible that optimum therapy (eg, response to tyrosine kinases or other therapies) might be in part determined by the BCR-ABL1 genotype. Experiments in tissue culture and animal models of Ph-positive leukemia suggest that different forms of BCR-ABL1 do have distinct leukemogenic properties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     p190 and p230 fusion proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;p190",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    is found in about 80 percent of childhood and 50 percent of adult Ph-positive B-ALL, but is infrequently observed in CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/39\">",
"     39",
"    </a>",
"    ]. A retrospective study of 1384 patients with CML by Western blot identified only five with p190 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/40\">",
"     40",
"    </a>",
"    ]. The presence of p190 in chronic phase CML is correlated with monocytosis and a low",
"    <span class=\"nowrap\">",
"     neutrophil/monocyte",
"    </span>",
"    ratio in the peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. When compared with other patients with CML, patients with the p190 fusion protein may have an inferior outcome when treated with tyrosine kinase inhibitors. A retrospective analysis of 14 patients with p190 reported a low response rate to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy with frequent evolution into accelerated or blast phase disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several patients with",
"    <span class=\"nowrap\">",
"     e19/a2",
"    </span>",
"    BCR-ABL1 fusions and p230",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    have been described with a disorder similar to classic CML but with mild clinical symptoms. These include lower peripheral blood leukocyte counts consisting principally of neutrophils, thrombocytosis, less severe splenomegaly, and delayed or absent transformation to blast crisis. It was proposed that patients with the",
"    <span class=\"nowrap\">",
"     e19/a2",
"    </span>",
"    fusion comprise a distinct clinical entity called neutrophilic CML or chronic neutrophilic leukemia, with a much more benign clinical course than that associated with traditional p210",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/15\">",
"     15",
"    </a>",
"    ]. However, other patients with the",
"    <span class=\"nowrap\">",
"     e19/a2",
"    </span>",
"    fusion appear to have typical CML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/43\">",
"     43",
"    </a>",
"    ]. Further prospective studies are needed to determine if patients with p230",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    indeed have a distinct clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Site of breakpoint in M-bcr region",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial study suggested that a breakpoint in the 5' region of M-bcr, with generation of the e13a2 (b2a2) form of BCR-ABL1, was associated with a longer duration of chronic phase than patients with 3' breakpoints and e14a2 (b3a2) fusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/44\">",
"     44",
"    </a>",
"    ]. However, later prospective studies have not confirmed any significant correlation between M-bcr breakpoint location and disease outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients with 3' M-bcr breakpoints",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    e14a2 (b3a2) BCR-ABL1 transcripts may exhibit higher platelet counts, although this is also controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Acute lymphoblastic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ph chromosome positive B-ALL is heterogeneous at the molecular genetic level. While the majority of such patients exhibit m-bcr breakpoints and p190",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    , about one-half of adults and 10 percent of children have M-bcr breakpoints and the p210",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    . Many of the latter patients have persistence of the Ph chromosome after chemotherapy-induced hematologic remissions and have the Ph chromosome in myeloid cells and in myeloid colonies grown in vitro, suggesting that they represent cases of CML presenting in blast crisis after an unrecognized chronic phase.",
"   </p>",
"   <p>",
"    In contrast, most ALL patients expressing p190",
"    <sup>",
"     BCR-ABL1",
"    </sup>",
"    do not exhibit the additional cytogenetic abnormalities typical of CML blast crisis, lack the Ph chromosome in myeloid cells and colonies, and become Ph-negative in hematologic remission. These observations suggest that the Ph translocation occurred in a cell that is more restricted in its differentiation potential than a pluripotent stem cell, perhaps a committed B-lymphoid progenitor. This hypothesis is supported by studies of xenotransplantation of Ph-positive ALL cells into NOD-SCID mice, in which leukemia-initiating cells from patients with p190 positive ALL had a committed B-lymphoid progenitor phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients with p190 positive ALL show persistence of the Ph chromosome in remission and in myeloid cells, consistent with a multipotential cell of origin. This is supported by a report of five patients with p190 positive ALL in whom the Ph chromosome was detected by interphase FISH analysis in granulocytes in all of the patients, suggesting multilineage involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/47\">",
"     47",
"    </a>",
"    ]. It is possible that some or most p190 positive CML patients have rapid transition to lymphoid blast crisis and nearly always present as ALL. In a second study, xenotransplantation of Ph-positive ALL cells into",
"    <span class=\"nowrap\">",
"     NOD/SCID",
"    </span>",
"    mice suggested that the leukemia-initiating cell has a primitive (CD34+CD38-) phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/48\">",
"     48",
"    </a>",
"    ]. Hence, further studies are needed to determine if molecular categorization of patients with Ph-positive ALL offers useful prognostic and therapeutic information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ph-negative or atypical CML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with clinical features of CML lack the Ph chromosome by cytogenetic analysis. This occurred in approximately 15 percent of patients in a large prospective study from the Medical Research Council [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/49\">",
"     49",
"    </a>",
"    ]. In about half of such patients, a &ldquo;variant translocation&rdquo; is seen in which one or more chromosomes in addition to 9 and 22 are involved in the BCR-ABL1 translocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Another subset of patients may be Ph-negative by karyotype but have evidence of BCR-ABL1 gene fusion by metaphase or interphase FISH analysis or RT-PCR. Initial studies suggested that patients with these variant translocations may have a worse outcome with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy than those with classic translocations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, subsequent analysis of 559 patients enrolled on prospective studies of imatinib reported that the 30 patients with variant translocations had similar response rates to those seen in patients with the classic Ph translocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, the deletion of the derivative chromosome 9 did not appear to affect patient outcome.",
"   </p>",
"   <p>",
"    However, about one-third of the group lacked molecular evidence of BCR-ABL1 fusion. In general, these patients have distinct clinical features, including short survival, poor response to therapy, absence of basophilia, frequent thrombocytopenia, and may progress to increasing leukocytosis, organomegaly, extramedullary infiltrates, and marrow failure without a terminal phase of AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31512/abstract/55\">",
"     55",
"    </a>",
"    ]. It is likely that most of these patients have a disease that is distinct from CML, most likely one of the myelodysplastic or",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    overlap syndromes. It is important to pursue a molecular diagnosis in such cases, as some of these patients have leukemias associated with other dysregulated tyrosine kinases, such as PDGFRB, for which kinase inhibitor drugs are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H64021188#H64021188\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'MDS/MPN syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1283623\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasms derived from an abnormal pluripotent stem cell that has acquired the BCR-ABL1 fusion gene. This fusion gene is the product of a balanced translocation between chromosomes 9 and 22, denoted t(9;22) (q34.1;q11.21), which juxtaposes a 5&rsquo; segment of a breakpoint cluster region (BCR) at 22q11 and the 3&rsquo; segment of the ABL oncogene (ABL1) at 9q34, resulting in an abnormally small chromosome known as the Philadelphia chromosome. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'The Philadelphia chromosome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Chromosome 22 is broken at one of four exons (e1, e13, e14, or e19) and this exon is joined with the ABL1 oncogene exon a2 to produce one of four possible transcript products: e1a2, e13a2, e14a2, or e19a2, corresponding to the three common variants of BCR-ABL1 (",
"    <a class=\"graphic graphic_figure graphicRef66610 \" href=\"mobipreview.htm?9/41/9886\">",
"     figure 2",
"    </a>",
"    ) (See",
"    <a class=\"local\" href=\"#H4596194\">",
"     'Distinct forms of BCR-ABL1 from alternative chromosome 22 breakpoints'",
"    </a>",
"    above.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      p210",
"      <sup>",
"       BCR-ABL1",
"      </sup>",
"      &mdash; Created by the fusion of the ABL1 gene at a2 with a breakpoint in the major BCR region at either e13 or e14 to produce an e13a2 or e14a2 transcript which is translated into a 210 kilodalton protein. This variant is present in most patients with CML and one-third of those with Ph-positive B cell acute lymphoblastic leukemia (Ph+ B-cell ALL).",
"     </li>",
"     <li>",
"      p190",
"      <sup>",
"       BCR-ABL1",
"      </sup>",
"      &mdash; Created by the fusion of the ABL1 gene at a2 with a breakpoint in the minor BCR region at e1 to produce an e1a2 transcript which is translated into a 190 kilodalton protein. This variant is present in two-thirds of those with Ph+ B-cell ALL and a minority of patients with CML.",
"     </li>",
"     <li>",
"      p230",
"      <sup>",
"       BCR-ABL1",
"      </sup>",
"      &mdash; Created by the fusion of the ABL1 gene at a2 with a breakpoint in the mu BCR region at e19 to produce an e19a2 transcript which is translated into a 230 kilodalton protein. This variant is seen in some patients with chronic neutrophilic leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) diagnostic criteria for CML require the detection of the Ph chromosome or its products, the BCR-ABL1 fusion mRNA and the BCR-ABL1 protein. This can be accomplished through conventional cytogenetic analysis (karyotyping), fluorescence in situ hybridization (FISH) analysis, or by reverse transcription polymerase chain reaction (RT-PCR). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Detecting the Philadelphia chromosome or its products'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/1\">",
"      Verfaillie CM. Biology of chronic myelogenous leukemia. Hematol Oncol Clin North Am 1998; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/2\">",
"      Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/3\">",
"      Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/4\">",
"      Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/5\">",
"      Maniatis AK, Amsel S, Mitus WJ, Coleman N. Chromosome pattern of bone marrow fibroblasts in patients with chronic granulocytic leukaemia. Nature 1969; 222:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/6\">",
"      de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/7\">",
"      Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/8\">",
"      Goff SP, Gilboa E, Witte ON, Baltimore D. Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell 1980; 22:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/9\">",
"      Abelson HT, Rabstein LS. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 1970; 30:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/10\">",
"      Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/11\">",
"      Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/12\">",
"      Clark SS, McLaughlin J, Timmons M, et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988; 239:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/13\">",
"      Fainstein E, Marcelle C, Rosner A, et al. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature 1987; 330:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/14\">",
"      Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/15\">",
"      Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996; 88:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/16\">",
"      Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/17\">",
"      Melo JV, Gordon DE, Cross NC, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 1993; 81:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/18\">",
"      de la Fuente J, Merx K, Steer EJ, et al. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 2001; 98:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/19\">",
"      Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003; 102:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/20\">",
"      Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003; 102:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/21\">",
"      Kreil S, Pfirrmann M, Haferlach C, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007; 110:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/22\">",
"      Castagnetti F, Testoni N, Luatti S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol 2010; 28:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/23\">",
"      Le Gouill S, Talmant P, Milpied N, et al. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000; 18:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/24\">",
"      Dewald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91:3357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/25\">",
"      Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/26\">",
"      Herens C, Tassin F, Lemaire V, et al. Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000; 110:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/27\">",
"      Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/28\">",
"      Kolomietz E, Al-Maghrabi J, Brennan S, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97:3581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/29\">",
"      Hughes TP, Ambrosetti A, Barbu V, et al. Clinical value of PCR in diagnosis and follow-up of leukaemia and lymphoma: report of the third Workshop of the Molecular Biology/BMT study group. Leukemia 1991; 5:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/30\">",
"      Goldman JM, Kaeda JS, Cross NC, et al. Clinical decision making in chronic myeloid leukemia based on polymerase chain reaction analysis of minimal residual disease. Blood 1999; 94:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/31\">",
"      Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol 1998; 102:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/32\">",
"      Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999; 107:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/33\">",
"      Wang L, Pearson K, Pillitteri L, et al. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 2002; 118:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/34\">",
"      Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/35\">",
"      Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/36\">",
"      van Rhee F, Hochhaus A, Lin F, et al. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood 1996; 87:5213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/37\">",
"      Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/38\">",
"      Ponzetto C, Guerrasio A, Rosso C, et al. ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises. Br J Haematol 1990; 76:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/39\">",
"      Selleri L, von Lindern M, Hermans A, et al. Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript. Blood 1990; 75:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/40\">",
"      Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol 1999; 107:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/41\">",
"      Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/42\">",
"      Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 2009; 114:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/43\">",
"      Mittre H, Leymarie P, Macro M, Leporrier M. A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease? Blood 1997; 89:4239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/44\">",
"      Mills KI, MacKenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 1988; 72:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/45\">",
"      Shtalrid M, Talpaz M, Kurzrock R, et al. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 1988; 72:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/46\">",
"      Castor A, Nilsson L, Astrand-Grundstr&ouml;m I, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/47\">",
"      Schenk TM, Keyhani A, Bottcher S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 1998; 12:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/48\">",
"      Cobaleda C, Guti&eacute;rrez-Cianca N, P&eacute;rez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/49\">",
"      Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997; 96:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/50\">",
"      Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 2007; 173:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/51\">",
"      Huret JL. Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum Genet 1990; 85:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/52\">",
"      Richebourg S, Eclache V, Perot C, et al. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet 2008; 182:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/53\">",
"      El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004; 125:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/54\">",
"      Marzocchi G, Castagnetti F, Luatti S, et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood 2011; 117:6793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31512/abstract/55\">",
"      Kurzrock R, Kantarjian HM, Shtalrid M, et al. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course. Blood 1990; 75:445.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4537 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31512=[""].join("\n");
var outline_f30_49_31512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1283623\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE PHILADELPHIA CHROMOSOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nomenclature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Structure of the Philadelphia chromosome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4596194\">",
"      - Distinct forms of BCR-ABL1 from alternative chromosome 22 breakpoints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Reciprocal translocation product",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4596364\">",
"      Leukemogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Detecting the Philadelphia chromosome or its products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4596973\">",
"      Cytogenetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - FISH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4597093\">",
"      - RT-PCR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4597105\">",
"      - Southern blotting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Western blotting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Type of BCR-ABL1 fusion may influence the clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - p190 and p230 fusion proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Site of breakpoint in M-bcr region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ph-negative or atypical CML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1283623\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4537\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4537|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/20/16719\" title=\"figure 1\">",
"      The Philadelphia chromosome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/41/9886\" title=\"figure 2\">",
"      ABL1 and BCR genes in CML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/58/9134\" title=\"figure 3\">",
"      BCR-ABL FISH in CML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_49_31513="Rectal leiomyoma Light";
var content_f30_49_31513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61429%7EGAST%2F74175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61429%7EGAST%2F74175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rectal leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a rectal leiomyoma. There is expansion of the submucosa by homogeneous, eosinophilc cells arranged in sheets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jejunal leiomyoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAbUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDbj1M3N7cxHT3soVCvHdlgyTZ64qzZadq/k3S31wtzC7b4mIAZV7AVxP8AwjF/ptqYNL1CWawjXCrcSklPcAfyrtdIubvTfDVzBfymW5ZNkUhGSSemBXj1El8LPrPZtWaG2SMspinAjVskAjgfSpjCVjRjKBGsvHHX2NYHhzTda0ubUBrF0s9pLKHthnJH+H0rehimk+6QFzk7emfWplo9GdSbaNUQXAmS4tA7iPkMr8kelY/iDx5pei6nHFqssqPgnBiyDx0zW9pOp29rGVuZG3qDwBjJqtqF/b3scJutItp5G/56xgrj15HWs0/e95aGNpOT0uUD4m0zU4oZdJniW3X5t+BkNWfqF1pumLJqQsZ7285/exLubBPUelS6t4t8G+GmMGpWMcFxdYYx29vkH3PYVsjWdB1KzT7F5yJ1V0jx0FWk42fK7DhO0uRxMHwX4mi8U295mCaJI22DemDu+tbepacdX0eXTpHVg6lTtbbtHqD65pIVMMP7qfNvJgpEUAJ9+KinRg3mFDluRu4AFS3reOh2Qg2tWYnhb4c2PhudLlpZmuUyd00oYEn0A4rrCZ7p9sQMir/ETwv+NZ0k8NrZtLcysigAY5PPtWX4c8Q6lra/8S+yaOABlWZlIRecA5PBqmpz95sH7na5uXenXEMQclWBOCoO4mma/aajYeC9UudOtg+sGPFojYJGTgsB6gZxUlk+qafpssccST3ZJIkfO0N6461zKabr2oXIkvrxkYnczBiWweuAOPoKILXVrQznKrNcpl/Ca08SwW96fE91cMZiohhuX8yQc/M2f4R7VreOfFNv4Y08AIZ7+Y4ijAO3A6lj6e3eulsbe3t4duXOMA5GXf6n1p15H5ixiWC3XacI0qDgfj3qnUUp8zRpCLhHkTOa8JE3oTV5rAW2rXMWwp0bZ7A9M108KWrBnldoyTuIPt2/+tXG3/gW91DVZr3/AISlbQSuHCwgsyY6HOf0rqL3TpLuK3ktbuSTYoWSVlCOzLwXx059KKnK3dP8w9om7beZsWum+HbobmignlBLbXQEZx71xU3whtzq0er6FqFxHH5nmtbk/Mhzn5GHb2NdTJbgRociNs5wRgj34rQ0e6uY7uOMN8inJFZRnOF3BmM6copzhL7yrEEhcic4kPLL39PyqeS18kRtEVVAOwyCP8asa0+nXFyxjUC8AwxbODz0rBS91ODVwiwK+nuMMd2Qp7Ee9JJyKi5VEpJWfY2k1C4DbY8x7gRwMZHvSKhmTcjgbRyTwajWYsi741crkc8Z+tPtv3drNMIg0gz8q9CfapsJxUVdKxGVKoS5bYMNkjnHbiqOq2rvEbqwligm8kxrJKQAnPWvN5E1fWdYi1EXNypt7jdcSklUhxwIwvQ9Rnr613th9n1Dzra8QXSxkbkzx9fpXRKnya3Ls7XZHbeHLa3uoLu/vJLqRD5vlR4SHOPQcnJ55NLetqGsyGe6HlQtlBEOGA7AU/V7jUlkiTS7EXM0hABbhEGe34VqSRFWcdS4wB79xUuT3Y42jK73ORvvBkEsN5JYJCmpXTDzNjFAqgYAHp2zWp4P8M2fgfTH1HU76OUIDJLKDvfP93/61bKQbfLlmBSLcAzKOvtmuW+JXiSz0iFrGAeZPcqRBHEAfLzxlieM1UZTqe4mKcfaNQT0Ok8HfFW18T65e2S6c9pYQ2/2hLqSQcDI4Ydic8D2rSvIPtMkl3asJbZwCq7u/qK8p8HeA7X+znn1iOSUykfu0kZVBx9446nOfYV1OjeHxoxeZLyVbCLMge5mxsHcOxOAKU6VKMn7PQxhhY0JOUHZeZ0qSxqFWYgeh71mav4n0bQ7u1s726EV1cnhCu5gCcdunpmrsUqTrFdwtDcW7YKvGQysPqK53xF8PZbnxCmuW8wMUziSRWXLLgDGD6cUoKF/fdjSTjpd7nSXJQLiPOd2ASc4rk9Z0nxXP4ja40jWBb6Q4XdCeGQjqOnPrXQ6tocl/o6xpdSW1wjAo8ZPP1/xpbKGdYYYZ5Hcx/6sSHLE9ySOtOL5dUVdS91GhZb7SBEnkM6r6ryze59PaiXLSAAAoefrTgjBlV1Zh6EU9YQ7hY1beB26YrK5F0nciVNx2kng7cg81jeMdGl1eWwht51jhtHxICcFs46e9azgx3Man+90/wAaddzquDGUMgOCT/nrVRbTuirNtWKev6xJo9gIYAWnf5EBGef8Kw9J02SG3kv7lJL3UnG8IzcE+n+elam8CdJJVSRs8Fxkirv2hzFiMoAOcqMYqk+VWRr7Pl2RTsIZZLbzNVdI7r7wt4/uqD2PqacFMQJVmznqTkj6UFfMYvIxODz61dtrSW5wucg9SOoFDdtR6U1eTFt9KnuoRKOOhUE8fU1Br66Xo9rA+pXDCeWULEqfflb+6vt6mpPE+vzeHNNjg02ze+1F1xEnRQfc15L4fTWdZ8WyXGqzpczrxPdM2UtBnmNB0DduKqlTck5N2Ryr2lVuWyPX0giuCkqbkiLBchs59ajvVjWTgYiGSqnkk9qv3F5bm0H2IIkcabVbHT6CsRJ3AMkpV2PPPU1nFM1pKU9Wc+nhbVtUuZptZeKOANu3BuNvbj1rdhEGl2O2wjBizuJ4Bl9zUs8sl0hjLEdz7DFRR2vkxCPO/vvft+FW5uXxFqnZ3myGW9dwktzJFBH2XOSfzqdLh5GQxlWJ56DJ/HpisDxLoM9/Ojr86qmFUnA/nWjpls1hpsNqxLOBjI7+w74qmly3KSu7JGnJevtOxMsB1PQVgX13NcMI2nW3jPc8Fj6Af1qvretiK7FhYkXWpYx5aglV+pHGav6J4Ylkb7frLvJJ1WHsPc/4U0lBXkRNxitChBosbrjyhKV4LEA5NFWb/wAd6ZZ3b2mjaZeayYeJnslDJG3pu7nr0op2q9jJVe0WNNuXiRYJXVyNzMBwvPOa12uElKBx5bLhgQu7IHp70l0bdYf9EUYLbCQe3pVXUIrix0d722g+1NHysJbazD+6D71he5zKV9TnvGGq6los8Vzp1j/aOltkyMCS0fP6fWr+ga2mq2Xn2TSwKwwUbqo9DVDRfGWl6wXW1guYbpfllsH+WQHoT7iuqstLhS1edREJsE+VnB9q0k+VJTWprGpH4SvLasRvlkKHAKSZ4Ptimavd6nZ6Vc/YY4r+6jXzEgkTIZcdQa5fVvGdvpOojT7uxuZZGk2Lgj73+6TnH4V2OmtHMhlwThOEBIGKUoyjZyRb5ZLc4/wzqN9rWE17R7eJwchmjDD6bT0rsrK0ispFwAu/ooUYi9P/ANVGVWZ5dqLt5GB3+tc1r3im10JB9vjuJGc738vBPXvRdzdor5GiTtqzrLucSR7Y2V8dNo2sB7GnRKQmZ4ixK5Lg4OP61laDff25bpcrDLAmRtV1wSPXArZaWG3jdZAzqvUE9KyemhSaS01IT9lWALMiXC7s7T0Ue4qrqniGzsdPmu5mT7LEDsVPlz7KBUVrqEN45SG1mSNMr8/Q/wCNO1rw0NX00W9rOIZD0Kx7wpzzVJRT98OaO7MPTvE+ta/aRjT7WaBHYj5CAVXsAfX3rrrWyuo4CLwgMqgkhj1qtouhLocKK5DNEMABs8+vtVu9lLcqNzMRn5uppzmpO0FZExj7147E8GASGCiUqMew9Qa5Dx3d6vY6ppv2K4srTTI+bl5pAfMYnpjqfw9a6W1M6yohieQBSS2OB7ZrkfGXhs655BS1zNkYlPWH6DvVUbKepThdnQRaqdT1AeQIBaIu1kVOST3J7UzWU1KX7OtpIEt0J3FQCSe2KTw5pH9j2At2Z5XTLNIxwXPv7+1aqQmVz5RBcDgZwT9KltJ3iWkktTOnvxpmnLdarMEiH3329Py6Vo6NqcN9pyXGn3SvHMMxyjgj86y9U0jVprdkSaIIw+/Nzt+oxg1r6Ppsk1tEkcKKcbdqjYOO+B0ok42v1InKLWr0Jjb2bQyRXswRZjywU5H4iiy8P2mnxSfYdSlmZjuxKdwHsPSrN/YSWTr5gU5G0BG3ce3vWWXB+SOLEmfvA/zrJNvZmcU6nvQl+RaTzAf3vyq64U/j3rQ8PaZcTQyB5E81CS3ow7VkCZjbgMWYMcgmtzS76PStI1HUblj5cMZfk44AzRK9rIjFc8ab5dzkBc3114ourAx250qNAZWUc+Yf4T2P/wBerem6ba6VFfCLezXModnLchR0Ue1cd8ONaubtLiW7UJ9rlkvMD+EMRgk/hjH412dvLLfyCUIEhUYAPQ+9bzi4vl6GyV9yzeaubOxkkCeXDGMnAy2P7oqro97cT3g86ziiOzcke7cQD0J96g1EWutWMllp2oQPcLtdtr8HB6HGcVa0y0OnQqkjhpR87uQcufY1OijruTZdEYvj2N3S2ub29ubeGFSDFbruBDY6D+9Whp+i2ctqkjW3mmNQfMnw0hJHU+9Lqcd1qM9u6yxCONizqy535HB/CpRcSWELyWts87JwUT+L3ptvlUbmii4r3dGatm3kBGZ1YYIHtVLX7S312waw1Fd9pJhmIPUg8flWRovi/S9XlaF7Wax1GNiGWQfKcdwa3RtkDMpXcTuHPBqHGUXroZJJvmaOA028k8G6zL4f0HT7q5jKmUTTPhHyOTjH8q6Pwr4k8TXeoXFrqWni3skGUlCEA+3J5rWaEu0TmIfITy4BI/8ArVoR6hIqLGAjZH3l5x+FayqXW2o6kU1tche7IugmQIQCGHUnPTPpRJIoTbHGCwBAX1NZcOn2dpqF1d2wkFxcYEryOWyOwwemKvRq+AN/mHHygHOOeuazaRXIkrhpuo3l1HKL+1W1cttAzyQOhrjPFOta7bfELRdPs7lYbB0DsijBc85DH0GK7J/MMnVnfGN3esy8sUn1y3vWRnaJSm49Vq4NKVwVOPY1i583byePmcfrioXYGTgAKOnsP8acSchMjOP4a8q8a+K/EUfi06Xo1tPDFBhSEh3vK3XPQ8U6dN1HZFrQ9Rew86eGZj/q+4Jxip7oKqxpFkuxxgd896xbfxALTTLa31WREvXQb0XqG+ma0Fk3bWSYsSud2MZqXFp6glJu7LiLDEFjblv4jjP51MLxoLjG5ViAy+Bzgjiq8BLyIsQLMvJ470y8VhdSMVManG0Hvx0FRoyHFSdpEGqxi7hdpmaNJP7p2tj0B96pW1klrbBFhWKH+FAuAT6+5q5dSKqG5nZVjTGPMOAuOprHtNYTUr14bdZZRtyHxwxz2HX8a0je2mxvC0Uka1tG00m1BkdTUs1tiZlDAkdSOlSx2z2luBKwE0nO3P3APWq8kmSFQgMeCQalO+wlJyd4vQc6LCeTkYz6YqCK/wDOdggO0fxepqlLq1vJqA0+J/Puv41jG7YPc1qlEtUyxQN0CA02mtwutnuDH5SWX5scljzn2rK1Bbu5jjhtAFL5V3zjaPQVoQxyXEoQNlxgufT2qdnhsnLZ8y5HygLztpKXKJtLRblGCx0rwrpb6lqs0cO0c7hyx7Ko9T6Vy11JrPjRxLqDTaR4dJytqpKz3KdgxHQH0rpL5I53jk1ARzvG3mIJOQjdmHvQC0itK2drcByCT+FaQdtevczVC+s2ZcGmW1rbxw2FstpAo4ihXGPcnuaKZqNxfG6K28U7RqBjyRn8SaKtJ9wlKKdizJJKkSIsZz1I/hB9fr7Vb+3O9uyiPdkAE9CB64qvfXqTsZUUwPjA2nIOPX0NYfiPxSdGWyuDpsmoWrZSWeEgGNj2IrFRcrKxzaaNmg+n2VxqEWoNAn9oINqyqArEdhx1NWt8scglhGWVuATk8VPon2bU4NysYpOGRWGOD/WtGXTreEpcTBpMchkOD19O9DlrZlc0VsUpxBqF3DNqdnA1wBwWjBI9OauS3ltbsBLHFbRdAyMOT7VBqOmNqFqY4nmEbEkMw4+h5Brg9V8BX/n/AGmG9YPFz5KgtgjoeTThGEvidikovZHfzYf/AJZGSJjlHB4/GoHCZjXyo+vzBl3k+3NUNHimstMimuSwl27ypGMH0x2rb0e+ingLOiiRyPm7k56iokrLQq+m1zH8YePbTStMfT7W4iXVNo2x7fuqOxPauX1XVfEGp6PZXmmyJp/mxgyiXAO48fKew7j611OvaH4YjguNS1ZbWKWEmV3YFmP4d81lWL6F4msIojcz2losgEZlAiJ54x/9ataahGN1H1M1OFNPoQeBb27Jms9U1mC+uz91BLvMY9d3YV3GjeItNur6602y1KGe4gUNKsJ4X/gXf8K5nxb4P8KaD4ba4lnnsomyshVsvOx6DjB/pVLwEmj21vKPDtisePlkncFncj3PAHNKcY1Yuav9wRk6ultDsdQ1zR7W7S2k+0vduQAVQkAHpn2qUIJAwiB3jgH0rK1O5ttKRLm6eL7S4+QnBb8PYetW9NlknszNI7yIw37UUEgfWsnCyujaKULpO5ga9aeJNV8uK2vfsVivysg4dufWsPWtB8S6hOtpFqK2+mSZMkwcjPtjqa0b/wAS6zLqscFnoYWzU8yM+929yMgAV0g8QW0kEFvdR2dvdyceSZQWB/2RnrXQpTglZII+SMvwpFp2kY0myuZJ2gOZGJyzN7+n0rNv/iDN/wAJCNJi0ZmQvsMmSrbvQcYrrtK0rT7Sa61CRPI8gebK/c8ZJNc1ql0nxD0W8GmSXVghlKK8kW08d+OcH25FTHlcnKSuu4nrLl7GxqfiCy8PWH27XL+OCFzsSNxvdj6BR3Hc1v8Ah3xjpGqWr2+mX1vJdogkVUbB2n1HUVwkvgLSL/w9pWn67LdyXFhuC3COAZATlgevHHHes3wh4An0Dxily88As4VcIyklpAfugjHHHXmk6dKUXd6mc6bqv31oenXjT3yTSJcRTXQUhE8wAHn2/KuRso/GEGpKuoR2rWwZgfLQdD0Gf61ha14Huv7XF/4cuXihnLudkpDxSkjqDwV68e9db4as79oY7fVryOeRVCu6kZb/AOvRyxhG8WmXFNaXsl5GlEzGMiUbMdVzyvrU2oRxT6BfW18N9mYjJszguQO/tWrfaPbvCZbTlwuG5yDWZc2pFkwuAzP9zHT5fSsFJNk+0hVWjPNfAtkbiKW3t/MtoJrhpsMPlMQwq4+pBr0O8SV9Pnt9NH+lMgQs3CovrmorG2itFdY42ULj5s4IHb8K5bxFJrXiHw/eweGJRCqOA0zPsJwegY9B710OXtZX2RpJaamvpejR+GLaa9unSW6eP5njHyIo5A/+vXJaxbp41a3udL1CW3FmpNxbSS+WUJOd5PTpXceC1vbPwnZ2Wr3MGpXRYmRl+dTGR9wtjkj1rP8AFPhiw1W1WGzgjt0Db9kagLkdC3r/ACpxmozbb17kQ5ma/h/SHg0qOJrxZiB5kmx88Y7e1PZ2gP7mNJFJALMcYHqKz/C+gzaYsXlTyXUyptMjcZPcBewrSvb2ys/LGp3cEKvkBHcL37e9YvWWmpSfLpJlkGJykjRQFxhCWX5hTrvUbC1kU3HlwxHAO58An2/wrOuLyyto/NutQt44ecSudv0rD1G30nxJbpMt3DItu4YPE4dePUetVCF9XsHJGWzOj1ZZZos6Tv2uMpIRnn0Oe1cvNcavp5QX2oaelw3WKQgbvyqpa+NPslwbIBCrEhC+QTjjIp0Xhc6yyXtxqEkzuxcyGAbV9hntW0Yez0lsWk46NnX2wie3hNzPEJGABYuNpb2JqxcC3sb+G3nuI/OYZSNedwqto3he2j0uJZpDPCpLIHGQPoKRF0xNUkm2h57RQpkbjauOlYOzbsZObk7RZszXNmIi0bN5mcFMc1Ud1b5tu3jJ9BUCX8GoZliKfIcKwHWoZSQArZC896nl7jpU0Z2raoLZvkcK/Ud8CuBTxBqt9cXP9jwuGGYvPcfO7nPTPAArsF0ee61Ge4mZf9kk44HQe1Y+pW+ji4t49Q1K5uoxIHS2s1xEWU9GfHJyegrrpcq0tc6JSUSx4e8NSB47rWGS4vCAQuSSW9WP9Kvaj4htLK6Fjak3epFivkx/Mc5A7fWuiZRLAsOBC83ykqfuZ9D61WEHg74e6cL6eOK152i5cNJLI56jPJJPtWXtOZ6q76Iwq1vZrRbjNFg13T5y+p3ca3MwJW0jUFYR257mrtxKNzPPMWlxyzfy9qgt9Tt79v7UtZFuFnH7sg/Lt9jVS+SV7aRIgrXDkKqk4qWrvU0pw05pbmJrlzdalNBFagG3LlfKcf6zHtXTaPZx6NEXJWa+lAywHCY7D2FR6NYQ2ime7cGZsKzAc8dlHYVIXUudh2ZyMZ6CnJ391bDced26El5IyHOd8sg5weSa5PX9alWWLSdIUPqVyOfSNfU+ldI0TOjBRtj6Z7t9PSsq30aC2uru7toma6uTucg5Yn0HoKUHFayNYrSwzRNHi0aMtPKsl+4/eTA4C/StLTxbySvDbyxySAZKxtnH1qPT/DF5qmZdZn+y2ysR5MfLMPetW+uND8Iae7QRxwI57Ll5D6AdSaJT5nZas5XWSfJTV2VZRd+UYYAIYs5Lsccd+O9IyiOMO0n3fl46ufUetYnh/wARXviK4vJJ7XybSNhHDuxyff1PSt15/wB+XTKkADcQMD6USi4uzN4qW5GIU2r9pBB6hDyfbNGJJW2xhliHvjAp3nWccplv7rYDyR3am/bku0aKyg2QA4y38Q9SfSlqDnrbqBuRbqI7SJSgzls9TRWbqesWenTLGyPkjpGhP4miqUG9eUiy6nNfEHxJb+GdIilOmtdi5lKIxbaqgdQT61fu/ENrp3hew1D7NM9vcxB0t0j+Y/71aTJb3tmbTULSOW3I4SRNyb/X2NXLadRb+XLukSNcIiryAB2FHMkkrbHn8s+bmvoYel+KtK1qNEtUltZsYMMybXXPX6irmpXeu2MiNpwspbMJhhJw31yegrnB4mS514RXPh+dfKPlrO64L+mOKm1Hwbeazfyz3Os3a2xUhIAh2RKex5xWnJGL97RfebJ8yszpdBvJdRXZPd2zHeUItnyqe31rGu9Y1H/hKrqzYxtbQAARqw8w9sn0Pes7wp4Gu/DmstObxpoGxloFIL47e1dRoXw6s5/FNxrx+0pcvlsStlQxGMj1/GplKlBt3urBKXLHyNaKFJ4lDzDjkBhyfWq2oQNdWRgt5RC7E5OO3tW3qWjTWimYurqOcqOR/Ss7T0RS8kgkfjAG3t7+lc8Zp+8jRVIzWjuec6jp8HguK41W+ufOu5k8iGL7wdz357964jTdE1PxJeG7aWVirCRZMEruHIA/GvZPtej+IJms4oLa8CNlhKDKFOeo9DVo6b9msXWxYxOG2j5QOM9FUcAV2xxDgrNe8F1a9rmTe+D5/Eui6Lb69czGXT9zSovy+Yx6Z9OK6GxtbXTLOK2ggEcSfKqouBj0FS2ktyLdI7hwZCMYHUfU0+9vrPSLCa91Rj9njHKDOSfQH3rmlOT90qPuK9jgNQ0K4a/uPEGvt9skD+Xb2sJIjVewY9x6itjwXqmoX/iFo7pFtLaNlC3EjbIjx91V71zGueP/ABB4muF0/wAM6OttCOQ+PNaIf3mJAUVoaN4ft9AthrXi3UXvb6EbkUSGRY8+gHU/TgV1Si+W09+iM5+/o9D0TV5ZriaZJUAjJKDaAML9R61g2PhPSbbN5bWgF8SDuZ97Y+p6GmaTrltc6ZJfyq8FlCuTIwycduP8KoeGvE+oeItXkjtNGns9LjY4upX5kx7Yx+AJrnUJxTS0sbe7GKijtIbuFbWSxNkimUYXech/c1JKsJiUWELKYhtLgYz68VHIQlu6GWNZMZDNgYHrVHT7UQ66mptdzhhGUERP7vnvWKSd2Q42vKO/5l97i0kO2X5JFGNxGAfXFKlqHCGGRnfG0dwR6GoTbKYwzTq0gJ2+4PakSKeDb5LHd/zyBzQXZW0ZYmiEduyopRiNhyc7D/WuIlh1VIru2e6mmeVSolxlVUjkj0rs0jka52yM6SHu3Iz9awINeuLPXrfTNViAjnl8qNxEcr/tFhxtNaU7q9tSZNRWrOR8Anxt4Ru22IL3S5DtdWl3qR/eGeVNeny+fHLLksBKRKuTkKp7Ul3aArvhUqDnBA4NNnkijspnm+WC2hMjMT0AGcUp1PaO9tRKEE+dfMi1J5hpt0IJEeRYX2sB2xXE2P8AaGuPDYwgW1rcfMEX/lmij77D+Qq/4Y1U61HeIku+RTHIV6EqwJ6dq6jSIU0+bzpVEkkiqzbQFJx0HsKvWlddRzV1dHO67r9z4eJ0/TNNe6nSBREx4XuOnfpzXI+HvEWteHb+ebxPPK91OS0VjIwJYnplf4F9K9t1t7K+05ZBbqbrOFJHzL9DXmniDwomlrNr9noR1DVN4kMMszfiwB706NWDTjJb/wBfIzpyVSN5qxFP4l8ZXnkstjZ6faM6lvk2ZHcbj/T1rQ8UeFbHxKYLy4uG3KcGWFxg+3tVuw1vTfFGjRxsm26jb95ZM+XgbvzgZrRXR2bT3TT3UOjZ8onAY/UU3Lle3K0XDlj7y0K2oeF7HV9JWyvgZjHEEhdX2NgDhSfwHNZOmaH4N8Iagu+7nt9QlAR4nl3RsT/CTWv4TsdTTTHTUpGDq5OG5ZPbPeuC8f8AjnQZpvs1l4ee91iB8NNcxsq8f7I5NOClKTgndeRFR22b+R12oKRNqNxfaNFDHakG3lRtyzJ7r1BFc94PubGXWN1zdansmfAS55Uf7voP6VpeCfiXp+o6hZ2L2hguJiF/eOPlfHKgHt6Z5r0DXobKQW7R2sIu0fdvRRkUpSlT9yS3CUm5KFjyb4p654pk1cadYJdJaZAge2XAlH1FekWFr5+iF7iLN1Hbok5HO9gOn1q9p0G9l+0RO8IOCCvy1x3gi71HUPGuv3rXxGmRSG3htUP7tSD1x0zx196TlzwslawSajpBbHQadZiK28uCIoqgswxzk9qRSAfm5JHftz0rWu5444JUiwCeretY11cwW9k8s8gEagMXPGBWUbtnRTk5atHPeMXkvbZNKs5WS4uiAWXjYo7fjWxpemWtjBAqRB3hTgsPlj9cD1rndOuUur6fV7xlt7CNcRs4JLHsB/8AWrpdKs7vXNs15BNZ6a3McGcSzj1f+6OnHWtp+7Gz2JqVIx1ZJFdo82y3JuH6naMj/wCtVD4geFIPF2hwQ3d1JBNAxkjdRnBIwRj0/wAK9AkSCztUSGCGKNRwiKBz6VyeoXTXEjAnEYP+rX+ZrKEm5KUdDGnJ4l6rQyPD+nw6FpFtp1kCYIV2KzDLue5NaEY2vl8h8Y6ZIJ/yKfFGSQed3TI449BVy2somf8AfSLHGoyfm5Y+gqpPqzscowVigVVwwyXcHqewqykCQweZKWXHYDrWJbeMtMvden0PTYiJowSWYcEjrW9DKcq7IGVRuBc/KD9O9KUXHdEucpIh8tlYO+7p0NXIiyRoy4Qnvjms3U9RjgXzbmVgWbAXGS59AK4+bxbf6jfS2ul2zKg+XzSNzZ9gOh+tONKU1cJJtaneXl86blUl3PUdxXM63oMOvX9vdX1zdbIODbxthX+pqxolteQQMtzK7vIc4c7in1NacgSCMlmAAHzA8CmrwfusqMYpbakMNulunkwxLFGBgLGPlUVFOJ5UdYtqKP4iO9TrPHMAYmBRRnK9/pT7YIqlmRioPCE5LUtUaN6FPTtFjup2ubnDKg5kfnJ9AK0b0RS+SEwIo1wI14H1qSaZnCBiII+AFXrTLuZILZvJVZZQMjOOT7CldvVmGt7sY1vIuDbwgq3JLDk0Vx9+PGd1OXs2gt4ccAnk/nRWqo3XxL7ylc1rm4MUO5QdkP3UHv3Nc3YeLXvNYgtbWxkVXbY8zcCLnqB6VpWesabd+YLHUba5k7LDICcfTuKq+JbwWFtm9s5pLGUAGSL5QD2zSiktGtThTTWh1dzbrJG7vIJQpyrryG9/aqd7rcOk6RJqE0U06Jx5aAgtg+n41N4N1XTJtLjjjV2YDAUjDA+4rUuIhcTFSY4SpGN33yO/FY/C7SRNOba1KnhDU11uMXNrHNAhwfKmOWFdBf60dPkKfIWQA7FHDjvg+1cB8Q9Gvb+wgj0G48mA/NIYn8vJH97HJHsK4dNcu9I0STR9IguLzUnclpwjMiHttzk5HvVrDxq+8vuHyKestT1D426/qmn+HIzoNxAjylTLu++FPQr6mvN9H1rWPGFjbaXbao9rqqIfP83I8xexyO9dJNY6nF8K7u78XxXWsXKzKyIf3LQZ4ByB0HesL4X2d1BqWoarcRBV37fO3FsqB0VjjPufatqKjTpNK109zKnZRsjv/D3hfTvB2h29oJTcalOS00qjDvnqPoK0EIcFjuWNePnOWP8A9esR/E0WoSu2n7SB8ryhst9B6fWtiO4t4tPEu5UkVS2ZDwG9a5pRlvPdnTSXLGxI8yIyh0JJGVGcDHv6VYmXzYI5Z7UmEkE+aQVP4VxLeKo4bow6PC2o3x+cs6HYCe/rVvTtN8RX939u1u982Q8BI8BY/RVUdPxq3StrLQq8rjvER0zW7qPSNR0K+gjT94JYZPKjJ7fd+99DQ3gbTJEtoNxjsYCS6zOSWHp+PH5V0z/ZNMjjm128WNiMBHYZ56delZ0PiLR7ydo9PullZjhgnzbfqfSiMpW9y9hRUU9PvJL1rez0mUw2lvJbxps8mV/LG3sfYVQ0u51cXRaWxs7e0AAijgfcNp7k1T1yfRdYRdIm1GPddHCLHJh2Ofyz9awWgTwkRo2hXF/fatfgJCt25KW45+b0HetIQurdfM1aje99Dv737Pcjy5ZPLb2YZ/KpFgVP3VqC4PBJb9cVm6NocOmxwvKJLq7I/fXEjdWPXHoK6CSSbynjgSFM8HJGfwbmsJaaIOZrYba6e7y4fAUYIXOOavy2eJZPnVQThcHg15L4lu/Fj+IpLCG5m02JQDFJJhhIPVSAfyzXRaTPqdkqQ63qkd6WXEeFwwPrwBxVyouyldEPmm73OxlsrxcZUktnDpzj61K1pO5je8WJmUYDOBuNZsd/L80UN0RIqbnjzgkHuPap4nLXAMZCStg9eGNYtMTjPq0SXJ8hjAVZBjAR+gz0x7VQ1+yfUPCWo2kfyyzjyuDjIx/Kr160kkoZyXdAUj/HqM96NVuI9KtWed0WGGPe7ZwF4oV01Ynol1OJ8H6Dd6LcRfbZYi5jWJY4+dig5wW7nP5V0t1dwwG5kkly0P38fw1z2q+JLO28ONr9o++MnyrdW4w59u56nmrXg+wlt9KeXUYhcTX3zsspz8uOhB65rpmm/fmaqVitbeJ7bX5JLbThcQTQkLHM/wBwkdcGtq81O5021UzwXGoNKwG5DkR++azXsdF8N2jXKwC0jdgfLh3OST2UU/Ttdk1CVINP026a1Y/66UbP0NJpPWK0E0tmWbHUNETVJESS2j1NY97iQLHI3qPf/wCvVM6y0vnOkcamEnzFL9R7etaeqeCNB8Tyx3Wooq30eAJrdtpOOzDvWvJ4N0iy0qO0CjYDlSzHdz9Kjnpx73M/rEIS5WYNz4muF8G61qGm28l1NDGphXGSSwwT77a8t0nXPFOiWRuLnR5tQnuMMr3ER3qPQY5wa9u0qxms3SCxiPkr8qorYI965/xhqXifQtTuUh0M3to6h47sSsMDupCjg1pSqRTcUlr3Jc4wm9VqeVab4F8Qa/frrDWsWjB3LLuyrKT3A6969i8M2EmjaNb2l5JLqNzGpLynJZ+ewPaoNJ1yS60x7/VrRdOWBM7nlLjHc89ar+CvFzeK9Vv003T5IdJtI8NeTN80kmeAB0A6mnVnUqJprRBzacz6mr4k8XWnh7Shc6nKQ0qkw26/KxHpjtXM+B5JY9GLpZi0ivJmnCs2ZXVv4n9CT0rZ8UeFtL1ie2m1S3MtzAdyndj8x3HtSado7y6u11hvMkAhhQD5Yk/lmoTgoeZrThFe90NS2t7m7LGNGYgDCDqBWdrmkLeBra8DpBC4Lqf48dv1rtooRpKG4mmCxouAoPLGsaG2fUrwT3ACxFtxOe/tWMJu9+hEMTzNv7KJtO0Wyit45poonljGUDD5Yh7D196RNQP2suBuRhtDn7oA7/jTPFOpQ2Vg6kja2FAzyx9BWDpslx9kH2o7nkOevQemKIxclzMmjTdS8p9TZ1G7a7kEUHToZM/e/wDrUkmkvFbPPIyLgfKAeWrjfHmq6lpfh/bocMkl7OdjSqmfJTuVHrVr4dtqq+GYLfV5nnmaRiC77iFzwD79a09m1DmTN+ScElDRFLUtT1O8llsvD1q014uB5pGY19RnpW1oOg6pp9ir69qUVxeE5XauNg7gnvXVWotbG0JUJGgzkLxk/SsS8ujcku/JPAX0+tHtOZWSsvxFGpOrLTRIpxaXptldS3kVvEL2fh5VXDMKshfMwGYZB+7U9tb7iu/kn07f40msX9ro1q77czbeBtyxz/Kldt2WpbnZ2WrMjWtFt9UuEa5dktUG3ygfvGp7LT7TTYRFZRpEqLgADmuZutUuoQt5rEyrHIf3NugO5h6YH8zUOkXGra1IzqPs+nH5l5IJGf4u5z7Vt7OVtXoWu518tyIYXkG0KgLMVHTHtXCavqN/4ivXtrG3c2gIVkzh29z6Cu1srTy0YMdwbgR56irVqFtozHbpHEgyQoHf196mE1B3tdjlzP4SvpemJaxQWwLZC5ZicgU658TeHdJk2PfRvedFBOQD70++W+kgaOzAPmLhmYH8q52x8J75RJqIhkk27dipjP1NJKMtZslrm0b0JPEMGr65YrJoerW0LMSWdlxuHoD61V8MnXLaOCLWY5ZLiMEMxIbPoc967Ky0mYWoh8iJIF++zHAX6e9O+yYlWLzFcjgkNnimqity2JU1e19ijPqMNuVFy7hyM4TnH1oqtd6PI87PEZFDe+6ihRi9bjaRyOkz+A7fxQ11pECi9cbStvnyznrgV213qCXEZCRLsIwoKZ4+lcl4HuPDd6ftdhYQqFzG8hiCk+3/AOqvUPsVtc20ZEAKgYVVwDWdeShJXv8AM8luNKS6o8zj1jwwmoXGnXF39kvnGxsIV5PbPb2rEsfANvZa2L3TdWv2AkztmbJHPZu9d54r+Fek67qC3q/abK5wN6IMpJj1zz+VLp3hm80W0P2lFWGI5DM4ZQo6f5NXHEQS9xu73RpCcKj1OS17xdfWV5Np3h/Sxe3kD+TLK0ZYK/0/rXT+EtT16ztzLrsdlJPglobaELsPuR3xSXy2sUp1C6ALkbVeNPmf24607w9NqupBsaf9igPESyNmQj1PYUTcXDZGrjzK0mb1xrlxcRmPy4xbyJyHXcW+orifEugy66kQ+3PZW0YKypGuAfSuskspIk3yEhQeXJBGfSp9Jso7rm6UOu7iNlGCfU1lCSpq8S7U6cXJI5DRvDVjpyj7KJZ3CqjO55Pp04rUkszPthmXzAx5VunHc13lz5EFqYo4k3gfIqgD9e1ZMmnskTSyzW8JIJyRgn6VPt3LVhTxKerVjCg0+2sUMKxGDdk4jHLf1rYtb37LD5cds77gOowRWJZ67aL4gjsLWGW6uIzteZoyI0+jHqa6W71PS0XekSyyKMnIwB780TUr6oJVOZ8qjc5DxBocetXDS397PGhQx+WIwcKfQnv71nxX1j4WxZaLYi6dFHmQrweR/EfU12yanbXwCi2Ub/usrdaxfEd94d0C5Q3wma5IDyPDGWKDpk+tawnJ+41fyLc1HRq1zM0qOxvJPtuoeEobO5X5o2LBmH0I6V2FpZWt3brPBG0E3q3zZ9q5i38W+EwI5LrWYRHMcQgljkjuRjI/Grlr4i0rVLgWeiSyXzSPtDQgqAM9ie49aKkJvWzX3/qTKUY6RdmWNS8Oy/bGmneUxP2DfLgjBHsKoaD4JOi3dxd2t3JJaSjiAvlIj6geprtoZLu2gnivrcLb7MRuz5LH0I/rXPyW6ALLAXXPOGIB+gI4NZxqSta46VSU9NPUtLPC8CR3iC42cgY5Hriquo2EE0nmwJ5sQHDYAYD60mY43P2idEbaCdxG76moIfMtQoikMlvIWO4YZfzH8qEramqik9Gc7438PX99Npmo6NcCG9tHU7XOAy57f1FdAzM0KuocMoGWHr3I9qtRskibVkdQRgAD9cdqbcj/AEaQWMYe4VSY2YYwxHBx061fO2kn0NFaPQ19Nt5XzdTH5I18zyx1Jx1rhfiXeS3vhe6CoS9zKiKhXnJPQiqXw90vXvCEetax4suZM3o2eQ83mOWByGJHAz0wPWrumJLrWkC81ZnM6XMksSqu3HYL9B61cYqE+a90jmpNyk5NehSXwg2sW3hqwM8UVpYktdxMfmlY84Ujtnj8K7m4AYlIUTOdgx0UDsB61CPP03w9bnT4Bc38igSE43Lkc1zFzrst7rVvoGlyuJwN91cpyIcclSfWj3qj8lcIO7bXQ0NU1aazmFrptpb6jcfeaGSdYmX0Iz24qrp95rAhub3xLGtqDxFb237zr/ep+saOviLWrO41DQrRPsgPl3yTMJfYMuMEH/8AVW4FlbckcMIijUAkMSWPcY7UXiklYtNybb0Kmo6hbWOky3n2eeUSMsWyMjIPqPSqXhq/8QXupXi6nbGLT2A8gkfMAOhB75rbFiFQnllkbOQOPxq3GJEliLZUKuFGPlHvUc6s1YJW3TuQeJ9bvLCK3TTFjFyf45FyoHqcdfpXnNz8ZvFdtqh02W10h3IOH2lVA7MTnpXqF1BFNEyXCoyA55HQ+1cTrPw40XWNXS6lF0FCBGt4mAQ47njP61VKVJaVI3MFRpSXvLYzfAd9eeJn11tUvrbUr+aNSbSPmJcZwR2A7YHpUereBPFlz5LjVrfS7RW4gtyUjiHrgdWNd9pehWujQLFpdlDZpgAvFGAzAep6mpp5GxiRyCP7/wA1N13zXhoaqN/djaxnwQHT9Ms7ae7a4liiSJ55PvPgY6etdBY3NrZRMyrJK6cKq9ye5rBU/N8q7yRyT0JrQsfOjUqkYZiPmdhgCs567l1qa5OViX9xPcXRnfcTjAB6D6Cia7Wx02W6vz8gXOE4A9B9ahkQGQBhnqTg9ah1JFukiSRQyRkMqDkE/wBaSS0Q/ZppRRzdpBPq14b3UnyFP7iPsgpuu65czzJp2gJ5t23ytIF+WP3rau7E3tsbaBzDk4YoOg/xrHeKO31KLRdHkMalS97cx/eXHQBvc966IyTd2aStGyRVsrO/M0mn/b2uCObycHIj/wBhT2PrXU6dcW1nbra6fGNkXykgcD1we9ZttaCa1S1sEEFihx5nd27knufetCCyt7LhCbiQdQfuof8AGlNp7k2voyafc8wd1xnsp4x9KfHKijG1snvjimMWwVUAY5JHAJ9PpVSPVbN78WaTo9112AZ4x+VQlfY0drWZfF3IrDywVTp05xVS4tEkk81wSMZGT0Ge9aU32fT9Pe7lEssi8qPU+gHSuO0my1PWdf8At+sTOtuBmCxQYjz2GPb1PU0QSd3sZKor+6ifWn0hJ4ru9X7TOqkRxx9CPU1lWGrajr5/4l9ssNsDtxjZtHrj+VdlLots92DcwQFm+8uMn8PSt+00u0trffKqRRrztAx+dP20Yra5M6sYavr2OZ0+wS3dNqs0qg4LHp6k1qxWfnTDAyQOnpU011p6yOyhndv4uv5CmtduYWjjddhP93GKzbbBynLVKwrQCAsPtJEn9zPAqJJFtcPGiGQfxMM4qrI4QrvdR3DHqabDcWSyAm6iMjcFEYEH60WK5dPe1OJ8X6H4h1+6TZqO20DFgglKjB9QO/pXU6FZXVhpUEMziV4k8tmQHLe9XFlij815EjEak84xx9arC8imJMEpMYP9/ofStXOUo8vRGltbJWA287gEnjsAaKlUE544PI9aKnUqzMfwVaeHpLT/AIkuJoFbcE27VU+471b8eXWvrpTWmhQLDJIMfaN3zKvf6Vxfg2312ztoxeSxWyYz5UKbSB2Ga6qeG5uyu66lJGCNp+b6HNOUbVL3ueUqWt3qcx4c0zxN4ftbie/1q9vCYy62gZm3N65P9Kq6dH4k8STeZrOoTW9h5gMaAEFx6Aeg9TXbrvi5D7dnBJbmpI7n5gCd3OBgc9eue1V7R6uyudKpRtaxJBAIYgkWMxqFQsMlR/jWnb3yWtt8pOcFj6/U1l397b2KSTXZMi4+WKM4LfjWTpN5qOs3R32f2fTsMHDjA/A9TWXK5K72G+T4bBeeIJNQmSGDJhJ4GCS+O4H9TXRQNIYFPmbJVUAx55H41Qs7KJZFSCBQ7nAO3mt2TTmsrFrm8DsPuqBxu9qJyjsiZWp/E9ynG8wlw0oAAyzMc8Us8zXAQ3EkaBR1k5UemBUKShy4ji2n7rITnA9RViKNWO2Q+YqrwoGMnsCajQ0stwhtWvH2wBpFXB8z7oP09aoeMfCRu7CNZryW1jZtruq5DA9s9jWVpviTxDY+Ihb3cbTQPKFS1aD5QnqJB6e9eiazqglgaIRsqcHeULD8hRLnpyTRzutUclFLQw/BmnwaXb28Kh2giPyeYMlh2rU8UaNpGt4/tSJOowy8CT0DYqDTpooQTPKrDGVOaoaxcm53pEzQxqR5fYsff0HtU+8581wnSdSpddCnb/C3wlf3KTXNmpEZ3LFEdij2JHUV0GpWekeHtIktdEtYLV3XZuhGCg+vWuc0Y3kZulkuBAXXarSfOMnvtGOK821ETeG/EKQm6uLy98zzWYHd5pJ4U5Pyit40pVXaUr2CVCXtVKTuux6Xo9teWtnIl/qcl6Gm3gT8Mi+g9a3ZYd1sjiRQhGc9s+9ZunGS/t7WeWEw8bmiVc4Pof8AGrvyh2iLf6NKCMMeBmspb6m7svh0Oa8ReB7XXN9z593DcNtDNGfklA6Aj0rnNO1rSvAs1xp91dPPcysJTbRg4HHAJ6AmvQWkkskVF8zAIyvUN26dq43xv4K0/W9Ut9RjZ4Zto8yP+8B6n1963pTT92o/dKULvXqdS2r6fLaRzLKlsZFVwT056pn271f01YpbglkzHEqyE9pGPT8K4vWdHutO0+zg0W2a9+WSJ0lbhXbbgn2xnrmuw0i3ksdJihdmLNGqliOuOuPas5xileLIk9HEy/GNvNc6Zcy/fnQedAoOAcfw1leCXkh0GT+0sLHE5MQZt20dcE966e4tP7Rje13kAjbwOg706Wx01NN/suK3aW3IIc7iDkdwaFU93lY72skc3f3upatefY9MY2Vqozc3bZ3BT0VR6mtrRdJ0nRrSRLNSZJvmd9o3SH1Y0lnZ+Qm1YliCtkRRnt6mqY1VL7Vfs1kPPePiVl+4nsT6+1U3zLlWxXKnq3Y3JURTuCq+AGz5mTXO2fh+2sotRjgmu5RqEm6R5JCcH/Zroo7IggRKzyLj5uo5qXWVbSbWJTay3V1cAhHPCx//AF6zUmnZdSHUhGy3Kun28VhYRWwkd44gdmTkimXWv2Vvdx2bSq10/wB2Ect+XasnVl1u2tYoNIjE+p3kuGuJ1HlWseOWPqfQVb8M+GbbTDI87vdX03NxeTfelPpjsPYU7RtzSYvcW/Q0454GmzKJm7/cyMVrQ6nFbqFtbDdnq0jbc1Xup7HSrPzbowxKOdzNjP07mq8F2moWyzRRlBJyPMyDj6Gs3G+pjLlq6NO3qNu76aeYkMkTAFcIS/frWeyMrEOxdjzyBVya3jhGZJF5HIyf5VzniLxLDo0RWwsZdSvemyL7seehP+Aq4Rb0idUHGC91G7BGzMBnqMjHata5P2O1hXjLA555Nc8NQhsEhfUTIt+6K72seCyE+pqf7XHqV0z2zqQhwwBztP1olF79CH+9kuyHPOiyM8qYjA7nAUepqtcTRwxZ3jLHIdjxip9QsoniAuAoUHfsLfeI7sfSvIfGniTU9U1iKx8MvKzK3yFFBMjdNw9FHvWtKn7TRG0He76Hs+n2xmi8wHy4yPvHqayLTS7SyFzGmZmmkLyStwWGen0qfwzp8ui+GrHT3mklkVczSMxLySty3XoM1w019eax44hgj3/2ZaSFmWNjtYjIy34jj8KUIuTdnojODcnzP5Hd4VEwBtxwFXoB7URJucZIPBOB/OpIonlYn5iQfwH+fWnXJEMQUFUD8HA3FjUX6G/NbREF0iSxtbuEeNvvc9vc0WdrbWWZLWCFbg/KGC+3rV6201zGrksFfnYE5P19KkeOO3XD/K46EckUubojOVSL91aldIWcFpsuvqeAKdLLiNo4AqbhgMOtMnnkljEajbH+WaILeQyoqxsxxkHrj/Cj1C2l5DraPySstwUMgH7sn+dQa3dtMo3yGVe6Jwv4+1T3FrIybiUaTByoPAqrFb3UrkRwlkAO52+VB+NJNXuwjyfG2Z2lWWo6hcPNdRNbWcLfIE6y4/pWuLdmICFQAeV3cioI5lkYw2WopcSJ9/y5OF9hWbex65a38LWKwtCTiVJhtOO+CO9aO7dtgjJyu1K5sT6NbXZH2iPe4XAxkcema8m8aXa+H9WZ4fDs7zQHbHcTZSPjoVA+99TXrRluI85LAnooPbvUU8swjInIeM/wyLuWqp1HB66oFGV9znvAsmp6xokj+IrVVFwOAFIZl+nY0n2XU2kaLT7WOys1JBkl5kaujtbmbIYOAo6BRkVS8S2sus6Pd2trdNBPKhQSqcbPXijnvK/Rg4Svqc7d3ul6eyw6jrcEc+MkNJzRWBpHwl0OC3I1aW6u7hjkssnlqPoOSfxorfmpLS7MOat0h/X3HZJPsjKeUN3TceuPSphk4VY9nA4X+XtWbF4t0DUdQFjpiXdxgEvL5RRAR71pW8pBDxHLk8ZOcfU1ytNbqxEHzapGdqWlXV3eq5uDHbIMCMjjPr71cMN59n8uzAeZiAWcYAHc1dSQO+923AckAcH6VT1/xnaaHD5FvZ3FxeOPljVcAe7H0ppzlaKRbbjstSOz0ZpHMj28ss4+9LKpwPoK1b7RdUv9PjbT7kQOhJC5Azisnw/q2q6jbNeXokgDDCRlMKB6Y710trc3dvGscp8oMN+AME1M3JPfUhqTjpZEHhpZrIxrr7JLfhSDOBsDfhXFat4P8San44ttR1DxMbrSoZfNSL5lKqDkIEHHtmuznf5ld2bJwW3AHH/16mW4KWzAxB5WGNxIKj39aIzlFtrdhOgpNSeppadaC5sniIj3FuHkOCtQXekvbOBKyuhONyGnaB5shXfIMbegHb/Gt/Up4ILJ1Y+WdvG4fe/H+tc7coysYyqTp1OVa3OZW2EMAlkIl5ICrnioHnd5A6ElGGBtbOcVIlnPf3DSu/lIPmODksR6Ck+1wW94kdzMwd+UVlALH69K1/M61Kz11Yh0m6vrVxbTLDctgITz36msrQ9L8W6bctH4lawvLAg+XMXHmhs8KuPvD6810NzdqsqtaxjL/e28liPeuFk1/wAdXGubL3S7K10dXKgSyKzsOzKQc5/Crpqck1pb+tjGftHJS6Hbx6OpTzZFeCGJSzOTkY75rD1uy8N2t9/bV5ZTXUkaqqCNwDN6H2/Gm+IvHkmn27Wd5pcksLJ87QkgsP8AZ4PNWbS503WdCt5UtpfKfJaO5XDBf8c04xnH3pbFrnndT/AWz8caUJUtoI5ra8uSUZJVxsI/hJ6fSsrxfdeMY5oH8MLa3VsD+8t5FUEAe5I461qf8I9Y6hbvFOu8NwuTyMdCD61uXcFnYWyNPl4mQKDuyR/j0ovCL91feJxjB8r1Zz5mu9R8OyAxtZXk0ZIjfnY+OmfTPeud+Ga+Ila+tfEUMiWoYNDJN94HPzAHutd6IcI3lSEiUBo8t271z2q+ItP0zUGt7tmFxEnmtEvUJ0z6fhTjJtOEVubJpolhi1JtbvWuJUaylkIiCjG1R0rpQsL26STTBIY/vAnkn2qJQhbLDdGVARgeCGGc1gKJNQ1VwFKWNufLjJ/jb/AVD9/cn40kmb4uI9srx8Kw2r2wKqHghQxZz6fyqUIIkckABOckdcU2e3mNtuaN44yMk42j/GoWhUeVbHHeMIfEl4lraaDIILaZylzdBhvjHoO+MZ6V1GhaNHo9tDBYrEkSKOTzubux96LdGRkkKgJ/dBzxWqPLPyJy2OR3rSU3blHVdnp1LASS2m8wXOwzEKPc9sVau7ucRrHdLAxU5BJzz6getUJI2V1B+XuG6gH2qm1tLcXHzM7sDzluOKxa7nIqUZu8mixLMzs26MbWOfm7+5+lYeoazdKv2HSIGnvmz++fGxfcVuz2sQtjCxDbgd+w4GKi0+3gszkIW9Se4/wq4tLU00cdDm9M8G3Meqf214ivG1C/jTClm/dRf7q1reIdXSG28u3mBuH4VgMkfhVvUHmu4isTL935QOn6d6ytO0qOxumu7oLc3LEBWYH5PbHrWilze9Majpd7k+nWFyunCXVmL3M2Byfur6f1o1W7sPDnlJahLrUJFzFboASCehJ9K3pgtrG891hVQYxnrXFTajoUpmvNLzLeNKFkyuG6/njjrSheTuKMnPToY7Wlw1xO11L9o1adzJtU/LCSe5747CtnwoWSa4tIYSRbgZnY/fc9TWnbWVpp1jNq+ry29nD95ppu3sPU+wrkZNTtda1BH0O5eTTLZ/PXy/l3kd2PXrxit03NNW0NlKL9yBd8WHVNauxpOnr5UTruurhvl3J2RD71NpWkWHgnQLnU7uPddYDyMOW54VF/lV/wvBcSCbUryM+bMxKKzZwOwx24qh4m06fxjqEOhw3Hk2gInvJ1YM20cCNVzwe/tikpa8l/dW4pSS1exY0zVk8XeDrq73S6UCzQyPkZQDrtPuOKseG9Js7O2MNhGUgcB2lJyZB6k+tZOoyWUk+n+GNBUx6ZbNtd+pkYdcHv9a6OdRb2RSNTuAwqDvjoPrUT00WifQKd2r7E97Pb2pRRIBCoLOc44Hqax7Txho73ixaPay3ty7bPM2/KvqST/OuY1DRtd16/ittQYW+kr80qRH7+P4c9TXcaTo8VnZ/uoxHCnAVeAPqe9DjCC1d2XKMeX3mW2vrmZWy4G7jIPQ1GkDqcyuFRed7nrUc9/bRpGA6oucAep71DdXcaoZbm4hjt1ODK7AL+ZrNRfQaVtlYnMitISBhFzgHqf8KkOpuUSJAEycBVOSaykv7O8lEdhdpOG4BQZz9DWa/ifR49RGnnUA15u8to4lJKsOxParVNvoNqDV2dBqtxqMPhvU7nTET7XBA0kMZG4yOBx/8AqrE8D6l4j8QeFlTxnHEryyMY0RfKd4umGA/H8K6XTLK4lgeaKUhAOjA5qaENARJGiyynkMT9z3xUc6ScbHNKMHLmTu0ecx+A9W0m5nbQruEQyyHCOxBRD2/CvSYbiezsY0vZEuZ1UKxRepx15pt3f3gV1KI/Gc7sfjVFXnclmHA9e1VKUqq98pUnP3pWLjOtyFJQEhgR2xTn1dFjMBRJYx/Cwzk1i6hq39nxK8e+SZ/4VHLH+lZGlaxd3155UkEUDM33pMhRR7LmVzR04/a2RFrtz4qv75/7NktYLQNgeWQCF75z3qHTdG1QKs2r6sH/ANhDjFXvGcHixI4m8Pabb3kW07mSYZU+w4zXPjW/EVukcV94S1ZJtuGdCGUnuQMVtFtxtG34XHGdJaXsdpbGJ1PPlnjIPNFZOm3c9xaiZ4ZYmY/cnQqworNx1N1Z6pksbQOwQJDAgb5iqY+lKZIftHkodwfkKv8AFVVFa43CNQAMncegp9pp5twDPJ5kpPMhXt6Clp1OKMWnZG4qWtiITNE5ZxkENnI9MU24EcrMriMIOpCZIHpmo44QFZnkLYwFbOAB/jWV4lsU1Vv9JvJreEDaUt25P1NRFXeo+T5m1aT2UTMkatKE5Pse30q1JeRsfMl+VcfKZHGB+JrgJ9W8NeCraOxgvp1kPzmIoXds85JNX1g03xvZQm5t5ZShDxNvZGH5HFW6X2nexKS+Z2unrY3qhVuopSPutGcg/jUdzYojrHbsCQSCXODXJ3Hg+e1X/Q765hYn538zORW3ZwxwCKJmUED7w6n3JqHFLWLCCmndsv2kl1YLu2kmRd21h1p95rE9+PLktgIypUd6syySCJAFMyp91wvI+tRgu7q++MEnB9MfSs1Z62GrN80lqZErTwFeZAQcD0//AFVk6l4k8PahLLoeq3UENzEQMZKsCecZ/wDr16alpDLbZIjKlMhiM/jXnXjrw5okdjcTX2ii7diqvdWo2zKf72f6VpRnGUrMlYmNTS2wT6at/oEmnWE0ilmDRyxtvBA6gkdq4zTvhVqzXwup9TUW6NuAiZyw57Z6V2nw78Jw2szy2uuXMunuCFgYFGXjv24qprXw71Sw1NL6y11obRCWEi7vOJJztPO09cciuiNVQk4KVvkL28VLliGqx600sVtoN/pnmoNpBbM+B1IU8NWzo8F4LVTfIgn5MuMLgnue3SsC68K2l/q1lq095eWl/A4ZQjDaSDyemQT3xXY61bJqmm/Z7lDHJjaWDZWRR6n396iUlZJG3POL1W5x+m69e/8ACRT2GrLYRWhybeS3mBcKO5HcVu6nHeyvaCFwYDyTj7x7fpXPWXw0tZ7ia6t552AOBHLxsHbaR0FdnYafLp+n/ZZpBhPuDqQPTPpRUlDeAc6UrXG+YyR2yOvEfRTwcZ61xfxI8FS67rFneaY7NKzeXcRHqRnOfpXZuQJFkd8oRksOhA7VbgmFtFd3UcSbymAc9KiE3Td0Od0rx3Kdisovo7ZI90NtGIyCcdAAcVh+Kr670zTbmHwyqz324tKVUv5R64x3NMv9d1Cx05VtIy+rX8hjtkK8KveRvYdad4Usbyyd7SKdltISZLu7k4aWTqzZPQZ7elWo295k2a1eyG/C3TfEdtZ3eqeKp52+0lSkE5GRgk8DtXTXV5dXp3S8W5JKRZ4P40ya+S9KNHJ5oU5Rl+YE1fmkW7tt00fzQ4IZRispycpczRKi4NSktX+BTtY8MWmHzEcL6Uslv5VzDIs7Z6tuHJ9s1MsOI1knk8ot0BUnp9KZLKkjqIpQYz1b1qS+Zyeg+0vGluVhm9cBvSrAtriOZ2Ctlj0rPslW41BEidWJPDY6U/W/F+iaZdPo8Ly6hq4XJt4RnDdgzdj7UcrbtFGNd8kkorccLVzMzliATliO/oKJrmztoGkvr2K3QHBDkDrVSHVo0ntLTUhHHeygytFHkqo9M+wxXMeNtMj1m5jN+4t9GtczXGM5A9K0jTu7SNUnLfQwNa8MWdvq1xqem+MhbaYQw8xZzugbuowcN7DrWpoPjmO3068vkt7i40iwjWGC5n/117P9Owxkk9hWbrXhCz8XJYXGjN9g0qBBGLcR7QwznePUn1NX/EGlQeGdNW709UlMKLb2tnIMxiRjgyEdz3P0rqvGVoyd2PlbVmP0PU/EWr6Df33iBxFDdZa0iKbdqY+8O5B6DP1rJ8KeHtXvPFthcRhlsp1C3UhGFiCNnA/p9aXw3ba9rGt6fp19Ncywwr51w7k8sf4c/wB32r1U3K2dy8NpGGIXG7oq/hUVJ+zuo21CbdnTgjzj422WseIPE1paaXbr/ZdvGFjlMg2ByfncjPUdPwro/B3hq30DRYLSJd+5d00hXBkY/wAqqah4v0SLXYLC0hl1TUCwDm2H7qAZ5LHv9K63zBICXYBFHUConOagoWsiYe7FRj0K93au+l3MVhIIbtkZI5MZ8vIxn615z4C8D6l4UfUr+5vluLyeJoohC5ONx5dif4jj+deimcmQBRkgfdB4H1qGZsuS4Ct0yOMVEJyinFdTRUuZ3kZmh6cbFWlmwbkqFDYxsX0rZe5RAPkjd/72M/jVGw0zVLi+82e4WK1QkeUq5Lema0n0uR9rBEBB27c4JqZNN6spzp3s2Ztxq9vHKkarPc3HQRwrnB9/7o+tZWueILxFSK4t3klJ2w20Q+XPq59q6S5sfs8citKqFv8AnlwVP171n2tkqOzQ5kmwN8rtj/8AVVQcd7DioyfMinZaVdkLcSRLcXTcsG+VI/b8KZf+EbTW939oyzTysefLbCR8dFXp+NWJvFFiL9NMsbg3l23DR243iL1LHpWvopW4mdprmLaDgBG5OPpTcpx12IlJ2u+hj6L4XsfD1kYLC6lkwT94gleaTTNMtbHUZtR/s+GMySCRnZAGkPqSa3bq4itP3dnhGZtzHaKpLc3E+BcOko6kOM/lUqcpXb6hTjJx12DxJrmsPBCnh9YQSSHLcEHsfTFVbrWYLaBP7VZbW9Iw3z53H149an1K/t7OBWZo7eFT8zHCjP8AWse01TQtf1qK0t7jzbhDulMMRI2+5I4pxhptoJU40lzJWJbLxHp9zP8AZhO7yv8AKmUIwa2JtwjG1iAR1Iwa4vQviR4R/wCEzbRF0Sa3ieZoY9QchmdxxyuMgE+9eoajpkBKvZS7XI+4TkmionBq6auZU8ZGUmmjkLCxntJN11NFKck7gpBxUl3qC2zFZbVZYD0ZRkir8xuIoHBhaRkB/dvyW+h9K5PVPE0OBBdaPMYmwrKM7mb24qknJ3OrmR0Wk31peI8ml3bDYcMgPCn0IrSbXbq0CAxyyAcZ65rmdD1XSLi9+x2dp9klZS67otpfGMnPtnqa2by0vZYHNjlpVHHOWqZRV7NGcowl8Zdk8RxTtmWyaQjjPFFULCG7FsovowLgfeKr1+vvRUONNaWJVGnbT8zF0qC7kMFtJIjXBUea6cKGrsbbRLKOAfbXkkkc/eLYUn2rI0a5tLLkZlmJzgDPNPudZurlmEaKgDfMrnPPWonzSdlocso1KjtF2RHrk2j6JIkX24rNI4RYfvcnoM9vxrOuFMNxMu0K6NnKnIPHNUR4btb/AFATSiYuX81i7EhjnPFamoqNKtnkuZi0KPvZ4xnA9DWsUlpe7O+KjSSXNdkLx6fcNm4sbe5lj4WSSMfLx2NX9Jha3XdDbKgBztiUqDiuVh8eaA9+bBRKVf5hcsNqsT0AHWuttrjy0WWB5Dbsdu2nOMorVGbtK9lqWm083KB7R8cZeBySfqD2rlJLPV7fWszWzupYssrcoi9uK617xlmDErGXIAXuB6k1XWCOHVHuvtDSkYDLkkA+mKiEnG5hKM3oZWqXErwiCDU5oZ8Fl2DG4jtt6n6CuU8GeObnWr+azvrJ4kDbI52U5J7hx2PFdj420DTfE1kkN5E0UkfKvA+x0/oar2Fpp3h3ToH1W9SWKBPL8+cfvZDnjp3HTNaxlHkta7NOZr3tjft5Z0CpE+0HI2lsflTRePAJIpQJDIdu1j1+oq5pt1o2qad9p0+4Eq4yhJztb3FNTS5LlgTJ5jg7t4HJrnuk9dBRq05ayWhzkHifTHZ4bK6s454H2OscuGz7A9an0ePUI9buLu61O4uLeRP9Q4+X64/T8KyfEnw30ptQS9JaG7kfzWCD92+D3HY/SumhMq2ixzkSN/A7dQM8Vu3C3udTRcs1ornM6PFq58VXqXM8ctlKcxqwwUHYj2rrYGNpuS5jJjYZBPfHp61zOtafqtxeRTaWyRSK+Q6N8y+xHpXayXu7RIra+g3aiyBtoX5Vb1z2pVHezJqTcWo7pnPeKJ9Sl0OaPSATcPIoJQkfIeDx2qPw2b9dNij1l0e6jBQuM4I7de9Ydn4s8/xmdJs4HMEchimmIJAYKTkewPHNdpIvmhGyVO3B24JomnBKLW+pSjGMtCvNMDAQFA52j+n51qWNvEtvOl3hYFw0hPVm/uiqQtRPdRwqoyGVj6AA5zWR8QvFNl4ciEt7IcyHEcKDLN6n6CoUXN8sSajUvcTt1LCafBPqkmoSlt0gEcQY8RqOw9M0nibR11qytre1uhHGG/fRg53j1OKwILO+1+FY9OvromVA5uQAI3jIzt29AO2etdFo+nLpduysFRyM8NkqO5J9/StJe5rfVDbUnZGlo2gQweTbwSeVHjls8k/0rT1OKPT48QlmLfebGce4rLvNWttHsEluJI4suEBd8A+w96q6nqkdvotxqdwkslqkLzMpPzgDrisbSbTZg1OUrt6LoZ+qWWpajqCywazNbWnIaFE5P51laxqmo6dqtqlhaLPp6ArcHocnpg/0rp9G1C21HTLW9iBihuYVljEg+cAjODTo9M+2Thgpa2HIQcc/3j/hWqnZ2kbqcUmZ2hJdaXpd3rN3DJc3KjNtbr94kj5V/M5JrJ8F+FZNOu5tW1Mq+tXWXfHIiJ6/U+9dhqLk3MWQFeMAIueFHf8AOqN7FcfYbwWDbL2RD5UnXa5HB96Sm7PpcSTleb6mctzYHxRPp0KeZeLFvmkAzsBPAPp9KseJNBm13w9qWlw3H2d50VRKF3FsMDjHvisjwH4Tbw0J7me6a9vro5llYEdO3PuetdgznZI3IHUEcU5ySl7j2Km3sjnLuO4RbXSNEdAyqizXJHESqBke5NU/HlvvsNPtVEitPeJGu0ckYJJ+gxzWtq9ytooSFis7kZbOcE9/rUMGlvLrS6lfSGYxW/k28eT+7z98n1JHGacZW95jV1sbWkRpZWryZBlZAuT6etVr3TGv7fyvtJgDNl2UdR6VaiXjc7bV4HWqmr6qtim9yqbuFBOPyrNXb03Jd2209yvYaNpWjF49NtoUcjLuB+8c+pNSLM9y7CIAoONy+o7D1qDSQ0sTXt0GJk4iiBwfqa56XxlFa69babotrHdRJKsN0/UFmOMR+w5y3qK1UJSb6spSUVpqdfDEII9xYFsZz1NSpAiRG4umCu/Ecfc++Kc7pHh1jAC8qCenviq0Vw1zOzu+7oo6fKf8ax1Y/elqZniDxTDpNtIZC6FBkQRAu5HqfT8aztN1LWtWQSgNZWT4K4G6Vx6+1W9U8PaRFcedrHm3jbvM8p5MRKR3b19hVi21Nro+XZROsQAC7FwuM+tbe7y+6gilLZaGrY6e8qoJ5HVf7x64rkfGnhDWtevzE+vw2GiocpDEGLt7nHU/U4rpPOnhJVHbcvUbs1i3cmq3l8YkQpDuwWzjf/nmlTclK6Y5Qk9W9CWx8P6Xo+myWumRG2R1KPKDmR/ct/QVZ0jSrTTLXEKyyN94ZbBH41pW2hyxW5WVo5ZMZyO2f51ZjsHaUCSZXfHKxjIHHrSdS97slzp23KxuLd3jY27Yx8xDjqKJbuHYHRSqqM8gHP8A9artzFY2SkT3EIc4xG8gG7+tc14r0NNZ0p7V7+WBGcPiAcsP7v0pRs3qEZQntcm1OxtNcSJp/lt1Xny3HPoQD3qjfaBbQ2qQaDuh2qxkdJNrysehZsdMnmtzQfDzrp9vBFDLFFFwHlb5j7mneJbHWLGzCeH9K/tC6PV5bgRxL9R1NNVEnypmc6lJOzepxng/wPYaLeNqV/IL/Vid5dl+SPPZR1/E1V1TwbqEniptX0/Xrm3ichmtt7Fge4z0xTdT0L4l3sKsU0vSVZufKl+Y+vPPFc9d2Hi+HVLf+2NSCWsBUv8AZ8kuo69MbjiuqN5Pm50Vz0mro9etIw1qguJnadefN3c/hSanYxXaxrI7SLnr/Ep9QRWRPqU19YSXHhWWKV0UAw3SlWP19ar6T4nuUVovEGjz2dyOkkILxn29q53CW63K5klzLY1LXRbSzeS6gVJXbgtuy+M8/hWxp/locZkTPIZW4zXNBbs3zXwubkW8qD/R5VGB/tA9fwNNu1mYs0N6Nv8ACkhxt9cGpcebdlODlE7dZ5QOEjPuvIP40Vy0DSCJd/3u+WyPworJw8zH6tcwriXxPc6zHbW+nR2Wmxnc25d0jDsSw4Ga3ksNR81EliwzYwzKBn/Gp01aTy8PLI0h9uBUzO97ErTXLMQOMnHApty7JGMHOO5FFp90k6Iku+YfeUEE5z0z04rRvtLuBuuJI1J/iGODnjkd6ZYSLatF5bRsWHy981pXV7cz25DxhYh17tWblK6sKcqnMrHMSaVZ3M+Lqwty0fOfLVdg9KuxR2yLtt2GxB1zwPrVfWYbnUtLkg0maNZ2z5iynaWHs3Y1xHh6y8U6fqbx6w6GzXIXzDuPt061vGPMnd7dDaMm5WO7kSKKO5maCSeRAZdpGQ4HUCuS8L+KovEU148ML2j25CtnlWBJx9CMdK7uwddodm8vjBG7IP8AhVcNYyTiIRCJN2chAvPv61Kmkmmik2pbE1tFHfW0YmZVmUYBxkNWZr/hmTVrVY9qnyXyChz/AJFdNGbWKMiMqMD7oGSa4jxzqGr2Nl/aOkxwT28Dlp0diG2cYIx75qaXM5WjoRGTbdtF5l/Q9FexijhiiMTbjvA7fU1rSRNHIypM8TgAuU7+lZfg+5fxFpkWo2UjQzYO6OVs5PoaoagPsGuvNqV5ydqIhbKox7H1q+Vyk09yuZuXLobhZ7hFd5h+7YiOR+SxPqO1RRarYR3sekSygXb5deOHPPf8DRf6hZ6bp63N180BcKQOxPSuZbSZdQ8R6bremzwDR22XLnq6uoZcD68fTFVGCldy0CWrsjodXjnm0q8i0ifbdzRsInPG1+wJ7DtWD8KtS8QyRNaeKY3b7M2yJ2UbynoSOuD3rp4VZ/Mfg4bPsRUdzqlvo3lXE2SZmARB/FQpPlcEiqkE9epwHiOHXNE8aXKaROsVnOwu4UEQKyAkBkf8a9Dtcnc7n5wBwOAv+NUNL1C312C4vREirHOyKw5yO/NaSKRIgXnJzyORTqSbSTWqHTVolu2aRQZV+VTwAfX1rzT4s6BPqt/Y6ja4nddsLRbSxxnPT8TmvSrriPaGZAM4XGc8cZ/nVBLixnuIrV5lW8kGfLzyoqaU3CXMhRaT52FnNNDbW8aKkSoqxqIxjGAOntVuGMxP843En5sc5+tOZot+xEXZH8oI7+4qxAIi25skkgZH9aiTCUklojnPHPh6DxA9g2W220hdUJwM46msX4iXE6eGLvSoZNtzcIsbO3OF/ujHUnpXZXhWMBVLE8kZ7msnX003QYv+Eg8Qk7I49sUCj5pJf4VHvWlOTuk9bbCuoQV/+CR/DnR9R07wvJc+Jboy28W37PCyjzFAX7vHr6dq42SLx34p1+3vpr2LQbSKbNrZo+BgdC4H3yfQ/kK3/Ceva5q94t7riJDp06nyLSNNqoufXv7k1xNjc3Xi/wCI2pzxTGW10191rKvAXnhQewrohGSlKUrXMXDmd5fLsem6Boq6DHN5t5cX97cyeZPPN1dsdAOgA9K2rllt0JnZY1XhixwMnoKREEpaVySOCAemR/k1h+JtObVzZWxkkUI5dtgzmub45Xkza3RGvPeNFBtJBkGSB/dX3NVrvWbC10f+0pLhTaQDBcHILeg9a881jW49R0LxlDFJnUVZIVMfI8sMRtB9Tg10ug6d9r8F6R/wkUMcMdqgmdMYXA6Aj171bpKKvIbsltY17UW1xAl+sb7ZlDosowwz0yK0I/MbKoDvOMEjH4CoLO8h1W2W6ttyxlerDGAO9VBq0l1K1joK+bL/AMtbvGUjHt6ms7Nsbl7vmbypHAzNcnL/APPP6Vyz6M+q6m1/rDiTaf8AR4B9yLnj61txweXAiSZkdOrMeWPvU0UnlMGUbpD3A4FJScb2JUeu7MPWNB1Oa0S3ttRWGSTJuZMchD0VfT+dVbLRNM8L2ouZH+eGMoJmAAROu0D3P411BLFSVwzkZHpWHqkentcwnU2a5Ocx24+7u/vY71cZyejKjffc5X+0Nb8Y3rW+kRC204HEk0hKuw9c9h+tda9xaeGNEIgV7lowAxTqzf4VWuNavJrtNO020jjG3LNjCov4VsraRhIfOQOwHzEDqfTHpVTnsmrLsDT+2cdp+kajr9ympeIAYbYHMVkG6/7THvXUyQXaQFbC0PlgDCr0ArTnkjM4aNiuMHAH3sVXeRmmEgJiY5+71xWbqOTHGUmjJ0/w9NJJHeeIbmRAj7o7aF8FwOgfH8hV27uGMp+zRbST8gHt2qFtRtJNQaGKXzrlVyUyTtHuanZpAADhd3GB39hTbb1Y6cLO7d2QWbzjPmM+D1QN396sXssk0YgaWSJB/BF8hI9aqfbLeC9NpJJHDIq5JHO30/GteOz063twhlurl25Z5W2gH6CiTtqE6kOZaXOat9F09HE32dZpFbGZDv6nr9a1Ne8Uab4OtIpZrWa8upQdgXAXj1Y9BV2Y2iKfKVQoHbvWXM0eoqwMkToP4GwSPwpp8zTlsKcfaqz0RmeF/iTqviKe5+06MLCzjjMi3QclOOxJAz9RUTfFFJZ47bTrdro5KyTEbUXHX9Oc1bv9Bhu9Nns5mneCQDcU+UkDsDUGjaLp2k2862lvsQplt3LSHHQ1pajq+X5ExwsGrJaEMfxM0ibVBaWcwllZTucoTHu9jXY6frVpqsK+Zbc91Zen0NeW6brtvb3Un9t6ba6ZpmSFeKA+Z7EKB81K/i7TJLvOk2+tXTuMD9xsB/wpzoJ6KJVXDxhLlluehPbQ2Vw32aNIl3ZVvrTBPJHN5wDSJ/EvY/8A16qaLJLd24laOeM7fuS4/Gr7RbirRk5XkLj9KxtZ2ZqrJWZr3ESXOmSkHG6POD/KuSh0VJoWg1AR3C84LZDAelbNw10WjSIkbj93FY1/exWZX7SeWcqpOcg+lFNPZGUIcqd2WrGwg022S0tsJCnKq7k4z9aKSG+M0S4HmKvQ4wR7Gim+bqNNdyW4mjZJbeBY5AeGdByaZF5jqqxROykAbupx34p0NjFLlUYDaCG4wceo/Gs/RtJ1DTNFmivdQ+3ahLKzAq5AEfYD3qdLbnOmlotzZnv3jjjiW08oqMA9MfSs1PG1hZ6udLuy6znCruQ4JPQZ6GrWm3wg3pqkH2hDjYG+8p9jTrx9LubpJRasBF91CBjP1pJLZopRv7vKa8OmQX08ssbmON1yvqD3xXn3iKx8T2uv8XbyWBbdEdmABjpjr68102h31+0Wb6SASeYSPIbKKM8KK6F9WkxudYWkGdu5OQPaiMpU5dxWqRd1sc+M2mmrd3MDMVUs+OQMd8d81ycGr6hqV7b3HhmFrvT5ZVFxbzYDqO5U+wI7130kjBJQpLZBB/u89jWPYxabpob7NGLRM5ZI+FXnkirhJJO6NGpSd0c9/afiKy8UXGmXdgn2BjmKcNtJHseh+nFdLrcXkaVNLNE06C2YvCnVwORXmNprfjWw8bbLtLq8sppCqxsu6JlzwYz24r2We4xMFXaSiggKORxyCfSqrLkcdvkZxm5No4/4U6xp+pPPLYJNbzRptaKUYUH0B6Hn15q5Y2V3e2nk69JCNQmkcp5Y/wC+TzzmtTTxbRGc/ZobNmbLOfm3j8PesbxR4bfUNctdVs7tSYY9gaMnKkHIbHtS5k5voOLabaOE0HxHcaldnQtaiL6ZdzfZJRtIKEHAYHqGz3r1XwzpsWiaK2lSvviik2oxHJXOcfTnmsOy8OLJqZu7gw/a7h1kyBt+cdSo960b7VoYNdi06UlbiRS/T7y5wP5VpVkpu0C3HmdmaUSSxl9g3AtjA5BGaxvFGnf2pb2kcJE7x5JjJ2gZ7k+1bazjyy2MPuwvbjHNRWaNe3rLAgC5AB/qKxjJxdzVq93LoU9Is3sNOjtlEWd2SqjAB9a04oSNxYgnoxNRTlHvCqBtkR2s5GMmr1k6SXIeYKIYssS3AwOamUm9SZS5Y3RS1Y3EaTLaBTdhQV81vlB7A4rm/BHh2bRLue71q6W5vZ8kyLkjnvzz7Vs2XijQ9QvpTa3NncTSOQQsmWJ9h3FHiHxxoHh4KhuEkuW4ZUGcD+laJVLciW5m5OyjY3bS3j8xHmwkLHA3ZGa32k09Itr+SRj8a5MXUmowRTRjERRWT6EZqhqVzDpUUt1csTDbLvfaOfoM96xdNydupnUw/tdZSt6HUH7HLO81ttnjxuABzXPeJ7S01ONbnX44/sNqfOHmn5Y8dzXMQ+M49WYx6KQkOBuf+Pn+H61p6lo6ataWcOsXhGmQfvXgJI8xuv7w/wB0elaxpuDXNp+ZUKTjr+Zh6VrkvjTUryysYDb+HoojD9o+6zA8AL6DGeOtdL4Y8Nafotimn6PB5MOS7EnLSH1ZjVjRZdMmQW2jiLyIjtIiTai1J4h1B9E057ezjSXVJxtVD90ep98VUm2+WKsXKVrW36Fe513TF1u20ZWmmuJCC5hXiMerH3xWH8RPFs1vcQ6FoEDG9ux5YmUZ8sHjgdziovANo9r/AGjfXSie/nk8t5HX5hj+Ef1rqdP0rTNKv5dUuZYbjV5kIjLkZhQfwoOwHc07RhLa9vzJbUbPfsYfhnwhb+GtKWzcJLdTkS3DuM4x6/TmtG6zrUccNoY5NKiPL7uJMfSub1jUb7xVqD2WnSmLTicvKo5uexweyDp74rstJ0tbLT7bT7NAsUK/dUY+p9qJtr3pbl6pLmONv4LvxXqaaXo0z2uiwNtnljJXJHBBHcegz7121jZafo2nx6fpSiOFRy2SWc+pNVLLWNImLWOiyxyOXILQ8hiPvYPTrUOtatbaNGfMU3N2R8sKH7vHc9hSk5StFKxFubVmmIy5DOCFzwc8t68U+acJGPkwpOOT1HrXI+HtK1C71GPX9fuXMu4tb244ESEcDH511QIuZQMYHP3uBUSio6J3NN9ZbGXrOrxadZPli77cpCv3j9B6e/asPwxBJqd3cXWpxbguEUIflXPYN9K2Lvw9aRz3uoX01xdKV3CAHA+h9R7VlRy65exxx6YqxWuD+7ijCKnouTyfXIrWNuWy+8XM3tsaF7rOm2GoJYWokkmLBCE5CE+tdLCssMDyXD+XxgEck1g+EPCUWh27XV4yy3DEkzMMlSfSpdW1GZr+OC2t5Lgr1dhhRWUkm7R+8V3P3eheneUxtIi7Yx02jLt+FY01hfajblrn7RYKTjIYZxnsvXJrYSe5BVpDsYjJbHC1T0/UINU1WS1tTLN5Y3SXBGY0P93Pcn+lEbx2KbcVq9B+n2VtYW7R2kO1Scs5HzH3JrQjEincUGThQSM1rJFbWcStLh3PTJrLub6WZT5e2CEMS8h4AH1qLuTM41Of4VoUbmzgMzOsUctx/fwMip004zRHcyx+xyfxFcxqPiW1NyINNWW8kDHGRtViOuPatzTNRv5USW6hxlfuMfu+9aOEkrml3b3DN8Q+GRqgAe6vII1yCI38sCpNF0PT9OVJYnuWlix/rWyG+uK6CG7hfcZYmMmMrkbgahkkkvMqlsdzcjam049KSqStysT5pP30Qy+I4LyIKkS/KxjBVjyfTGKplRKiklSCfmBPI96uRaNdhiPICA+nNatpoctuwwqE9z6VHPCOw/aUaKtFnEa7JqkE6rpmmx3fXLNjI498e1N03VNZjtN934dk8/GBHG2FJ9DnoPevTZtLtriIGdQzKp2uvBH41w183iFZ3hhkjitwSFaUDI9Pc1cKsZq1kYRxHtdI7mpZWkl9Yx3EtubO4eMmSAHO38aYkO2F2k3Bx0LDAApmn3ur22jym9jjluwcR+UcbwfUetNDXU8WJIfLTHID5x9aVndmtJz2ZYjv9qKzK29OOeMe9UtSt4LhMy2wOW3bnBOG/mKlRZ4wQ771PABNIoLSlGBZ/VjjA+lNaO5pyRvoVrdSsYRHVCvXaNwNFLNFEzNuUMqnau1iOMD+uaKrcFBPY5ddb1ZJZY59C1D7L0ieEbmceu0c4q9Z6jdSRhk0i/gUHBaQDpXU6dqoXC8RsBw3ar8WoW+/BImdh8oUZz65rOVRr7JxupNdDEdXljQsyEsvIJA5qrcaelxbGGWMsinqrEH8x2qxr+oHT7eaeONWmALEY6+gFZ3hXxPb63E/lXCPJCQrxN8uw56H1pxUrcy2OmM9Ni5p2mw6fC0FnbbIi3mMueGY+5regSO6hk89CkkS/K2ev0q7ptpDdZaRgIx0XvVXxHFDC8UNsGVlOX9xWTnzSt1MnVU5+zWjMNpJ3E9u0rKoAMTAcnHUGs2/SQWdy8q+dGQpjjU4IPfn9a1ZQHRGQ/vixO7OMjvXKXLanF9sFzb3EkcREieQQxkGegHbtW8NT0KUIt2bsWLSO7ClbO9InADxxy8fL6Y65q7puuPHei11WIwzuMCVeVk9RkVyGgnW4PEAudeieWGdG2MCP3Q64wOhrqRrfh+dIZmudsyMYo45oiJM+w7+5rWcem/oRVwsoSvDY6a6kt2jLCOVVAOFXrWVpet2F3qn9mwb/OkDMuCOg65x9a1YkCLEzr5kTjcGzUFrpmn22rPfW1pFFcSKQ0qjlh1rnTSTuYNNK0Wc/fw6vN47tJN8a6bDhvMHBZcHKkeua6OXT7a61R7yVAJiQVbHQDgVzfxZmki8G3EsLn7RHLGUkXgqCwGM1e8Da1/bfhuyuph/pH+rlzwN6nBI9jgGtZKTpqa9At1NpEbzSNwywKjFW9IdbHftVQ20qD/dPrWBrd1KJPstid85YZI4CLWuojhSOEkFtoyM9R6n0rJrT1KmuZcr6nM+Ptak0awt4LAkanfzLHFnkqM8vj9PxrrLqNJbK9tZ2wrwmFypxwRhjXHQQ2+reJpr2QM8Vp8kZzwWz2/Guzt7YTRnc2wZ53cE+9XO0Ul1IklvLY8WuPCOo2GuW1tpMt1dywptiufJEaxoeoz3OCRn3rqNN+G0b6l/aGrTPdtG29IQPkUDoD3NekAQx5WMEnHX1P8AhVbUdb/sa2jijgae8nYCOJRlnP8AQCreJqT0RMqrt7qLKrFYWiTTHBY/LGvc9q8n1ua78ReKZI3iQ6TYsxk85ikRcdWkPoOw716lf3LmKP7WoFxtG8JyATWTrHh3TdXtbIa2Z1gWbeLeNsLO3YNjqKijPkd2EHyx55bswPA2k2cyyTWKiS3WRgt242rJjlnXttHQfSna1O+saj9htA6WUY3O4OfNI6E/7PtVq71uy1LVX8P6aVgSBCrrGMBEXHy1rWdhBZW7LAoyRksvf2zWjk0+aW/Q1i29ZE3hxILbTD5KK29txOMFveqN1bX11r95dosJSGLZZgscmTHUjHr3rWsS7JJuUhugHbFN1WO+aD7NpQRZGOJbhuNo9BWSfvGU7KTOQu9Ui8PC20qyEmpay5wY05zI2SWfHTJ/T0qZPD+q3DiG7uFN/eJmadFyI1zzGp6AeprT0XRrbRZZpbcb7255uLk/xeoHoKr3vifUk1O30/QbSG4JkHns5PCdyPb3Nbczb9z7xtSSujY0/SLbRoxBaxqnb1J989vpUHjGDULrw3NY6LMsV5cYBcttJXPODWneBLeFrm7fygRvDu2ML71j2WpRaleL5Ej4HKhB1HuewrKPM3zdhaSWpmeC/CI8M6ZsWVZNRbOZB91M9h/jW1Bo9vAyvMVkkzkntn1Pqc1qHhWM7bmIyEXt+NVwGdiZTn5vkUcYGOnvRKpKTu2VFvcW5nt7K28+6kVI84GTyfQD1PsKqWU9zcmR5VEEDn9zGw/eAep9z6VIdP8AtFwtw4M0qH90p/5Zj29/et6w06KzAmuDmU8471DaS8yJ1I09W7sq6XplzcHdJlFHJyeTRf3cVq8kOnRebKo2sU6D8f8ACpNf1u3s7Z3mk8uAKThVyT/jXm8Fxrev6s7wwmz0vAKFjtdvwqoU3LV7EU4yqvnqbdjtHe4uJEFw6vg4WNTgA+9WnjFpb7yEMhPQn7vvWdZRHT4RGrO/Ulj97NJdSkAvJub2XvRbXQ6OS9ktjE14al4hmfTbZnstN4+03JXmQd1XvW/pLWGk2yWOlWzCGJchc5LHpuY9SeKo3EjRQGSctDbryw/iYUumaxaCznupXSC1QFVaQhVU+tW03Gy2JlGL6F+aea5kVpGAyeBjgCo5beTyHWWMGFxypyAeafBdrNpqz2ssfkMu4TAcEdiK81+IuveK7SPTYfDE1w9sWaRmtl3FpM9D7c9KKdNzfLsOUnGN4rRHpFjBb2sTfZbSBCf4tuT+Zo2vJhihG3q4HH/165dfEr6Tp2mS+K51s9UuYgXITgn3A6e9bkmvPYwJeTSxy2LDO9cEKccGlKEkNaK8bDdV8QQ6PCwNjPcsCNojYL/kVz138Urkaf8A8SnQZJLosVRXcsQR3xgZFdJB4m0/UI1S3vLVxIBhjgE+ufSrGp6Sup6T9illaN2ALSxEDA+vvQlGPxxM5Ri3eRxFr8Ydbhu4rK98PRveqP3kcUp3EeygHHFdPp3xD1jUtqR+G5rSNs5lnkwFHqAQCawovBUehaktzplxNDg5kmYbsoOq4PY1e1y7vr7Q7seG2RNQZMo04+UHvjtn0rSUaMrckfzB4ei9VE6EajezuRNdoFI4UYUH3qbP2Y75FZ2wMMRkZrwLRPBOua/rkr+Iry6VUTLTgnk9lH69K9q8PWr6Xpotvtcjwp/z1fdn8aVWlGnpFlRu1dR5V/XYnvLqe4kLBw5wML0I98CsDXbiK4mtZdlws8D7gsb7AT6MO4PpXQ3mYtk1xJbwgnarF8KSenP9Kpzw2tzn7ZaxSMy43A8Goi0tTVJNWijirz4l29hcyw3WmXqshww+XBNb3h/xVZa8GEKXCSjkq45HtuHWptZ8Pztpaf8ACNtp6XRJIF0gYH865vRtN8dWd4Wu7jTG2n/VhV4HfbgfpW9qc46aP1M51LHbGKRzvbcyn7pJAoq5c2V3cQ27u9tI2zkhsYPpRXPddyVX9DIt4vNyqEELyAVxmr1tcmLAtfkdjlmZeTjt7fWtOx0fZbtLKoRfLz74rMlihDttRlkU7tuOtZ8yloZQqRm2kan/AAjx1zT3i1IAxyjIDcMc+4rItfDmh+GZmgsShvO6/ecA9ya6fS9VuPKCT2xd0O1Sv8XHWvFp9W1XRvi5dtrcCzWmszJEkmCPJXopT6HgiijGpNuN9F0MYuop+/t5HodpHNY6i1zDM7JKM+Ufuj6e1b1k5u323TCVypyxHA9MVWsrV725IgZSYuCCMAj1/wDrVYl066spmlLbM/xY4NTOSbt1N5Sh8N7MyZ4mjnYId7RngYwK3bS2g1HSpJ441edVKqGGPm9Ki0u3MyOGjJyckkd/rUVvOLdrkFWWF8Ku3qGGcnFS3fRboKs3PSL1RyEugzw3MbyQpGC4cYl3EEHlSAf0rbi8B6TcakurrdXFuiKS8BAdUz1Kk8ge3NcLexa94b8WW/8AYgkvbPUZgJ/NTeFy3PP8PHNeo20r6h5yhWjs4nIGP+WxHf6A1vVcopNS3NKmJrW0fK/La3oVNSkMsEaIrw2q/JCqL1X1Y+tQWgO7EXTuuM5rbuIpHt3aCNX2ttYHp74rPaNYpQsYI53FiOmayjK6sFKa5bIh1CxgvdNu7OYJJFMMOrdMf41g297a6c0WmaXhrtcbUIHP0x/OuqlgSO1zCfMnJ/i6KO5+tYOj6LY6GiR2sXnTZOJH5YA9s+lawkrO4Rd9Ua+lad5MRzGSFy5djksx6n6Vz3iTWP7Jil27Zr+YEoh+6B2JPoK625uFgtkgBy7j5h/SuOj0H7bqr3OoqGRHLADndzx+GO1Om0/ekOm5O8mUvAumPHaw3N8cyNlyAcKSTnmu6dWK5YHa3P4e9cl4r8U2nh6RLOztftOpyj93AvG0ereg9qteGtL1gQvqvijUlt0lAY25bbHAvpk96dSLn78tOwTaWr0OgTIbejEjOOvFACrdCZQDLjZuI+b6Z9Kksbuxup0is5NsXPLpy59R7VpXEdvHGzLtDj+I9qwbszKVSzs1uVWtljhWRyGlb73GAKrHBdpZVBdVKxDPr3xSajc+Uu7ltw4Jp8cXm4XIAUDPtVdBxTSvIwNA0Gy0hpFtkcmRi8kkzZY5Odo9hk8Vi+Ktd1oapDa6HAjW6yqrmRMq/qufp3rsZRGZcFyV6AAYOanFoLYG4vNvmsMoh6KKuNSz5pamkpJWJlCxERgkKWDY7jHanXl1NcEggKOuFGOPeuRn8UNdeIDpWj2jXcqgNcTM21Ix3+p6fnXStEflad9i9wRyfbFKUHG3MZ8ivd7kVxBHewbFZljY4Zv8Kks7GG0tWtbBGVWxvbPzMPr/AEpYgzEsBtjUde340kFwJYd0eRnlmOcfhS1sOV3p2OZ8Q6BqWsajt1BvJtFfK7mBwo44GfvEdz09K1rW1Szi2EwWtpFwEBAJ92Y9azNd10RRMY1lnm3bY0A5kNUtF8G3eqXR1TxPM3Lb47ZWISMeh9T7Vtry++7It+4rt6nR2moRaizvYkyxRkgTBcI30PpVy2j8wtwzKBuJ7D1qc+QsMcNsixQIPu9B9a5nVNanvra6s9C8uC6ZSIblhuG7HGV/u54NZ8vM9CU21ZLU6iO7WHa0bAZH86TUNRUxKc/vCMc9vrXP+H7XV10xW8RXFnPqMjbitpHsSIEfcH97HrXQiwt8+ZOyIqDlyeAPU1MkkzO1NWnIht4ZL0MUClj/ABHH9akFi9q/71e2cDnP4VegnjtZJcBTnhfQe/1pl3rEMStJIyj5e/H41N3ch1KjdorQpGB2nG9FVD6npUWoMiI6whGnAIRnXgGqserrfSbLYnaRkEDrWjY2sbTqbh+ozj1qrW3NX7q5pHLx6NNPcltRuwwfA+TJLH0HYVJrnhDRL14Rq7zrDbKGMCthMDnLD+ddxHqlpAJIisbGNjjaM4HauH8a6XP4i0ya3S8a2M75ZlGcrnpVwqSlJX0JpylUbTVkXbHV9F1i0ksNO3SwRHH7nAAx29MU61tbe13C2h8snuW3cZ5z2qj4W0TTvD+lQafZbySfmlY/M7HqT6V0Qtbb5gJ0YlSGXpjB6k0SaTtHY0Vqe5k63o2la9arFqlv9oWN/MiYH5oz7ex7ik0+006y0w6ebFJbV8iSJ+R04x6Vp3FnbtZmOzulM4P3s9RXCz6d4nUF5pRcQB2ZQCBuA6KPenD3la9hLkl3Og07RNF08yNZaPbpIzbjjLMT+JrQDxCUKQyJwoA6fjXlPiG71vU5dJudGsdSj1GOQ74Y8jp6+lenaJJqsekxT63py2t5LkSQht2MHg59xVVIONm3dlvli7LqW5zIrKU3SRMNrIw3fj9KtR6dbmMtE5jDAAFcCqH2iRgzqFSMLyelYWv+JNOt7iKwe6Ed1N8pIPIz0FZRhKWiBwlbR2N+7RIywaUu4XAbqMelcv4r/wCEgisBJ4a8ppFGWQRhmb6bjiut8L6NaR6eqSXkkxLmQM5B2nHaoGOwMsQcgHaDjtTjJKVlrYKdRSvDqYvhOPU/FPhOfTPGmjINzZjlKhCSOQcc4I9RVNfCt/4finkjvJTp6ncAx5Qeme9bF5f31jKvkq5tQCS46qfSsHVfG7WOtR6VqljcJa3K4S7fmKQH1HpnitFzyk+XZ9CIwlTbael/M0NL1fSNQAjt7yKS/X70THax+gNbFrGt0cTL86c4xjPuK4/TvBOgQatb6pax3MU6tvUGXcmf8K6u2nkt7lFkXO7OCPSpqKP2DZqTTsWZLuWE+XEUSNeACufrRVa8O6diikqedw70VFl2IUI9UaGn6tHbKv20kLtwc8gkd65P4o+Ip9F0gaho7xqzkfM0YbPI4PpWxNaPNEHAG+MFTkcYqmbI3cEsVzCptwPuvghqmmoxlzs5oUoXckyr8NvGd7qmizS6nAluVYKkgGN2ec4rYmmi1e6VZDC7RHerugLL9PSq72cUMEaiIICeFxgAD09qt2FvDFJKY0HmOMu2e31qpcl3KKsaqEYe9HcvaJcpZ6jIi/NHLxuPSuij1KGW8ezliIccAnkGuUWaze+UxuNwGGCkHYw6VUfzri9XUGunjtUYKYgfmZu1YypKTuzKtRVV8x1CTvYGRGXMR546g003Nm8ZmRYmduy8kn3rMv8AUZLhFktyByUfPVeKqackkcctw/7wAdR34pKF1d7jjQ05nua4hY6Ff3XAMqhV28FF7t9au6XFFZ2QxtWIDjnoP61SkkK+FrW2iYF5fkJ/u9zUSCWcRxRYPl4wPf1pWutSORzUm3bX8jUvCkcQVCmHOQo4JrLvF3ymMEqzdiO/+H+FXVtGjlea964GSx5x7VRvZm8m7vEQsoQ+VHnBYjqaqPkVStHbUwPFWsRaPZxWUEv+lXDYLs4Un1Iz0FJ4MeW7RmunMsStlSAcMemB7f1rmNB8LXPiLW01LxCrGAZZYCxy7dsDso/WvQNQkg0jTZJtoWKNQCsf6KBXVPliuSOrOhtL3UyteSjznc4HoB3+lS6Uk12u4ReVCwz83en+H7ddRsFu7iMW0aZdiWycelQa1qtpb6U10GkS1gU/JjG7HAC+54rP+6hupf3Y9DndZhsPDuv3+ualFFeSbR9iizuJkxjJ9hVC20/VfFUkWqeLJD5UzA2umAEJEv8AeYdyffmtHwzo91fZ1DxGP31wxmjtmGRboPuj610d3JHDbLIjBHwxdm6kAZIWtnPl0Wr7/wCQoQSlzPVhCkcTGOMYONu7pjFSMGaIxsfMYtkAnqKzvBOprrGlz3TMs0KTGONx0xjOPwrU1O/t7O4tI7hyouG8qONRlnPf8u5rFxalbqNzvKxJd2gmMcxb5TgKgPJ/Cs2bxboWl67baRevJNeXLBT5WCkTdgx9TXM6Rr82sfESa7tVddG0mNoB6STE4AHrj+lcuJrj/hLb2DRY4n1Z52e61CRd0dmnoM9WH862jQT0l2J5JTXLJ6Hs7G1F9vg2tsOWBOdp9Pasbxjd3Nxpk80LJGzfKpY4P/AR3NR+DbS3bTysbTtbQOWknmGHupDyW/P8uKj1bTk1bUS9yz+Sn+rhHAQd6yUVGevQIL3tN117GX8NTIkE7G1KwGQYuJAC8x78dgP55rs3WMO01y7SN0EUYy3PQegrzj4n+KdR8KR6dbaFb7Li4B2yeUXVMcbQv94+leieD57yLwha3/iu1EGozoGNtjDD0yO2f0q6qbXtH1MqtRRdo7/iMkR7hlFwyR2y9IEPyn/ePenXFy8ieUSGXOAB0qEp9snSVowiA/KM8KfT3p0ypH+7Rxvb8gKysaxik13EitLSOf7S0SNMONx/pVmaZpgQSQB2/oKgUbwq5yV5JqaZjGo2Ddjk0A1r5jVRCCjgHjG096q2WlW1qr/ZLcKSeQBnFWYI3mGUY+u4da4+XwH4k8TeJDPr+tyWGhq2I7OxkIeRR0BPQE9yauNtbuyIq1VSV7nfWVmm7fjGOCzcYpmoSiZHtkgRkOVYEZDD3rRdFtLYW8MISCFVAMjZYADAyT1rj9Q8T20bmG3bzrhjghOT9P8A61Zxi5vQypc1V8zNOBfLUiZtzd+eMe1U9Ss7fUo/ImDLCGBI6Fh7+1LaxSsomn3CRxnZ/dHpST3klqWXy1kLclumKuzT0OxRu9NWLPaGK0+z6UBbyYAEu3PHpXNXPhbWFWeWTUmMjsNjtK6lV9B710j6uIoi9xMkI4wMioIb60mQS3Nwif3TI4z+VXGUo6olwa+Ip6Tp89kN07ByV5y3FUvFU3iSQBdAgt4rQIDLPJJ82c9ACOOK14ZoGuHS2uo5GB+by23f5FaEwYJ823p0bnNHO1K7RbSskmZ/hkGfT4Del3nK8tk4P0p+raYl5mE3EiRo3PkvtJx2PtTdS1C20uFZryeK1jBwpZsDcfSsi0vdChnutQgO2ecqssy7sOc8ZHamk2+ZCtbqbsVtBZ2/7lH3DgoTnK+v1ra06ytntVc3QfjhVOB9MVmw3DR5jng8yNhtzUz2zIpaMnnB46/jWUvNmdSLfu3sP+0GW68pTt28B6qag13HMgnwYs/IwO4N+HY01TIrEgof6Gq8krP/AKzIYH5R2PNNKzNY0rPQln3yeagUOXXGcfyrzjxX4Y1PTJRc6VoyagJDvee43TOr57JuAA/A12OpDXmuD/Zt6ttEuCQuPm/A1fs5bwwp9pl86bHzunAz6itISdPVBaWyWhneBHur+0dNSgeCUL8rBCiA+ynpWxeQ3tmkUYTKMu7eFwDT7eZ726MKuGmI59R712N4vlaeQApMacZ57VjUnaRy1KzozUXrc4iC7n8jDIkg34YA9B7g9qbdiG4UK8MLxcMEkT7jeqntTYpVDLKkRiUnBD9W+oqUlRnIygOOBnir2Z2ci3aK6hUAi8tB0JXH8j2qaFTI+1ht28gnkGp/LjO3ysmNujL0B75pLmJY42k3KWUfIpOM+2aV+gcyexVuIoGkOx329cDPFFLFIrA+WMH+IEZoo2J5ktGNiuZZlCCTy+SW3GluBKrK5O9VxjsT+Fc1d6q9ndRoI3laX5RheFHqa6LRWuLssCmV4AJHelKLirnNy8t2PikmupEUsMj5Q3tUV0HhG0ZwDjitCazktZzIANuMjHc96z2uP3kUZUlJyRz1B9amLvqjWm+q2Oa1LQ7628VW+taSUR3KpeW54Eif3h712NqkVxDPFG8SyZLfKecj+tRxqXtiJz+8jBwe/vivPtDOsWOuTycGOKQgAD7ynu3v0rVJ1Vq9gk0tTuoUAkRdxDMfTrXQ6rJ5VmbW3jVVIChRxgHkmuV8QXl7Z6FPd6dE01zGQXRRltvfHqRVPwHrM+uaAl5cFjIJXgBI5ODkZ98HFZyptrn7BUjzzVzodI1CGVwwYlLUFHA52seua1/D8jtchQFKgFie2O1ea6WbvSfFd4inFrcMQ6n+LPIrvNOufKkkkHH7oYH49KVWmlsRUg5RloX9Yukn1AoE/dxpmVyeg9BVAq9zdKJMDPRTxtWmzLss5ZpDknMrnHO0DP51xHw3+IUnjW/1DTDp/wBj+zoZxKHydgbGG9D0+tKFNuLcdkRzQopQv5HoM1+I/wDR7LBZv+WmRXBHTtT8Ra1Gb2VrXRoZSWUtiSVl78dFrr1AWdZCMKrfKCuM8dao6hqcWnx2yyRsXncRpHEMseev65q6bcfh3OjkUY2Rp3k4ksRb2w2Wy/KF67vqarwxwyGNngWSRSHiDLkIw/i571PdKY0jjPKdRxTb7zf7LuHsED3YT92pOMmkmCtGFlsTIflkbd8wI3sfrXHaleyX3ja00u23utvgupGdwYcn/wCvXQeF7C6js2N27G6uDulB52gdFFUPFVhqNhYaxqGjxI2rXSLbROg+ZFPBb2rSnaMmjOcu25d0uHSvDnhuSLSQHt45X2oG3HeeuT3/APrVx8n9qW8N1q9zA17rt3/o9pHniGI9f90Gt7w0LDQdJsNCHmXlzH9+QDcFkb5iSa25IInuFkALyKOT0A96pT5G+o4Q6sxE0/UoPDlvZaa8EV2+DNOVGIieWZR3PYZp2m6LYabp/lSArbx5y38czn7zk9Sfeumh+z20ZluHAjUfMx6en4mskzJrtsbmMSwKGMaeYvAUH72PepU2/Qrn15UalhdO6KtvGFt1AEaDsKtPHDbRPJLs8zopJ4z9KW0t2TTmlZtsaL8pPBY14/oEnivUPFt/cLui0eKVjLczqfLWMHoo7n6UoQ57tO1jJcrb1seu6fPDEC0X7y4HzGV+3uKoXuprqN1stitzPnG0csD7t/hWLa2mqeLJ5YdMLWejo3768ZCGnH91PrW/q2k/2bow0zQIwl0cGSXcAUTvlu1K0Yuz3IlOCqe67swdU1eSyhki0+T7Xe7xBvUApCx7Ad2+tctaeK49MuYdH3Xus6z5hWRkAI3E5Khu4HsK7Hw3punwSPLCyXEsrZeZVwqN0O33461lXWjW1ub2HQyyS3OUutTlXBVP+ecR+vUjrW8ZQ+Fo3TcXtqSeH/FK6tqzWSW0j7SVlkVgY0OM4BH3vc+tdfbxSzlULkqDyQOTXPeFNItNGhMVr8xcANI3XA/hUdh1rqWnWOELFiJc4AVck/jWFVq/uiqtp2SNaJBblUeJQnA4/rVm51K1twPLKllPAXqK5qa5nkOwkj8cACqYQsg/ebgf7pzn8ax5L7nIsGpu82L4pubrV7WW3hbYXwMHuM8jNZ+l6Vb2RMhw0/UHHC/Sr4zuzGG3E496nhsZuC6lUAySwrVSsrHalGlHlWiJLf8AesAAcDqe4rI8S6XrF55Q0xbeCHrJLI3zDHbpW8Lg248u2jXeONznGaZBd7pCt5INmfurzQpNPmRjzTT5onF2Hg6OO7N3qN011cEdS/yj6VzHiTwbrt1q1wdHtYEiuOX8xg+ccAhiMr06CvVLuBXeQ27AKDkAc8VVhuLqByI42CA5wW4rWNeSdzeMm1dbnK+CPCWu2AVtUigXy2z5aSZBr0qyhQEJcoMfew2MD3rKn1C78pd6xx7uQwHJp1mt1dKMs23t6VlVlKbvI56kZyjebSJfEdt4b1EIuo2iXIhbeh28qfWuatrjRp9Qe202xdjGxDmSLKg9+TVjxKL7Sv38ei3d7bofmNuQzH1OKdpuoW9zbCe1R4X/AI4JUw6+zD+tVCNo33+YUo042UJXZqQ3EbF12mQg/e9fwq5bGRRI4jbpx3wMd81lRzbH+0GEOB1xxitSPUjJbfu0UbhhgOazkmOrBrZFCCzkuxJ5IBAOTtGMf/XpqxRxwNLLITtJATZkk1NpV+LScoVKR/w57nNWdTuraZVuLZVaQOC654I9MU23e3QqU6iny20K0UX2xlWEMHUAmNsDP19KLm1exkDSW5AJynOQfbNXlnhiJmtUcvIAXTqR9Kbf3B1KJIIm2Op3bCQefWoUnfyMlUnzLT3SgXtbcNMYRFcyDbuDZyKzRqMkFzCYXZo84dXbh6h1KG4Xz4lJ89IzgAZyT6DuKybKG7Rit5IC4OELJtP4itlBbnbSpU9nrc1bzxPpq63ZaVPbSRyTuUVwucYHBP8AjTr6ZYIpnWWKNI0J3yNhAff2qQ7Xt4pbkRvJCco4X5gO/NWWitNVhNvJFFPZTxkSKR971H1pPlVtCf4Zyui+KLLUJYrRnkF2ULMEH7s4/iVu9az3UL3AgMwMuCRGTk4+nauXufCFlb67Yy6Zc3KwWzHbGeWA/un2rrx4W866utTibbezxGIZH3B2xWtT2a1TD2nLrL8TOdXhA8ptoPXC5zRWTo/hm+gWaOW4lMgbLM5ySaKbsnuR7VPoarTEzEFBIG/uritWGWS0tJhwAcAMeAKxtUkn+xyDTYUNwFym84AIqro+nX9xD9o1jUFuJS24xjhF47D2rFxTWpnLXSxrwX74jJcmNiVOf4hnHNWQm5TIQPLRhhiMY56CmxwRTlQwVY/vA92zS6pOkVoVjBdPLZQo43HH/wBepvrZGqt0RfkWM20V3bSKZGyxHqf8KqPCspDgKrNhiAAOf8K5j4a22oQ6DFZ3wPmJK7qWJJVD/DXSxTq7t5QUqrBRznIolHlbSYU46EySgN5Yjy/G3PUGpzY21nIIoWEZZy+FOBu6mnxKJCx2ZdVyOe1Z7hZBFNN9+MbQSePrU7js5PQsX1hBJcl3O92Tn5Rx75p9uvEaABt2MseOB3qYRvNYPIpAyQM5zxU1qilguRjgM3oB/wDXqeZ2sxc1oktqA9w6FN6n93gjH51XezsdNaVNNs7eKSc5meOMKXOehIq0tzEkshVwQv3iPU9qzdWuIrKze4vJkhiQ5ZmP60JO9jKMeaV3sOlhAOZP9UMliTyTXMeGbK78QePY9SuVaOxsQ6ogOVZiOOPXn9K7BZBPZL5Sq8DqCpI5YHrWhaXEGmRxrDCpEnzHZ2Pr+lUqjimktWKrOTjaO5R1JVAVQQOduT1/Cs+K4hhmlhRkeTA/dq2SPqK0LeewvftV0l1EywqzSFWDbCBz9DXE+CNMubxbq/uWdHuCfLZxzHHn5jnuSelXCOj5uhUaiiuVnd6VcCC1nlMJJQ+WuejN/wDW71RmcGJmcuN38I6f/qqWWQMkUcYCWsQ2qhPf1PqTWJ4l8QQ6LbedKytO7bYYyMlj9P8AIqIx5noVTg7uT3ZNo2i/Yozc3ccRu5CVjjQYVU/vP6n+VbdlbwwQ5kIb+IjJwT61z3haa/v9OF7qsZjeZsrDnLKM9W+tbshjih82dwFXpk4q53u0wle1rkOpxQ3JUyZCR5wi8Bge1FugkMaKAsYGCqjGB6VFbtHfJ50RO0cAj+VX32WGmS3l0CiDiOMcs3vSemg5NQVuo9ZwkbREb8k5VhxXNT+P/D9tqkGnpOs8m7yzHbpmOL/eIGD+FZN2/iPVE8q2X7Ml6rR/KpyiE4yD2471a0nwBDpcUFrHtijDbpJiAWc9wPatYwhH42RKEFu9TqdJ8VS3Ukj+RHbadaoQzbcAN2AH9K5/Ul1PxA5iLtaacW3ScYaXnoTnn6V0k9lbJZRW0cSiCHnbnjPqfU1yOu+NLe1ia00iP7ZcLj/VkbBn/a9fpShG79xEUKcY6pamlALLRrRLYyxxxRLuCnO4jPJwPU96tIh1CKKSDmMjch/rjtXIeH9D1a6kkvPEN68Vqz+YlsMAsOwZuuK9AstWsoojbW0kHmkYADAkD0xRNW2d2dE5tawVyGKz2DJ3Mx+6cZJNGo3UWnWUl1qEohjj5AAyfpx3p0V1JyehHc9qJgv2dpZVMkaDeRtyeP61mt9SJc1/eOGu7HXPGZK6h5mj6AWylupxcTj1f+6D6V1+i6ZaaRYQabZp5UEK4RQSTj8efxrDhl8ReI4ymk2L2cGfvyqQzD1yf5VNqHhTVY4DbxajIt04Be9kYbIfXHc1vJ391tLyJ9rDa507r5MYkUY5wG61J/ady0YEqo+wY56n0rj7fQbPw1bG8udT1LVZovnLOxVC3TIXvWSPiRAbjZJE0S5wrSkLnHXA6k1CouesNRxp+0V2jur2ZiDI5iiTglnO0fiTUFteafdO4sr60unAyVgfd+tc5dSad4yt4IvOwSDsET84PXIrV8LeGtL8MK0dlG5d+XkY5ZvbPaiUFFa7lSi4qxslIY3xcTbZMchT+VS2d/YRgKGRic/N15rm/HPh+61m0ih0XV105S+65eRSXK+ikfqKTwx4Ut9CtHitrmS7diGe4eQNn8jxUqMeW7epFozVpN/kdNeS/aXLBDsHO5RVDW7vU30eS00Se0tbpgPLlkye/PHrWpblLTbvXA6qPUetZmvWGn65DNYXEDPGVDsBuXbknGHHGeD3zURtdXIXK/da0GeHLnU7KwEGpXJu7xgQW245+ncVOZGTc0sEZucYBxg1n+FtOs9Bt5YLKa4bdxvmkMhHsM9K6GxkaKGQuok7DIzg5q5NXuipJQ15TIZWMW13WMMfmZ+AfwqO61fS9AghlupzMZ5PJVYwW3N/SovFmg3Wq6Y7RTPDvwFO3OOf0+tZHgvwc+l6qtxPcQNGp+4zE7uwPzd6qPI43b+QVZc0HZmjq2taDF4kg0uTVoItQuFUraYJZSexxwD7GrGoWUMtq8UUzZOCWjO3afUGqHxH8CWh1SPxbo+krJrUDCVjG5PmsBwdg6ms3wxquqaro89xJYC3v0JVY5CVRmA68jIHP6VUUnFSixYWbqx956dv8z0uxt430MQ+arkx7C3QniuBtPCMll4hm1OfVmeOPBhjjXDggY25HBHrXS6Kt+ugQw6gsSXbJumaEnYW74z0qk2fP2Ddy2OT+tZxbi2kyKVHmctdLiGWe8v45fLO9vlbA6fjSeJNItLjULO4uZnjnt/m2KeG+tatzfjTbcQQhJJzyFP8Puawpi0jSz3EpTClmd+gA6k+lKLd7m8Y+11atFfiQ3MBv/MtVVljmBGVPIFaGl6NPplnEsQmOwZyw7Vc0KW2uYIb6xaK4UruSTPDD1q5/wAJC/mGCa3BPT73A+tEpS+FE1Ks27U43seb+NNRNvfEC9mtJVIYLBtBb1PPYY7U/S/GN8PCn27UmYorssc3l7GnUdGCjpXU6vpmnaozXE9uks6fc3rkJ64rntdsLfVLJ7KYN9kIAXyzgqR/d9K2jKMkk0axSkrsdpuqR6tAL22uf3MoBG4Ec96KzZEstAt4LWJxBAAdiueff69aKfJfWOxTpmrLIesXzSdvb1JqVGdsiPGwYBJHtSuvluEt2UrkMPUfUVqx24+y+XGVJPJA6g9ciuZySMedLUWN0bTFdgqyKwXION30FQfLI8zBNyAYBz+eKqRI7ytLOSYoxg7uw7E1pxC3kQmEqQkbMzq3GAM0rWGpKGrFhAtLOScAByhwpPf0rC8J2Bt5ZZJiXldi755XPt9KZ4X1c6x4Vs7i63GV/M3DHUBjgA1P4f1T7XPcpDGVjiPX69j71paUVJDSv7zNe0nfzpHPyyHjkdvp6UyWBbiVUJxETyB/EO496isRLMZmZTgE4z3Ht61D4h1mTQ9Lint4999ckrCxGRGO5/3uwqUney3LnJQV1ubdqY7e2FpFtIjGWUH7n+zRFubLKCAFOBnqay/D1lLbadGJyPPlw8rk/eY9a6BYVtoVmcE5GPQiolZN6mTairdWUrKN5nWAJtCjc2O/ua5H4rabfakmladp6EJJOHkOeByMZ+nJre0nUJ7rx/LZ27H7Ja2pkuAOm4/dU+9bJKuV3HefMyvr/wDqq4ydOSkZym5TaWlhbGEghV+5EojXPHQdaiupWWGWOBR8qMuc43HB/StG8cwKI4GALdfc1z+t3CtewaPbgNcOonmOf9WgPA+pNRFOTFCV2mzkPgfaSX2la3b3SEDzxk4xuGTn684r0K9gkV/KhiMVtEAoHZiOlXvD8MNtFIyRpErNjjA+v41S1K7uLiRo87bfJCoByfrV1KjqTckhRlKVZ22MPW9Xh0i1eecNIQMJEnJkb0FYej6De6pcDV9cYxvN832fPzKv8Kew9q61NNtUniu72ENJFkR7ucfhVbUrq7kLGytjPMx2qBwBnufaqjOytHfudN7v3dl1JLm+t7GM7sBFHCisYG98Qn9+rW+n7vlH8Ug9vQVfsvD0ssZk1aQXEzH5vLOEGP4R61sKgBCIowPlA7ChSjHbcXPFfCNtIUtIUjgjA2rhVHb3qtqd/apcQRXEQuZ48bUycKT3I9a1LdDhljHP8b9hVG4jgFwZY0UydC3c1CavqZK0pamjHeJBtdU+Yj5v8Kjklcv9pnR3UnhVH8vSqkJycyDJIziquo6wsSFIHMsq9F9KFF9Bey190tSt/aulutzZS28cm6Jonblh+HrXG39zovhu5jtdN09GvHP3IhuYZ6ZJzgV2cFxcPYrJNGyMwyQe1ZzSWtrI0ri3hLffkbALe9aQlZ+RpSjY5J7XX/Ecy/bNtpYDGVyeuenq3GPaus0fRbDT0LwQKr/89TyzZ/lTYNaiuLoQWSSXgJA8yJcqo9Sela93bTnT2+zD951AxTnN25dkOc1omIiRhTvZVUnkmuZn8fql/NaeHdM1DUJopPLebytsSEdcHvViLwTc6ldPJrWs3j2pxi0ifbGfXcep+ldOYtI8O2KI8yw2q/Kqrnk/TrmleC03Zz1Jwvy7lTTdc1U2yvdQrDIeMMeQPpUbM8suXywwcZ5/Knv4y8KIrEEZHGXU5JrPXxL4b1iZ7Owu5YLiRWj+VSu046jPcVKjK7fLYKU1uoWNATiKLyLuNZYTxhhkj/61Yk/g7Q71y4hYoxJ+VRuyevzdawpfAN+sglg8UXs4Dbv355H4iuv0dLvT0VJZfMIAycZDVbXIrxkb2TTcXqU7Dw9YaTdu1pHKJgODI24j1OfetFQ6cnJ4xz1zWlLsulEseF7HNV7+F4ZVb7y4Bz1U/jUOTlu9SYVL+69yhexJc2jw3CsVlQqyqccd65bw18MU0bUTe6dqs/2aQ5MWz5gD2LDt+FdzbwtcQyBCFJBAHc1Xt3nj4jZ1UjawzTVSUU1F7hL3lZPYPEWiXGtWbWFlqX2K7ki2pcoMhSOme9eefEPxXrPgG48P+Hor0SXMyr5940QMdxk475wcjselGleONbt/FAstT8O3tlbSTlFuRllBzwScYIPsa9L1ee2vlgt9W0y0u/LIdDMgbB65Hp0q1em0pq6MKkal+WOq7P8APoSQSQalY28k8CQXmwE7eOe+aqazqY0HTJbiSHeIgcIDjfxnGa1NPtIntnJTDkblXPArnhqNrqZu7G9iE0KMY3Q8Y596xSTfkOEeZuMdUv60N/wXrkHiLR1uY4ZrV+kkEw+ZK888Z2nih/EqxwNDLoijzWTcFOBn2zn8cV2VnPbWEUkVqCgxtRmbnHoa4q607xd/wmQnGr2f9iHG2D7zEHqDx9e9aUklNtbeY6NJ05OT2fQTw18W7eO2K67AIrdlLW8qNksqnaQR/eHt1rtJWuZ7f7fass9tMokikQZwhGQffqK8f8Y+FbzQNZhuNK0uDUtHuQy/Z5/mEDE5YL3UHHWvatA1aNtBh2xCJYolAiAxsGOFq60YJKdNbl1I8j56avfc881yXVfEdhcWVvdC2vE6EsyjIPQ46Z7VN4Ls9W0y08nVLgzuANhkO4q3OcE8100627TSSExQBmyNxC8/XvUCTxG/kgMmLiNclW/mPWnz3jypaHXHlSsXkifyFnU7pWf5i/Jaud8ZzQWejyprENzLbSAMRFHuI9x2/Cu38PuCCrR9e+K6CXymi2yhGA7MBXN7Xklqjhq4p0pOHLc+e9O+Ivh/TLW2stFTULiZVMSW6Q43HPA6+tdlFr1jpf2c+I50tL28AeO1L5dV7bvSudmvbHUfHbW8GiC0lspS4ukQAexyO+awb3wRI11NqviG7N/JEzSHaSGuDn5S57ADHArtcIS30v8AebxjUm+yPWHvUnCPbRsqqc9M5zVR4lZwYwSRzz0rmfDmv6hfXyWpmgeOJAxSOLaEXpwc8iuqtFZVmcn9xtIDe9YSjyaGiXKeN/E/UY/7XgRESULGc7+QDntRXoFt4b06Ge4mnUXLztu3SKCAPQfnRXZDFxhFRs2axqtK1j//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a jejunal leiomyoma shows sheets of short, spindled, and round cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31513=[""].join("\n");
var outline_f30_49_31513=null;
var title_f30_49_31514="Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults";
var content_f30_49_31514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31514/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31514/contributors\">",
"     Thomas J Marrie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31514/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/49/31514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/49/31514/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/49/31514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in elderly patients and those with significant comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=see_link\">",
"     \"Prognosis of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and microbiology of CAP in adults will be reviewed here. A variety of other important issues related to CAP are discussed separately. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic approach to patients with CAP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of sputum cultures for the evaluation of bacterial pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=see_link\">",
"       \"Sputum cultures for the evaluation of bacterial pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      How one makes the decision to admit patients with CAP to the hospital. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=see_link\">",
"       \"Community-acquired pneumonia in adults: Risk stratification and the decision to admit\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients treated in the outpatient setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment recommendations for CAP in patients requiring hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The evidence for efficacy of different antibiotic medications in the empiric treatment of CAP and issues related to drug resistance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumonia in special populations, such as aspiration pneumonia and immunocompromised patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"       \"Aspiration pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=see_link\">",
"       \"Pulmonary infections in immunocompromised patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prognosis of CAP. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=see_link\">",
"       \"Prognosis of community-acquired pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall rate of community-acquired pneumonia (CAP) in adults is approximately 5.16 to 6.11 cases per 1000 persons per year; the rate of CAP increases with increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/2\">",
"     2",
"    </a>",
"    ]. There is seasonal variation, with more cases occurring during the winter months. The rates of pneumonia are higher for men than for women and for black persons compared with Caucasians. The etiology of CAP varies by geographic region; however, Streptococcus pneumoniae is the most common cause of pneumonia worldwide.",
"   </p>",
"   <p>",
"    In 2005, pneumonia and influenza combined was the eighth most common cause of death in the United States and the seventh most common cause of death in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. There were over 60,000 deaths due to pneumonia in the United States. Mortality is highest for CAP patients who require hospitalization, with a 30-day mortality rate of up to 23 percent in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/3\">",
"     3",
"    </a>",
"    ]. All-cause mortality in patients with CAP is as high as 28 percent within one year. Given the aging population in North America, it is expected that the burden of CAP will increase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=see_link\">",
"     \"Prognosis of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs are constantly exposed to particulate material and microbes that are present in the upper airways and, by microaspiration, enter the lower respiratory tract. Nevertheless, the lower airways usually remain sterile because of the pulmonary defense mechanisms. These host defenses can be categorized as innate (nonspecific) or acquired (specific). The development of community-acquired pneumonia (CAP) indicates either a defect in host defenses, exposure to a particularly virulent microorganism, or an overwhelming inoculum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although microaspiration is the most common mechanism through which pathogens reach the lung, hematogenous spread from a distant infected site, direct spread from a contiguous focus, and macroaspiration are other mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some microorganisms have developed specific mechanisms to overcome pulmonary host defenses and establish infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chlamydophila pneumoniae produces a ciliostatic factor.",
"     </li>",
"     <li>",
"      Mycoplasma pneumoniae can shear off cilia.",
"     </li>",
"     <li>",
"      Influenza virus markedly reduces tracheal mucus velocity within hours of onset of infection and for up to 12 weeks postinfection.",
"     </li>",
"     <li>",
"      Streptococcus pneumoniae and Neisseria meningitidis produce proteases that can split secretory IgA. In addition, the pneumococcus produces other virulence factors, including: the capsule that inhibits phagocytosis, pneumolysin, a thiol-activated cytolysin that interacts with cholesterol in host cell membranes, neuraminidase, and hyaluronidase.",
"     </li>",
"     <li>",
"      Mycobacterium spp, Nocardia spp, and Legionella spp are resistant to the microbicidal activity of phagocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Predisposing host conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to microbial virulence factors, diseases and conditions in the host may lead to impairment of pulmonary defense and increased risk of CAP (",
"    <a class=\"graphic graphic_table graphicRef52808 \" href=\"mobipreview.htm?13/10/13485\">",
"     table 1",
"    </a>",
"    ). These conditions include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alterations in the level of consciousness, which predispose to both macroaspiration of stomach contents (due to stroke, seizures, drug intoxication, anesthesia, and alcohol abuse) and to microaspiration of upper airway secretions during sleep",
"     </li>",
"     <li>",
"      Smoking tobacco",
"     </li>",
"     <li>",
"      Alcohol consumption",
"     </li>",
"     <li>",
"      Hypoxemia",
"     </li>",
"     <li>",
"      Acidosis",
"     </li>",
"     <li>",
"      Toxic inhalations",
"     </li>",
"     <li>",
"      Pulmonary edema",
"     </li>",
"     <li>",
"      Uremia",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Administration of immunosuppressive agents (solid organ or stem cell transplant recipients, or patients receiving chemotherapy)",
"     </li>",
"     <li>",
"      Mechanical obstruction of a bronchus",
"     </li>",
"     <li>",
"      Being elderly; there is a marked increase in the rate of pneumonia in persons &ge;65 years of age",
"     </li>",
"     <li>",
"      Cystic fibrosis",
"     </li>",
"     <li>",
"      Bronchiectasis",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease (COPD)",
"     </li>",
"     <li>",
"      Previous episode of pneumonia or chronic bronchitis",
"     </li>",
"     <li>",
"      Immotile cilia syndrome",
"     </li>",
"     <li>",
"      Kartagener's syndrome (ciliary dysfunction, situs inversus, sinusitis, bronchiectasis)",
"     </li>",
"     <li>",
"      Young's syndrome (azoospermia, sinusitis, pneumonia)",
"     </li>",
"     <li>",
"      Dysphagia due to esophageal lesions and motility problems",
"     </li>",
"     <li>",
"      HIV infection (especially for pneumococcal pneumonia) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15449?source=see_link&amp;anchor=H9#H9\">",
"       \"Bacterial pulmonary infections in HIV-infected patients\", section on 'Community-acquired pneumonia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Viral respiratory tract infection, especially influenza; influenza can cause viral pneumonia and predispose patients to bacterial pneumonia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations of seasonal influenza in adults\", section on 'Pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung cancer",
"     </li>",
"     <li>",
"      Bronchial obstruction due to stenosis, tumor, or foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested an increased incidence of nosocomial pneumonia when the gastric pH is increased by the use of H2 blockers, proton pump inhibitors (PPIs), or antacids (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Role of gastric pH'",
"    </a>",
"    ). Several studies have also shown an increased risk of CAP among patients taking gastric acid-suppressive therapy, including PPIs and H2 blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, one large case-control study found an increased risk of CAP only among patients who started a PPI within the previous 30 days and particularly in those who initiated therapy within the previous 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/12\">",
"     12",
"    </a>",
"    ]. The significance of this finding is uncertain since maximum acid-blocking effect takes at least one week to develop.",
"   </p>",
"   <p>",
"    In a cohort study, not only CAP, but also several other conditions that are unlikely to be caused by PPI use (eg, chest pain, osteoarthritis, urinary tract infection), were more likely to occur in patients receiving a PPI, suggesting that confounding could be causing the observed associations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have shown an association between use of antipsychotic drugs and CAP, although the mechanism remains unclear. In one case-control study, use of antipsychotic drugs was associated with an almost 60 percent increase in the risk of pneumonia among elderly persons requiring hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/14\">",
"     14",
"    </a>",
"    ]. In another case-control study, current use of atypical (odds ratio [OR] 2.61, 95% CI 1.48-4.61) or typical (OR 1.76, 95% CI 1.22-2.53) antipsychotic use was associated with a dose-dependent increased risk for CAP compared with past use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/15\">",
"     15",
"    </a>",
"    ]. Atypical antipsychotic use was also associated with an increase in the risk of fatal CAP (OR 5.97, 95% CI 1.49-23.98).",
"   </p>",
"   <p>",
"    In a case-control study that evaluated inhaled drugs as possible risk factors for CAP, patients with COPD who were receiving inhaled glucocorticoids were at increased risk for CAP (OR 3.26, 95% CI 1.07-9.98), and patients with asthma who were receiving inhaled anticholinergic agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide) were at increased risk for CAP (OR 8.80, 95% CI 1.02-75.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/16\">",
"     16",
"    </a>",
"    ]. It was not possible to determine definitively whether these associations were due to the inhaled drugs or to the severity of the underlying pulmonary disease. Inhaled glucocorticoids did not increase the risk for CAP among patients with chronic bronchitis or asthma.",
"   </p>",
"   <p>",
"    In a meta-analysis of randomized trials and observational studies, ACE inhibitors were associated with a reduced risk of pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/17\">",
"     17",
"    </a>",
"    ]. However, an accompanying editorial noted that this effect was seen only in observational studies (but not in randomized trials), there was a high likelihood of reporting bias, respiratory infection was not a primary outcome of most of the studies, and there was substantial heterogeneity among the studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are more than 100 microbes (bacteria, viruses, fungi, and parasites) that can cause community-acquired pneumonia (CAP). Most cases of pneumonia are caused by four or five microorganisms, but the distribution of pathogens varies with the clinical setting (",
"    <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common pathogens based upon the severity of illness as judged by the site of care (outpatient versus inpatient versus intensive care unit [ICU]) are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/19-25\">",
"     19-25",
"    </a>",
"    ]. Streptococcus pneumoniae is the most frequently isolated pathogen. Other common causes include respiratory viruses, Mycoplasma pneumoniae, and Legionella spp. Chlamydophila pneumoniae is often ranked as the fourth or fifth most common cause of pneumonia, but there is considerable controversy over where it fits as a cause of pneumonia given the lack of reliable diagnostic tests. The \"atypical\" pathogens (M. pneumoniae, Legionella spp, C. pneumoniae, Chlamydophila psittaci) are not often identified in clinical practice, because there are no specific, rapid, or standardized tests for their detection with the exception of Legionella pneumophila.",
"   </p>",
"   <p>",
"    Influenza remains the predominant viral cause of CAP in adults. Other viral pathogens include respiratory syncytial virus (RSV), parainfluenza viruses, adenovirus, and, less commonly, human metapneumovirus (HMPV), varicella, and severe acute respiratory syndrome (SARS). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Viruses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas aeruginosa are pathogens in a selected group of patients (eg, post-influenza, prior antimicrobial treatment, or pulmonary comorbidities) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/26\">",
"     26",
"    </a>",
"    ]. In another specific group, patients admitted to the ICU with severe CAP, the predominant pathogens are S. pneumoniae, enteric gram-negative bacilli, S. aureus, respiratory viruses, Legionella spp, and Haemophilus influenzae (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The frequency of other etiologic agents, such as Mycobacterium tuberculosis, C. psittaci (psittacosis), Coxiella burnetii (Q fever), Francisella tularensis (tularemia), and endemic fungi (histoplasmosis, coccidioidomycosis, histoplasmosis), varies with the epidemiologic setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria are the most common cause of CAP and have traditionally been divided into two groups, \"typical\" and \"atypical\" agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Typical\" organisms include S. pneumoniae, H. influenzae, S. aureus, Group A streptococci, Moraxella catarrhalis, anaerobes, and aerobic gram-negative bacteria.",
"     </li>",
"     <li>",
"      \"Atypical pneumonia&rdquo; refers to pneumonia caused by Legionella spp, M. pneumoniae, Chlamydophila (formerly Chlamydia) pneumoniae, and C. psittaci; although imprecise, we use this term because of its acceptance amongst clinicians.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the individual patient, there are no findings from history, physical examination, or routine laboratory studies that allow the clinician to distinguish pneumonia caused by atypical versus typical organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Microbiologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A microbiologic diagnosis was confirmed in 42 to 67 percent of cases of CAP in studies that used specialized tests to detect various pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/19,20,24\">",
"     19,20,24",
"    </a>",
"    ], but in a lower percentage of cases in studies that did not used specialized tests (",
"    <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"     table 2",
"    </a>",
"    ). As an example, in a study of inpatients with CAP that used only routine cultures and urinary antigen testing for L. pneumophila, a pathogen was identified in 24 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/22\">",
"     22",
"    </a>",
"    ]. In another study of inpatients with CAP that used only blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory cultures, an etiology was found in 17 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/27\">",
"     27",
"    </a>",
"    ]. In clinical practice, an etiologic agent is identified even less frequently. In a review of 17,435 cases of CAP in the Medicare database for United States emergency departments, an etiologic diagnosis was reported in only 7.6 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/28\">",
"     28",
"    </a>",
"    ]. It is important to note that studies that included serologic testing may have overestimated the incidence of CAP caused by specific pathogens, such as M. pneumoniae and C. pneumoniae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/19-21,24\">",
"     19-21,24",
"    </a>",
"    ], since positive serologic results may represent recent infection rather than active infection.",
"   </p>",
"   <p>",
"    When considering the etiology of CAP it is useful to categorize patients into those who can be treated on an ambulatory basis, those who require hospitalization, and those who require admission to an intensive care unit. The rank order of the most common causes of pneumonia varies according to the severity of illness, as illustrated in the following studies (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 507 patients treated in an ambulatory setting in Canada, the most commonly identified microorganisms were M. pneumoniae (17 percent), C. pneumoniae (14 percent), S. pneumoniae (6 percent), and H. influenzae (5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/25\">",
"       25",
"      </a>",
"      ]. Despite considerable effort, an etiologic diagnosis could not be determined in 52 percent of cases.",
"     </li>",
"     <li>",
"      In a prospective study from Spain that included 2521 ward patients with CAP, the most commonly identified organisms were S. pneumoniae (18 percent), respiratory viruses (5 percent), L. pneumophila (4 percent), and H. influenzae (2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/24\">",
"       24",
"      </a>",
"      ]. An etiology could not be determined in 59 percent of cases.",
"     </li>",
"     <li>",
"      In the same study from Spain, among 488 patients admitted to the intensive care unit, the most commonly identified organisms were S. pneumoniae (23 percent), L. pneumophila (4 percent), Pseudomonas aeruginosa (3 percent), C. pneumoniae (2 percent), and H. influenzae (2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/24\">",
"       24",
"      </a>",
"      ]. No pathogen was identified in 47 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Epidemiologic clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting clinical manifestations cannot reliably differentiate between different etiologies, but there are a few epidemiologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical clues that can be helpful and must be taken into account when considering the etiology of CAP (",
"    <a class=\"graphic graphic_table graphicRef52808 \" href=\"mobipreview.htm?13/10/13485\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Know the local epidemiology and the patient's travel history (eg, endemic fungi, such as Histoplasma, Coccidioides, Blastomyces, and Paracoccidioides spp; hantavirus).",
"     </li>",
"     <li>",
"      Elicit history of specific exposures (eg, Histoplasma spp and bat or bird droppings, C. psittaci and birds).",
"     </li>",
"     <li>",
"      Be aware of national and international outbreaks (eg, influenza or SARS).",
"     </li>",
"     <li>",
"      Methicillin-resistant S. aureus (MRSA) is an increasingly recognized cause of severe, occasionally necrotizing CAP. Risk factors for CAP caused by MRSA are discussed below. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'S. aureus'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      MRSA and multidrug-resistant gram-negative bacilli, such as P. aeruginosa and extended-spectrum beta-lactamase producing gram-negative bacilli, should be considered in patients presenting with pneumonia who have been hospitalized for at least 48 hours within the preceding 90 days, reside in a long-term care facility, receive hemodialysis chronically, or are critically ill [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients who have any of these historical features (recent hospitalization, long-term care facility residence, or hemodialysis) are classified as having healthcare-associated pneumonia rather than CAP. HCAP is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Pneumonia types'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=see_link&amp;anchor=H249925653#H249925653\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Approach to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are severely ill with influenza pneumonia should be evaluated for secondary bacterial pneumonia, which is most likely to be caused by S. pneumoniae, S. aureus (including MRSA), or group A streptococcus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations of seasonal influenza in adults\", section on 'Secondary bacterial pneumonia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Bacterial superinfection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Never forget M. tuberculosis.",
"     </li>",
"     <li>",
"      Pneumocystis jirovecii (formerly P. carinii) is often forgotten as a cause of CAP now that antiretroviral therapy has resulted in a decrease in the number of cases of PCP in HIV-infected patients. However, it continues to cause pneumonia in patients with risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria are the most common cause of CAP. The true incidence of these infections is uncertain because of the difficulty in distinguishing colonizing organisms from pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     S. pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. pneumoniae is the most common cause of CAP. Many studies have isolated the organism in only 5 to 18 percent of cases. However, the rate of isolation increases when more invasive methods are used for obtaining specimens, such as transtracheal aspiration, which eliminates contaminating oropharyngeal flora. It is currently believed that many culture-negative cases are caused by pneumococcus. The data supporting this conclusion are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13386?source=see_link&amp;anchor=H2#H2\">",
"     \"Pneumococcal pneumonia in adults\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     H. influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-typeable H. influenzae is an important cause of pneumonia in elderly adults and in patients with underlying pulmonary disease, such as cystic fibrosis and COPD. The clinical features are indistinguishable from CAP caused by other organisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41608?source=see_link\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     M. pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. pneumoniae is one of the most common causes of atypical pneumonia in series from the United States and other parts of the world, accounting for up to 15 percent of cases of pneumonia treated in an ambulatory setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/25\">",
"     25",
"    </a>",
"    ]. M. pneumoniae is transmitted from person-to-person by infected respiratory droplets during close contact. Infection rates are highest in school-aged children, military recruits, and college students. Substantial rates of macrolide resistance have been observed in certain regions, such as Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     C. pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of C. pneumoniae in adults with CAP has varied in different studies from 0 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/19-21,24\">",
"     19-21,24",
"    </a>",
"    ], although the validity of these data is in question due to problems with diagnostic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. One problem is the use of a serologic test in many studies, which lacks both sensitivity and specificity for C. pneumoniae. In addition, positive serologic results may represent either current or past infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Chlamydophila (Chlamydia) pneumoniae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7270?source=see_link&amp;anchor=H6#H6\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transmission of the organism is thought to be person-to-person and has been implicated in outbreaks of pneumonia in residents of long-term care facilities and military recruits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Unlike other respiratory infections, which have peak rates in the winter months, C. pneumoniae infection does not vary significantly by season. Pneumonia and bronchitis are the most common respiratory infections associated with C. pneumoniae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Legionella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legionella accounts for 2 to 9 percent of cases of CAP. Legionella can occur as a sporadic infection or cause outbreaks. Travel-associated legionellosis is becoming more common. In most instances Legionella is transmitted to humans by inhalation of aerosols containing the bacteria. Outbreaks have been associated with exposure to a variety of aerosol-producing devices, including showers, a grocery store mist machine, cooling towers, whirlpool spas, and decorative fountains. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32680?source=see_link\">",
"     \"Epidemiology and pathogenesis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Gram-negative bacilli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative bacilli, especially Klebsiella pneumoniae, Escherichia coli, Enterobacter spp, Serratia spp, Proteus spp, Pseudomonas aeruginosa, and Acinetobacter spp are uncommon causes of CAP except in patients with severe pneumonia requiring admission to an intensive care unit where, as a group, they are among the most commonly isolated organisms after S. pneumoniae (",
"    <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'Common pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Klebsiella pneumoniae &mdash; K. pneumoniae is responsible for approximately 6 percent of cases of CAP in Asia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/21\">",
"       21",
"      </a>",
"      ], but is less common in other regions (",
"      <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"       table 2",
"      </a>",
"      ). K. pneumoniae must be considered as a cause of severe CAP in patients who have significant underlying disease, such as COPD, diabetes, and alcohol abuse. In a study of 112 immunocompetent patients with severe CAP, multivariate analysis found K. pneumoniae was an independent risk factor for mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38426?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Community-acquired pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa &mdash; Risk factors for community-acquired P. aeruginosa pneumonia include bronchiectasis (eg, due to cystic fibrosis) and the use of repeated antibiotic courses or prolonged glucocorticoids in patients with other structural lung abnormalities, such as COPD and pulmonary fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/1,26,38\">",
"       1,26,38",
"      </a>",
"      ]. Immunocompromise (eg, neutropenia, HIV infection, solid organ or hematopoietic stem cell transplantation) and previous hospitalization are other risk factors for Pseudomonas pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=see_link\">",
"       \"Pseudomonas aeruginosa pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acinetobacter spp &mdash; Acinetobacter spp are well-recognized as pathogens causing nosocomial pneumonia. In addition, Acinetobacter baumannii is emerging as a cause of severe CAP with high mortality. Multidrug resistance is an increasing problem with Acinetobacter infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23402?source=see_link\">",
"       \"Treatment and prevention of Acinetobacter infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23402?source=see_link&amp;anchor=H1211125#H1211125\">",
"       \"Treatment and prevention of Acinetobacter infection\", section on 'Pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Moraxella catarrhalis &mdash; Moraxella is a gram-negative diplococcus that can cause lower respiratory tract infections in adults with COPD and in immunocompromised persons. In a review of 58 patients with M. catarrhalis bacteremia, 70 percent had predisposing factors, such as neutropenia, malignancy, or COPD, either alone or in combination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/39\">",
"       39",
"      </a>",
"      ]. Many patients with this infection are malnourished. Not infrequently, it is a copathogen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     S. aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. aureus pneumonia that is community-acquired is usually seen in elderly adults and in younger patients who are recovering from influenza (postinfluenza pneumonia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. However, the pneumococcus remains the most frequent pathogen in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Secondary bacterial pneumonia'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    During the 2003 to 2004 influenza season, 17 cases of S. aureus CAP were reported to the United States Centers for Disease Control and Prevention (CDC) from nine states; 15 cases were CA-MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/42\">",
"     42",
"    </a>",
"    ]. All isolates had community-associated genetic characteristics; 12 of 13 available S. aureus isolates had the Panton-Valentine leukocidin gene. Influenza virus infection was also documented in 12 (71 percent) of cases. All patients were hospitalized and death occurred in five (29 percent); four of the deaths were in patients with MRSA infection. Another outbreak of 10 cases of severe CA-MRSA pneumonia occurred in association with influenza during the 2006 to 2007 influenza season [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/43\">",
"     43",
"    </a>",
"    ]. Six of the patients died.",
"    <br/>",
"    <br/>",
"    In a study of 627 patients who presented to emergency departments in 12 cities in the United States between the winter of 2006 and the spring of 2007 and who were hospitalized with CAP, S. aureus was cultured from the blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory tract in 24 patients (4 percent); of these S. aureus infections, 9 (2 percent) were caused by methicillin-susceptible S. aureus and 14 (2.4 percent) were caused by methicillin-resistant S. aureus (MRSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/27\">",
"     27",
"    </a>",
"    ]. Isolation of MRSA (as compared with any other or no pathogen) was associated with a patient history of MRSA; nursing home admission in the previous year; close contact with someone with a skin infection during the previous month; multiple infiltrates or cavities on chest radiograph; and comatose state, intubation, receipt of pressor agents, or death in the emergency department.",
"   </p>",
"   <p>",
"    Community-associated methicillin-resistant S. aureus (CA-MRSA) is often associated with severe necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/41-43,45-49\">",
"     41-43,45-49",
"    </a>",
"    ]. The tendency to necrotizing pneumonia may be mediated by Panton-Valentine leukocidin (PVL), which is typically present in CA-MRSA strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/41-43,46-48,50,51\">",
"     41-43,46-48,50,51",
"    </a>",
"    ]. This was illustrated in a study that compared the clinical features of 16 patients with PVL-positive S. aureus pneumonia to 36 cases of PVL-negative S. aureus pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/46\">",
"     46",
"    </a>",
"    ]. Hemoptysis was significantly associated with pneumonia in patients with PVL-positive strains compared with those with PVL-negative strains (38 versus 3 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\", section on 'Community-associated methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of PVL was more directly demonstrated in a mouse model of acute pneumonia that included PVL-negative and PVL-positive CA-MRSA strains, as well as purified PVL; PVL alone was sufficient to cause necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/52\">",
"     52",
"    </a>",
"    ]. PVL induced global changes in the transcriptional levels of genes encoding multiple staphylococcal proteins, including the lung inflammatory factor staphylococcal protein A. However, subsequent reports have disproven the role of PVL as a virulence factor in MRSA pulmonary infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/53-57\">",
"     53-57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Group A streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group A streptococcus (GAS, S. pyogenes) can cause a fulminant pneumonia with early empyema formation even in young, immunocompetent hosts. In a prospective surveillance study for invasive GAS infection, pneumonia accounted for 11 percent of cases with a mortality rate of 38 percent compared with 26 percent for necrotizing fasciitis and 12 percent for the entire cohort of invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest outbreak of GAS pneumonia in the United States occurred in 2002 among military recruits at the recruiting depot in San Diego [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Twenty-seven percent of 127 cases of pneumonia were definitely or probably due to GAS and another 17 percent were coinfected with GAS and another pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The epidemic occurred despite prophylaxis against GAS, but was ended after the administration of additional prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Anaerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic organisms may be the cause of aspiration pneumonia and lung abscess. However, their role in CAP is not clear since detection in routine sputum cultures is not possible. Some studies using transtracheal and bronchoscopic aspirates with quantitative cultures suggest that anaerobes may account for 20 to 30 percent of pneumonias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Neisseria meningitidis",
"    </span>",
"    &nbsp;&mdash;&nbsp;N. meningitidis is an uncommon cause of CAP. Meningococcal pneumonia has no distinguishing clinical features compared with other causes of CAP. However, pneumonia due to N. meningitidis should be reported to the health department and prophylaxis given as for meningitis or septicemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=see_link\">",
"     \"Clinical manifestations of meningococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     M. tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. tuberculosis is an important cause of CAP in developing countries and in some regions of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Missed diagnosis is common as illustrated in report from Baltimore in which 16 of 33 patients (48 percent) with culture-confirmed pulmonary TB were initially treated for presumed CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other bacteria that can cause CAP include Francisella tularensis (tularemia), C. burnetii (Q fever), and Bacillus anthracis. These microorganisms are described below. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'CAP and bioterrorism agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of specific viral pathogens varies with the diagnostic study used for detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/64\">",
"     64",
"    </a>",
"    ]. The use of the polymerase chain reaction (PCR) has increased the diagnostic yield compared with conventional tests, such as viral culture and antigen detection assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. As an example, in a randomized controlled trial that included 107 inpatients with CAP, real-time PCR increased the diagnostic yield compared to conventional diagnostic procedures (43 compared to 21 percent) with 26 viral etiologies identified by PCR compared to only 16 by conventional methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/65\">",
"     65",
"    </a>",
"    ]. In other studies that used PCR with or without other methods, viruses were detected in approximately one-third of cases of CAP in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/19,23,66,67\">",
"     19,23,66,67",
"    </a>",
"    ]. Since respiratory virus can be present in the upper airways without causing illness, studies using multiplex PCR may overestimate the frequency of viruses as a cause of CAP. Using PCR, nasopharyngeal swabs are positive for respiratory tract viruses in 20 to 30 percent of healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Influenza remains the predominant viral cause of CAP in adults; other common viral pathogens include RSV, parainfluenza viruses, and adenovirus (",
"    <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/66\">",
"     66",
"    </a>",
"    ]. Other viruses that have been detected in patients with CAP include rhinoviruses, coronaviruses, and HMPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/66\">",
"     66",
"    </a>",
"    ]. However, in a study that used multiplex PCR, in 30 of 32 patients in whom rhinovirus or a coronavirus was implicated, another organism was also identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/69\">",
"     69",
"    </a>",
"    ]. The most likely reason for this is that rhinovirus and coronavirus were not causing the pneumonia, but impairing upper airway defenses so that pathogens can establish themselves in the lower respiratory tract.",
"   </p>",
"   <p>",
"    Although viruses are commonly found in the nasopharynx of adults with CAP, it is often unclear whether these viruses are the sole agents causing CAP. In addition to possibly predisposing patients to infections with other organisms, the presence of a respiratory virus may also represent prolonged shedding (especially in immunocompromised hosts), upper respiratory tract infection, or colonization.",
"   </p>",
"   <p>",
"    The rate of mixed viral-bacterial infection is approximately 20 percent; such mixed infections have been found to be associated with more severe CAP and longer hospitalization than CAP caused by bacteria alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Influenza virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza A or B viruses cause an acute respiratory illness that occurs in outbreaks and epidemics worldwide, mainly in the winter season. Influenza viruses can cause pneumonia, although they are far more likely to cause upper respiratory tract infection and to predispose to secondary pulmonary infection by bacteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Respiratory'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary influenza pneumonia occurs when influenza virus infection directly involves the lung, typically producing a severe pneumonia. Influenza pneumonia occurs most frequently in certain groups of patients with underlying chronic illnesses who are classified as \"high risk\" for this infection (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"mobipreview.htm?32/50/33579\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <br/>",
"    Patients who are severely ill with influenza should be evaluated for a secondary bacterial pneumonia, which is most likely to be caused by S. pneumoniae, S. aureus (including MRSA), or group A streptococci. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Secondary bacterial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Bacterial superinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Parainfluenza viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parainfluenza viruses are important respiratory pathogens in immunocompromised adults, causing potentially life-threatening lower respiratory tract infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Respiratory syncytial virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;RSV causes acute respiratory tract illness in persons of all ages. Traditionally a viral pathogen of children, RSV can also cause CAP in adults, and can be particularly severe in elderly adults and immunocompromised individuals (eg, hematopoietic cell transplant recipients). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Adenovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenovirus pneumonia was first described among military recruits in whom it causes an \"atypical pneumonia.\" The usual symptoms are fever, malaise, and cough (often with substernal discomfort). Increased peribronchial markings with patchy alveolar infiltrates are found on chest radiography. Pneumonia occasionally results in fatalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Human metapneumovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMPV was first described in 2001 in the Netherlands. HMPV can cause upper and lower respiratory tract infection in patients of all age groups, but symptomatic disease most often occurs in the young children or older adults. It is an emerging pathogen as a cause of CAP in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Severe acute respiratory syndrome (SARS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In November 2002, an outbreak of SARS started in Guangdong Province in southern China and spread worldwide, affecting more than 8,000 persons. SARS was due to a novel coronavirus that jumped the species barrier from civet cats to man. The case fatality rate of the 2003 Hong Kong outbreak was 11 percent, but higher mortality was seen in elderly adults (&ge;60 years of age) and pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=see_link\">",
"     \"Severe acute respiratory syndrome (SARS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Other coronaviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human coronaviruses were first described in association with respiratory infections in 1935, but were ignored until the advent of SARS. HCoV-229E and HCoV-OC43 caused upper and lower respiratory tract infections prior to the SARS outbreaks. Since that time, human coronaviruses, HCoV-NL63 and CoV-HKU1 have been identified as additional etiologic agents in CAP.",
"   </p>",
"   <p>",
"    HCoV-NL63 was recovered from",
"    <span class=\"nowrap\">",
"     19/525",
"    </span>",
"    (3.6 percent) of respiratory specimens collected from laboratories across Canada in 2001 and 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/71\">",
"     71",
"    </a>",
"    ], primarily causing infections of the upper respiratory tract. In contrast, CoV-HKU1 accounted for 2.4 percent",
"    <span class=\"nowrap\">",
"     (10/418)",
"    </span>",
"    of CAP in Hong Kong [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41176?source=see_link\">",
"     \"Coronaviruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Hantavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In May 1993, an outbreak of severe respiratory illness, caused by a previously unknown virus, hantavirus, occurred in the southwestern United States. The illness was preceded by prodromal flu-like symptoms, followed by noncardiogenic pulmonary edema. The virus accounting for the initial cases, Sin Nombre virus, is spread to humans from infected mice. Subsequently, other hantaviruses have been found to cause hantavirus pulmonary syndrome, and the disease has been described in other parts of the United States, western Canada, and South America. It is important to recognize that hantavirus does not cause pneumonia, but instead causes an acute respiratory distress syndrome (ARDS)-like picture, due to the host response to this virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38119?source=see_link\">",
"     \"Hantavirus cardiopulmonary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Avian influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first association of avian influenza H5N1 with clinical respiratory disease occurred in Hong Kong in 1997, when 18 human cases occurred during a poultry outbreak of highly pathogenic H5N1 influenza in live-bird markets. The clinical features of avian influenza are variable, being determined in part by the strain. In the 1997 outbreak, 58 percent of patients had pneumonia. The World Health Organization (WHO) and the CDC consider avian influence a potential source for the next global influenza pandemic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella pneumonia is the most frequent complication of varicella infection in normal healthy adults with a reported incidence of about one in 400 cases. The case-fatality rate is between 10 and 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal infection is an unusual cause of CAP in the immunocompetent patient. Fungal infection is more common in the immunocompromised patient, particularly those with neutropenia, those receiving chronic immunosuppressive therapy (eg, organ transplant recipients), and those infected with HIV. Fungal infections can be endemic to particular geographic areas; as a result, the specific epidemiology of some fungal infections is important as a diagnostic clue.",
"   </p>",
"   <p>",
"    A retrospective study examined the microbiologic etiology of 94 cases of community-acquired pulmonary fungal infection hospitalized in Taiwan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/73\">",
"     73",
"    </a>",
"    ]. The criteria for diagnosis were a lung lesion on chest radiographs and either the presence or isolation of fungi from a tissue biopsy, pleural effusion, or blood. The most frequently isolated fungi were Aspergillus species (56 percent), followed by Cryptococcus species (31 percent), and Candida species (4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Cryptococcus spp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcus organisms are found in the soil throughout the world and a significant percent of the population has most likely been exposed to these organisms. Primary infections occur in both immunocompetent and immunocompromised persons. In immunocompetent individuals, primary infections are most commonly asymptomatic and usually discovered as an incidental finding on chest radiograph. In contrast, cryptococcal pneumonia in immunocompromised patients is usually symptomatic with the most common signs and symptoms being cough, fever, and dyspnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/24/37254?source=see_link\">",
"     \"Microbiology and epidemiology of cryptococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Histoplasma capsulatum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasma capsulatum is found worldwide; within the United States, infection is most common in the Midwestern states located in the Ohio and Mississippi River valleys. H. capsulatum proliferates best in soil contaminated with bird or bat droppings. Less than 5 percent of exposed individuals develop symptomatic disease after a low level exposure. However, the majority of patients develop symptomatic infection following more extensive exposure, as occurs with activities that disturb heavily contaminated soil or areas with large amounts of bird or bat droppings.",
"   </p>",
"   <p>",
"    Symptomatic patients with acute histoplasmosis generally present with a flu-like illness with pulmonary complaints and radiographic abnormalities, including bronchopneumonia or signs of interstitial pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Coccidioides spp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coccidioidomycosis is the infection caused by the dimorphic fungi of the genus Coccidioides (C. immitis and C. posadasii). These fungi are endemic to certain lower deserts of the western hemisphere, including southern Arizona, central California, southwestern New Mexico, and west Texas in the United States. They are also found in parts of Mexico, Central, and South America. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link&amp;anchor=H2#H2\">",
"     \"Primary coccidioidal infection\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary coccidioidal infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective observational study of 55 adults with CAP in Arizona found serologic evidence for Coccidioidomycosis (valley fever) as the etiologic agent in 16 (29 percent) patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/74\">",
"     74",
"    </a>",
"    ]. This study suggests that valley fever is a common cause of CAP after exposure in a disease-endemic region and that patients exposed in these regions that develop CAP should undergo laboratory evaluation for this organism.",
"   </p>",
"   <p>",
"    The most common presenting symptoms of primary coccidioidal infection are chest pain, cough, and fever. Although initial infections usually have a respiratory component, chest radiographs are unremarkable in up to one-half of all patients. Common radiographic abnormalities include unilateral infiltrate and ipsilateral hilar adenopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Other fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other fungi that can cause CAP include Aspergillus spp and Pneumocystis jirovecii (formerly P. carinii). Infection with these fungi occurs primarily in the setting of immunosuppression. Pulmonary aspergillosis is particularly associated with severe neutropenia, while P. jirovecii is particularly associated with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Mixed infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of more than one causative microorganism in CAP is difficult to establish. A prospective study of 1511 consecutive hospitalized patients examined the incidence of mixed respiratory pathogens in patients with CAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/75\">",
"     75",
"    </a>",
"    ]. Microbiologic evaluation included sputum and blood cultures (and pleural fluid, transbronchial aspirates, protected specimen brush, and bronchial alveolar lavage, when available), paired serologies (for influenza, parainfluenza, respiratory syncytial, and adenoviruses and C. pneumoniae, M. pneumoniae, L. pneumophila, and C. burnetii), and urine antigen (for S. pneumoniae and L. pneumophila). Of 610 patients in whom an etiology was identified, 82 (13 percent) had more than one microorganism. S. pneumoniae was identified in 44 of 82 mixed infections (54 percent).",
"   </p>",
"   <p>",
"    The clinical importance of mixed infections on outcome is difficult to assess, although there is a suggestion that patients with mixed infections have a more severe illness as illustrated in a prospective study of 493 patients with CAP in whom an extensive microbiologic workup was performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/76\">",
"     76",
"    </a>",
"    ]. Compared with patients with monomicrobial pneumonia, patients with mixed pneumonia were more likely to have complications of the pneumonia (39.3 versus 18.6 percent); however, they were also more likely to have an underlying comorbid illness (64 versus 45 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     CAP and bioterrorism agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biological agents that may be used for bioterrorism and can present as a CAP syndrome include Bacillus anthracis (inhalational anthrax), Yersinia pestis (pneumonic plague), Francisella tularensis (tularemia), C. burnetii (Q fever), Legionella spp, influenza virus, and hantavirus (",
"    <a class=\"graphic graphic_table graphicRef56078 \" href=\"mobipreview.htm?4/10/4268\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Bacillus anthracis (anthrax)",
"    </span>",
"    &nbsp;&mdash;&nbsp;On October 2, 2001, a 63-year-old male from Florida became the first case of inhalational anthrax in the United States since 1968, and was the first due to an act of biological terrorism. Anthrax was deliberately spread through the postal system by sending letters with a powder containing Bacillus anthracis, a gram-positive bacillus that forms spores. Two of the 22 persons infected in the postal attack developed inhalational anthrax. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhalational anthrax is the deadliest form of the disease. The incubation period following exposure is one to six days. The classic chest radiograph findings are mediastinal widening with pleural effusions. A WHO expert committee estimated that if 50 kg of anthrax was released over an urban population of 5 million there would be 250,000 casualties; 100,000 of whom would be expected to die without treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7224?source=see_link\">",
"     \"Clinical manifestations and diagnosis of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Yersinia pestis (plague)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biological weapons programs in the United States and the Soviet Union following World War II developed techniques for aerosolizing Yersinia pestis, the agent of plague. The hypothetical intentional release of aerosolized plague would cause widespread illness; the case fatality rate for primary pneumonic plague is close to 100 percent if treatment is not initiated within 24 hours.",
"   </p>",
"   <p>",
"    The time to onset of symptoms following exposure is two to three days. The most common chest radiograph findings are bilateral infiltrates, often with pleural effusions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Francisella tularensis (tularemia)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tularemia is caused by the gram-negative bacilli, Francisella tularensis. During the 1950s and 1960s, both the United States and the Soviet Union biological weapons program developed aerosolized F. tularensis. It has been estimated that dispersal of 50 kg of virulent F. tularensis over a metropolitan area with 5 million people would result in 250,000 incapacitating casualties, including 19,000 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/49/31514/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tularemia has a longer incubation period than either inhalational anthrax or plague. The classic chest radiographic findings are bilateral infiltrates with hilar adenopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     C. burnetii (Q fever)",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. burnetii is the etiologic agent of Q fever, and is a CDC category B biological agent. As a biological warfare agent, C. burnetii can be easily dispersed as an aerosol with a high infectivity rate and pneumonia as the major manifestation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12502?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Q fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/29/12754?source=see_link\">",
"       \"Patient information: Community-acquired pneumonia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=see_link\">",
"       \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456952782\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Community-acquired pneumonia (CAP) is a common and potentially serious illness. It is associated with considerable morbidity and mortality, particularly in elderly patients and those with significant comorbidities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall rate of CAP ranges from 8 to 15 cases per 1000 persons per year; the highest rates are at the extremes of age. There is seasonal variation, with more cases occurring during the winter months. The rates of pneumonia are higher for men than for women and for black persons compared with Caucasians. The etiology of CAP varies by geographic region; however, Streptococcus pneumoniae is the most common cause of pneumonia worldwide. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lungs are constantly exposed to particulate material and microbes that are present in the upper airways and, by microaspiration, enter the lower respiratory tract. Nevertheless, the lower airways usually remain sterile because of the pulmonary defense mechanisms. The development of CAP indicates either a defect in host defenses, exposure to a particularly virulent microorganism, or an overwhelming inoculum. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to microbial virulence factors, diseases and conditions in the host may lead to impairment of pulmonary defense and increased risk of CAP (",
"      <a class=\"graphic graphic_table graphicRef52808 \" href=\"mobipreview.htm?13/10/13485\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Predisposing host conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presenting clinical manifestations cannot reliably differentiate between different etiologies, but there are a few epidemiologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinical clues that can be helpful and must be taken into account when considering the etiology of CAP. These are discussed in the following Table and in the section above (",
"      <a class=\"graphic graphic_table graphicRef52808 \" href=\"mobipreview.htm?13/10/13485\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Epidemiologic clues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are more than 100 microbes (bacteria, viruses, fungi, and parasites) that can cause CAP. Most cases of pneumonia are caused by four or five microorganisms, but the distribution of pathogens varies with the clinical setting. When considering the etiology of CAP, it is useful to categorize patients into those who can be treated on an ambulatory basis, those who require hospitalization, and those who require admission to an intensive care unit. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacteria are the most common cause of CAP, and S. pneumoniae is the most common bacterial cause of CAP (",
"      <a class=\"graphic graphic_table graphicRef72014 \" href=\"mobipreview.htm?8/18/8495\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63248 \" href=\"mobipreview.htm?39/50/40751\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Bacteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Using molecular methods, viruses are detected in approximately one-third of cases of CAP in adults. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Viruses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fungal infection is an unusual cause of CAP in the immunocompetent patient. Fungal infection is more common in the immunocompromised patient, particularly those with neutropenia, those receiving chronic immunosuppressive therapy (eg, organ transplant recipients), and those infected with HIV. Fungal infections can be endemic to particular geographic areas; as a result, the specific epidemiology of some fungal infections is important as a diagnostic clue. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Fungi'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/1\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/2\">",
"      Marrie TJ, Huang JQ. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J 2005; 12:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/3\">",
"      File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/4\">",
"      Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/5\">",
"      Wunderink RG, Waterer GW. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 2004; 18:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/6\">",
"      Strieter RM, Belperio JA, Keane MP. Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis 2003; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/7\">",
"      Mason CM, Nelson S. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med 2005; 26:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/8\">",
"      Almirall J, Bol&iacute;bar I, Balanz&oacute; X, Gonz&aacute;lez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/9\">",
"      Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/10\">",
"      Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/11\">",
"      Hermos JA, Young MM, Fonda JR, et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012; 54:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/12\">",
"      Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/13\">",
"      Jena AB, Sun E, Goldman DP. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med 2013; 28:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/14\">",
"      Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/15\">",
"      Trifir&ograve; G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010; 152:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/16\">",
"      Almirall J, Bol&iacute;bar I, Serra-Prat M, et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010; 36:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/17\">",
"      Caldeira D, Alarc&atilde;o J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012; 345:e4260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/18\">",
"      Barnes RA. Pneumonia and ACE inhibitors--and cough. BMJ 2012; 345:e4566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/19\">",
"      Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/20\">",
"      Shibli F, Chazan B, Nitzan O, et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. Isr Med Assoc J 2010; 12:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/21\">",
"      Song JH, Oh WS, Kang CI, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/22\">",
"      Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/23\">",
"      Lieberman D, Shimoni A, Shemer-Avni Y, et al. Respiratory viruses in adults with community-acquired pneumonia. Chest 2010; 138:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/24\">",
"      Cill&oacute;niz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/25\">",
"      Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/26\">",
"      Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/27\">",
"      Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 2012; 54:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/28\">",
"      Bartlett JG. Diagnostic tests for agents of community-acquired pneumonia. Clin Infect Dis 2011; 52 Suppl 4:S296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/29\">",
"      Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012; 54:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/30\">",
"      Cao B, Zhao CJ, Yin YD, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis 2010; 51:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/31\">",
"      Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/32\">",
"      Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/33\">",
"      Janssens JP. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med 2005; 11:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/34\">",
"      Coon RG, Balansay MS, Faix DJ, et al. Chlamydophila pneumoniae infection among Basic Underwater Demolition/SEAL (BUD/S) candidates, Coronado, California, July 2008. Mil Med 2011; 176:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/35\">",
"      Oktem IM, Ellidokuz H, Sevinc C, et al. PCR and serology were effective for identifying Chlamydophila pneumoniae in a lower respiratory infection outbreak among military recruits. Jpn J Infect Dis 2007; 60:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/36\">",
"      Kawai S, Ochi M, Nakagawa T, Goto H. Antimicrobial therapy in community-acquired pneumonia among emergency patients in a university hospital in Japan. J Infect Chemother 2004; 10:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/37\">",
"      Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24:779.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.qualitynet.org/dcs/ContentServer?cid=1192804535739&amp;pagename=QnetPublic%2FPage%2FQnetTier3&amp;c=Page (Accessed on April 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/39\">",
"      Ioannidis JP, Worthington M, Griffiths JK, Snydman DR. Spectrum and significance of bacteremia due to Moraxella catarrhalis. Clin Infect Dis 1995; 21:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/40\">",
"      Verduin CM, Hol C, Fleer A, et al. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002; 15:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/41\">",
"      Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/42\">",
"      Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza--Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/44\">",
"      Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/45\">",
"      Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010; 138:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/46\">",
"      Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/47\">",
"      Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007; 45:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/48\">",
"      Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/49\">",
"      Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 Suppl 5:S378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/50\">",
"      Stankovic C, Mahajan PV, Asmar BI. Methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia. Curr Infect Dis Rep 2007; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/51\">",
"      Vayalumkal JV, Whittingham H, Vanderkooi O, et al. Necrotizing pneumonia and septic shock: suspecting CA-MRSA in patients presenting to Canadian emergency departments. CJEM 2007; 9:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/52\">",
"      Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/53\">",
"      Li M, Cheung GY, Hu J, et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 2010; 202:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/54\">",
"      DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/55\">",
"      Olsen RJ, Kobayashi SD, Ayeras AA, et al. Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates. Am J Pathol 2010; 176:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/56\">",
"      Diep BA, Palazzolo-Ballance AM, Tattevin P, et al. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 2008; 3:e3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/57\">",
"      Peyrani P, Allen M, Wiemken TL, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis 2011; 53:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/58\">",
"      Muller MP, Low DE, Green KA, et al. Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada. Arch Intern Med 2003; 163:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/59\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of group A streptococcal pneumonia among Marine Corps recruits--California, November 1-December 20, 2002. MMWR Morb Mortal Wkly Rep 2003; 52:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/60\">",
"      Crum NF, Russell KL, Kaplan EL, et al. Pneumonia outbreak associated with group a Streptococcus species at a military training facility. Clin Infect Dis 2005; 40:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/61\">",
"      Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/62\">",
"      Hooi LN, Looi I, Ng AJ. A study on community acquired pneumonia in adults requiring hospital admission in Penang. Med J Malaysia 2001; 56:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/63\">",
"      Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/64\">",
"      Cesario TC. Viruses associated with pneumonia in adults. Clin Infect Dis 2012; 55:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/65\">",
"      Oosterheert JJ, van Loon AM, Schuurman R, et al. Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection. Clin Infect Dis 2005; 41:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/66\">",
"      Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011; 377:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/67\">",
"      Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/68\">",
"      Jartti T, Jartti L, Peltola V, et al. Identification of respiratory viruses in asymptomatic subjects: asymptomatic respiratory viral infections. Pediatr Infect Dis J 2008; 27:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/69\">",
"      Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/70\">",
"      Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis 2011; 43:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/71\">",
"      Bastien N, Anderson K, Hart L, et al. Human coronavirus NL63 infection in Canada. J Infect Dis 2005; 191:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/72\">",
"      Woo PC, Lau SK, Tsoi HW, et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J Infect Dis 2005; 192:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/73\">",
"      Chen KY, Ko SC, Hsueh PR, et al. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest 2001; 120:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/74\">",
"      Valdivia L, Nix D, Wright M, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis 2006; 12:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/75\">",
"      de Roux A, Ewig S, Garc&iacute;a E, et al. Mixed community-acquired pneumonia in hospitalised patients. Eur Respir J 2006; 27:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/76\">",
"      Guti&eacute;rrez F, Masi&aacute; M, Rodr&iacute;guez JC, et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2005; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/77\">",
"      Karwa M, Currie B, Kvetan V. Bioterrorism: Preparing for the impossible or the improbable. Crit Care Med 2005; 33:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/78\">",
"      Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/49/31514/abstract/79\">",
"      Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6990 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31514=[""].join("\n");
var outline_f30_49_31514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H456952782\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Virulence factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Predisposing host conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Microbiologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Epidemiologic clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - S. pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - H. influenzae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - M. pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - C. pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Legionella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Gram-negative bacilli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - S. aureus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Group A streptococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Anaerobes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Neisseria meningitidis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - M. tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Influenza virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Parainfluenza viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Respiratory syncytial virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Adenovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Human metapneumovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Other coronaviruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Hantavirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Avian influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Varicella",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Fungi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Cryptococcus spp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Histoplasma capsulatum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Coccidioides spp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Other fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Mixed infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      CAP and bioterrorism agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Bacillus anthracis (anthrax)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Yersinia pestis (plague)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Francisella tularensis (tularemia)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - C. burnetii (Q fever)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H456952782\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6990\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6990|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/10/13485\" title=\"table 1\">",
"      Risk factors pathogens CAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/50/40751\" title=\"table 2\">",
"      Microbiology CAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/18/8495\" title=\"table 3\">",
"      Microbiology CAP site of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/50/33579\" title=\"table 4\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/10/4268\" title=\"table 5\">",
"      Bioterrorism agents CAP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/5/15449?source=related_link\">",
"      Bacterial pulmonary infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12502?source=related_link\">",
"      Clinical manifestations and diagnosis of Q fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/3/7224?source=related_link\">",
"      Clinical manifestations and diagnosis of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/36/38473?source=related_link\">",
"      Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41176?source=related_link\">",
"      Coronaviruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=related_link\">",
"      Epidemiology and diagnosis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32680?source=related_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38119?source=related_link\">",
"      Hantavirus cardiopulmonary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/24/37254?source=related_link\">",
"      Microbiology and epidemiology of cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39079?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/29/12754?source=related_link\">",
"      Patient information: Community-acquired pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1801?source=related_link\">",
"      Prognosis of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13433?source=related_link\">",
"      Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_49_31515="Infections and inflammatory causes of tonic pupil";
var content_f30_49_31515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F60816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F60816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious and inflammatory etiologies of a tonic pupil",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter jejuni enteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cellulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chickenpox",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diphtheria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes zoster virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HTLV- II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus B19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pertussis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scarlet fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iritis or uveitis causing damage to ciliary ganglion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vogt-Koyanagi-Harada syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31515=[""].join("\n");
var outline_f30_49_31515=null;
var title_f30_49_31516="Indications for catheterization";
var content_f30_49_31516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical use of the pulmonary artery catheter",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Differentiation among causes of shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypovolemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Distributive (sepsis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Obstructive (massive pulmonary embolism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Differentiation between mechanisms of pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Noncardiogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluation of pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnosis of pericardial tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnosis of left-to-right intracardiac shunt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnosis of lymphangitic spread of tumor and fat embolism (case reports based on blood aspirated from wedge position)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management of perioperative patient with unstable cardiac status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management of complicated myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management of patients following cardiac surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management of severe preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Guide to pharmacologic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasopressors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inotropes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasodilators (for patients with pulmonary hypertension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Guide to nonpharmacologic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluid management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Gastrointestinal bleed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Traumatic exsanguination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Burns",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decompensated cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventilator management (assessment of best PEEP for O2 delivery)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31516=[""].join("\n");
var outline_f30_49_31516=null;
var title_f30_49_31517="Contents: Genodermatoses";
var content_f30_49_31517=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Genodermatoses",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Genodermatoses",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/12/24776\">",
"           Darier disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/21/39255\">",
"           Diagnosis of epidermolysis bullosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28106\">",
"           Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/40/11912\">",
"           Hailey-Hailey disease (benign familial pemphigus)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/5/44121\">",
"           Nevoid basal cell carcinoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/63/3066\">",
"           Overview of the management of epidermolysis bullosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/0/24586\">",
"           The genodermatoses",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-0A84507AD0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f30_49_31517=[""].join("\n");
var outline_f30_49_31517=null;
var title_f30_49_31518="Monthly pain scale";
var content_f30_49_31518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Monthly pain scale",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 387px; background-image: url(data:image/gif;base64,R0lGODlhTgKDAdUAAP///wAAAICAgN3d3YiIiJmZmSIiImZmZhERETMzM+7u7kRERMzMzLu7u1VVVXd3d6qqqu/v70BAQCAgIF9fXx8fH+Dg4PDw8KCgoL+/v9/f32BgYMDAwC8vLw8PD8/Pz7CwsHBwcNDQ0H9/f4+Pj09PT5+fnzAwMG9vb6+vrxAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABOAoMBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycp1FhgbEhMB0tPU1dbX2Nna29zd3t/g4eIBExIbGBbL6r8WGwElJBkf618fGSQlARvp9P21AgFGRPBHJsKIAAIIKmx1QUIHDQvLaOgg4ULEi6VOlBiIcUyEEic6ivQUogPHkWEidAiBsqUlDh4gugyjwQOHmTgfSRiRM8wI/wk9gyIS4eGk0C0RPIg4yjSQAApNu1BIGLWqHgkprGpJAVSrVzoqZH6tokHF2LNvAqC1onatWzRt30aJK7cuGLp2meDNyxfL3r5H/gIeDEUwYSGGDytGkvjIgwAOsjyOjImAtAdOGARAUMRBAAJEIGy+0nixacREBkgbAMAyZwALPk9mokAagySzEXkGvUT168yjiewGgCAAA9G/k0AoHmDBbSKlTy/GmyBAAdjSGhAP0CC3ktrGcUPGJDoBFM3JAQwfgpzJA9CWDRSJLv0wXssHtn9uMPpxgtgI3CbaNJgxF4B5RDy22XgKeLbZdQAUYIA0C7Am4TTPCTHhbfi1Rv8gAODdVhwE4D2G2RDVxdYciNQsoIB6n5VYHGVCgGdbg9PwZpk0kaHX2WfbHTeaZQuA6CCQQ/CXHn31DYYXfwbwF9sClkXmHwCPFTmEAhMWEGIRRGI5XnWgVQeBlB46t9mLRpgIwIazHRDAA1+OaOOcRFSHWWy8CRFbfruBR2Jx2rEXXGzaTdiAZaDt5qNwQBYnJALlvYjom9zV+Od8TXY6xF4zcmcAArFdN5tl5imgoDQEfJmndWI6oFoArD12gJzUIDArAg9AOIRmUR6I6XWiGVBnACTaZgSZabY2IY8wtqrsiKGNNis1BDw7jQOPDjGcpMgRCsC1OQIAbJ+feur/6V4AcoYrrbF6aF5skZHpKoqwTjZrrQHc2m8REDzAnK9+BtDlsAAUe2yy4RXBLJGoqjpeoNMiWy1n+xJx8K/BeRupcQNKk1/GRGiGIKfqNrnXjkUWII188aIKgL0TgiZuguPJWS+QZiInII0IE+GywULEiWeXCtiprMM8y7YivdEufLEQ1VHmQMAHvkjAA90K8S3ImzFAbdVeQ7AEkynXtZdmQM6aX8zCLmdwzR4Ku6WKZOP4oBAFVMdqyEgWQbcQO+IZIY9KN/zqs5gN4DfZFIdHraGvKfBuha0xZwAEXUcbZHvxKWD5NJiXF1ja9aG9h29sZsGsJaqjvlbseXjn/3rglNAu+1i6u9X77lr9jpbwwEdFPO/FK3b8V8snH1TzwTtPGPRWUS+9SwEYZVoE1l+PkgQZNJlBV97nFQIKTaLAUvl5gVBBkxWAwD5fE5ggnQkTzM8XBhVoP1gEFcCA/vgiAagshgLkG2BdLjABAxKGAhOwiALzIoIG+k8uEYDgUibIl4ZUIHx5yUAFKsLBwWBgAhUgwTzW8gESVGACAizhYUCwgWiM44Y4zKEOd8hDHE5gA/KToRCHSMQiGvGISEyiEpfIxCY68YlQjKIUp0jFKlrxiljMoha3yMUuevGLYAyjGMdIxjKa8YxoTKMa18jGNrrxjXCMoxznSMc62v/xjnjMox73yMc++vGPgAykIAdJyEIa8pBn28Lymke97gHAepC8Sxcc6cgxMlILl+QCJb0QyS80UpKCzKRfFDlJUGqSk6bEZCr/KErSkPKUnkRlKWMJS1kGspVseaUuZ1nLXfYyC5sMpS+rgMtR0vKXwFylMW0JyGJSwZm5POYwl8lLVUqTldOcAjSJqUxqWpOZybymH7c5l2xyU5zeDCc40/nNZpqznO1UZzXjKU9kuhKdfCRnYd6pzW7e0571ZGdA+6jPJxQUnusUaDQTutB5jlMvTihNdCQaUYM2gUlom+g+L2pRjm40kRUNqUjdCVKIllQJFPWoSlHa0ZEmIaP/LmXpSmfKmJaaNKYEvelJa6pTnvZUpjsFKk1PZ1OhBtWnODUCRot61Hz+FKlQjapSk0rUplZ1qFNlqlS3mlWtdvWpXL0qNq2KMqOGFTVYFetZofNRs7pVrS+l6lof6VW4xjWUPcyrXvfK17769a+ABSwiB0vYwhr2sIhNrGIXa8gGFMcAGarCABBQqCooCLJXUBFlt2CZymbhXc3DFbokWw3WaGFHCCBYFXaUgMhaYbKFcpw0VHtHBIDmASejwo48OwVuqQdoVsCtFobG2yvcqgsHwKwXsrWF2pjtATCzgmY4lNvVZsdrkRFN6+6omRfxB5jFpcIDgFsFB7ztCssR/014q4CrKGWhNuu9QtJoawUDOEABBCCvFERzm+5islCUQkx84/hdAPDHtGwZ8BMci+AquMwADaYCfxqgGgVT4QDpkfCCcIcF4XKBAP9xLxYcVJztJljAiKHvHP1bYNJYmAkScq0VmGvcarw4Ci2WbltEE2HS3hg43g2AiWecYWIC2GyP/DEbbYul6j5TyUdYQAKGLAXH1arIVKgwF1oLgANoCQupTZiQteCAL2tBM2ZzGZWn4NjRnvi3Yl7zHB1rMBlHoXDnrXJpq6A3EWdBy1twEJez0IAJhZnQiuOsNA5dYw5bV2Tj8puKGUvpSlv60pjOtKY3zelOe/rToA61qP+DwSgiWOZEePAMkjVRGywfQdVfqI6drSBrSM2ajGzDjGj0u4Yd9VcayeJMqYdwajN4BmY7krPXLCaFEqehVAVz8xNa/QRYP8HZxT5CrbecaM/ceoxsAxuv1bCjyDho1R5CV7bJ4CDQPEvZMEL3tceMBpcVKWkIgPd3OsYEazsB24ZbVqJvF1lvsxFYB9q1ufxWoVYDqL8qwtyHF+QyaiFA2EAaWnFQPQbPIMAABLj4mFfFG1xRq3BlggyyjlShI9HJQZsbw8XxyyCYB5tP4xk2i0hVZ/2Mp8uLZva/x1zsqrFqZiqHFQMizhoDZfdACWgttpDuoOsYHOVm1Ix5mzP/nlEpgD9THlLX8+2yPGfh1BNKAKwvnm5geYjjYtjNZUpc7NhAoErxLvaEZAtsj9lszKpWTXTBICcQZyrwBrsTvrmUHGqLxsyKwru/mwBwzFSnAUpCOgPw/Say/2sIigrZyXwka857W+/wwjVkuMQjk7FIyKPZdbil4eQrnNoyBVg7xgmg8HV3fOW0KjGsTfSYRgGfGhDYdrY+5GwDSUPfVoAS0Xz+/I55xjMcp7brV4Ws4scbCpXXPLVrLalqmIf7EFD4uI4kZPIL2dvsF7oYtS7msX89a7Efe49PG3Ddpxvsb2dsQkd3eGJ3dYcsHYIvv4ZxBQIvnjFpXvAsvPGA/1vSMeHWYNRWJWGiagcob0twKXJyHaU3GrIGJZ2HYBuILOr3NQpQgkRzep93RvQHIz3CcAPgeOOxdNvSBevmf6WmIHoigKvmbArCZNiBAGZSN7axbYKGJzvyctPgaoqWenqzJvxGNkRwJy7SgpuRhACShE8wACqCJCPIGX7TczrII1yIhCr4c2JzICV2hph1ddTwbaPWEpd3h3NmN3rYh374h4AYiII4iIRYiIZ4iIiYiIq4iIzYiI74iJAYiZI4iZRYiZZ4iZiYiZq4iZzYiZ74iaAYiqI4iqRYiqZ4iqiYiqq4iqzYilNkABCoBsd1BBMGBbBITNImNIP3BLiyf/+qsX9g8ItYcIudsABm5gTCOAm1qATJKAWzeAuFkwCsQYxy8IxTICGgF4tXgI1RoBkRNovNSAbh+ATc+CaxWI5aMI51oI5CwI68aHaF4I5MYI21QABasgCRQY1xQI9RUI766AXo6AQQsItd9jby6AUHmQT+eI4EeQUJ+Qbu+JBKwI+EIJFHQJGyYI98Ix+3yAB+gxn8QXsvUgADs3CXUQQHkADFkQAKco/TcB2qwQAGYADHJTbo8ouqoSKjRQ1vEnF8UxyMpikUYo7m6BkDQJKb0QDcCISuVWiz9UhDKQQh2Rw5eXRiciCuZQA+SZREaQAM127jciBWyZRFmXpQKQ3/PRmVY3gdPDkEquE3KXldMJI1VwlZY+hZaxkhbLhZJFkdm3UruOeUsFKVGQdZ/XJceIYd2aEAEacAv+hlUmmWBYl70wBZU1kkZImUsDIEkGlgtMJ3IwMvOGkcM0kEKZl2rJGYo6mTRSCMSJlaMek1+fGa1zGLxliP95YA+QGLSaMdsKUxNnMdBUAnm/WbnNlaSSONqoFuJBmWB/AityI2qjWamKFmugh6LrKchcYay7Fdt+k4XekcnqkdBEAA2KiRWGJmSQMaPBaQBdmOeKJm6PkAx6iVjmkxxHiL9skfkaFmqsGetDKfRaKVruWP2Sl/zemeqoEZpZaSzsIauumN/1hSAPKYoJsFXXqpHRiaktexnmI2AP/5oSRZcnkWk8lIJVRDAKN5G/TIoSgZGbMooMQhnBwXm8f1nbApmp/ZLyaWkhBaosZBnYezXb+4nQmTb+bFIgxgpN1pm8cIC4XjIuY4lbM1AO8CGlJ2ANdBpZspBLbJG7doeGiZjCkZlPAJojraYAupIQVQOKsBHZ6lnxCCnhupmC9DBC2WAOZJkOCYpmM4fdnIplwppyg2mqYFi3/KkbS1pkQppmqhoPBSYNiIokeaNAtwALehjo4aITDzi9z4mG+TpyqaerBYjsfVAHeZjNVwAMK4AHSSKaZ5XgIzlLZJDfKRpbTlqvCVZP9FIytpqo6ziI2oOg0UtqOsEY6/6Ka00p0gpoSrgZGxQKdsyh/b5QDSCBu8UQAp6QDUigRfyqaaARrfRaZI+KSGGpZqGl352aa1h2KBSozSOqlwlyRxoafu2afHSiuumgTrOqjXQYyZcq7EAQH7qjGLqq4QAovh6pmcagTCKKm3yhvLQTgYNqoRtrDfxY3dpbFCNouimoyUYqr5gQCUwR2qim4PyytPGqPupZG2Oa/aqnZF4Fj06a7jJYwCG6uEYx4kK2DniqwB6mSwGKbVBa1QWp9eggD50SANwJLmAnKOQ11Js7TcqrPYyqbLwRpygq5e+pw02ZrGyrXskW+COqX/Sldd32kehDqerbGnmXMb2pqFTOYyR0mQNcu1yRogEWJ2/eq0JPmvEBKwOwq3+RZycLubtNWdZQuLWQt0lQq2rAGxD9qCWnpfsPGqvNW4W9ucXdYyrwGZs+ihdBubJKkAIutch9MAuwobU9a2ybgxVitcLYiZWmK4exu1rSG0m3mb0om6j4GmPXYAkdGC0pJmJhu2QDsA/HEdHkk4M+eZzGseToqbgrOlNkhnCQByfaYdTUshDfatRBlxakGmI/O1bom8ksmFatGvIQdpqcFwXekrqKWUMGNyoyWYwkmQb1ghaQp0mzFa/RqSKgm4hbqjQFko9suVWeg3/qqYsQEi/wx8vpHbFtwoaArgkbSntXJZMFynlxnswQeiteeFv2F5wA3btXUDgtkhhrRXrKZFYyhpkH75H+ZSHEViv9trBDAMmoRDIWGLksxRuz7swjgrmcLYvp+3oMTGHPkxva4oBgHpnswomRGYi2AAcp8Fj08sCVHckElgkddItmZQulm8xWZ8xmicxmq8xmzcxm78xnAcx3I8x3Rcx3Z8x3icx6ywjHEEJPoIxknAx0LEmLTngTA2fTm2O3zyKzbYbEgms7kbBYAsBX9MxVtUKovXj3uTyGmDdSAyKgNgOlHgAJhBbeoxr71hyVxQycB4RbNiKV3qBC7DXAW2I8p1nKiphP+hiaas+RXr4TIIUhytjATNmnx6G2C2zKIHgHuXlYawqiFbmcwm+S+aScBeOZSuCZSqdZohbKcwuaO9PECPsh6gVw276DJvQgDfVYsYaprXqpupEaQ7Wp30phXrgXfb4Vnk4r4coyrjRQDdxc7y4aIS2ivqqJXjkloCrR75wQCREWbDGZ4JTaG0wqRi7KXvnGfNKaTWKc7BQc6y/KiUohboWRuRFazyMawrjL7DHBT3/HM3A37Jd3cO0KwlbRyhSyqYKrYG27U3zQAht8x+opsJS8AFmax7xplvc55niK5F3NLF88rYoVracqdC0xZaSdJaYtJW26w9m2Q/q8pM8cv/diPM8byqRrB1F0yyDLrVOJ1nBFCxBw0hpPzT5uJlxrK3Mru2pJys7fqeuYux48vSE1Qqk3XRIc03aFmLyfWiEFy8qRvWUJ0T5HxxR8mHUCAz22E2jD3QS225uvrMoAcaYoN5mdLYC7ClxsFlzaqfpE1ZRXq2jk28mjvYwMvT+kPICScF6FwwPdxzphnEv40okq0VyvoiGEyVU6AZJ+IZbCLNs5jc14orccocOvIyHJIjOayf1s21SGx2GKaWPuzU/YtGRutF/5gG5z1H681F6Y0G7a3H8j3f9F3f9n3f+J3f+r3f/N3f/v3fAB7gAh4Lup0AhowFrGeH4kU60DfK/9Ng4GDga10wez/XBSTXBfE3blRQhVosXzCnjVSwyEKQ3BKnQJj8vFxwJAo+BQtgNmHCBYyZ3V58BVO54ufxfGEg4mIwOIGGJ57R4eXlxwOHBZ7MeKGM2fMj1dDmBZIiBpkX4RXeXPa1NFvANg2+X0j+BfHhBVMCdFZMBU3uJl5A1sEs1tIzzo6WBU0eBimi5Yt25U8gZfdyZi0y2VDgH49l45Sc5lcgk1IW5VpAN7bT49dNGTE9P2j+5VWw5l6g21AGBcXCg7oy5xi+IlzgJg/2BY8x41bgMtqh42f2OAGX4kiCz4fOPkoey1vA6Fwgk1YJBuAB50xwhhgCBpE+cf9Li+MwXhyKDubhAcxsrupkhiTAvh12rsjWcdiyPnR6Pm0v+QUQYLma3ehUflpvg30TnnjFfulZHuh4ojNQ/qTD3ieWve0DVOAHbgXs99cbbg3pPgV8t3qwXu1Z8IavzgUDSSHL3huT4wXODORVEDKoTOTVgNyNPOAIn/AKv/AM3/AO//AQH/ESP/EUX/F4FFgYn/Eav/Ec3/Ee//EgH/IiP/KBZfEmf/Ion/Iqv/Is3/Iu//IwH/MyP/M0X/M2f/OAwOfv3RRiugCPvgT4xcTH7gRBLzJD3wRF3y9HzwQMcOET7vStDvVbEO0vA+JRQPUGY/WQ/uFi0PM/rwTRqOD/rHwUbfoiEiPsq8UbDh02nKX2HtfsS1CeI/726ch7QpB8dPlndp8w1dG6eo9keO/3WLAoz9G+AI9jAO28MTj4iZ85i78FZQ8iCqL1TYCe1soEYx8U6lwEQ7P0jvGNgHoFDwD6nH7npP9eZseFh0/0qV8dq4/0rf/4VADURfCGlJ8EtF8yxXH7SJD7v7L7PMhbnc9ZWsKNt+iU4pLVT0Os1ZIiz2HBtcEaDhAZjrXvBI7KsTHwUKCURpA08idhtOX97+4E3F8E4k/kPRaS1m9q6a/rM9b+9cxeRzDtVqDF9C//OtztfIb9ow4EAOGQWDQKCQuAInEQGgoKBGEZaAAM/wvFIADhDoyPRAGwcDoSCoWBauUmys7jnF633/F5/Z4PIRsJAuT4ih7AjBYC/giJDI8SFxmFHBEVJYkc5gICDi8BMo82Oy9BjUQ9lwaJGgIMUFOPWF1RFVSHZF+J/I4CbT0DN5WeCliHrLD+oL4QqT4fGDiFFqgQGh4QEJZzt7m7twsihwIfXg9GhxIhys+lu9Yf3VGFTQMUXueLNu3lNetRB3wBYAXnX8CBrwDGCkDwWzgkAchtSwLggIFDUIoJOQZlmDYiCNQBAFlglkh1BiCAFBTQW0uXL4swCJjuFQGHUvyhsmkE575fNxHk9OSA3cFXRI0YRYW0iFJPDImMy/8FVRzEqbyscpMJL2SuiWXSIFPgrsDGZFGOEYFmby2EAAzKzErggNpbmHfxwlxwhUjZUp6YnDsQoBmtBIIJ5wpcZHBhTw3wLUlg9xXkIkwoo7JMBDPcmo4BMEBgwOcv0KJJez09unSuvUX8dvsKIEEajmUX2uWIjOImvgAIEAzeLsCCQwsIJoicl3lzSQOmCFHwIMBfVBB2M3CQeBv2P9q55/IuBDxoTw9eA4CQoBo39HzXt9/2Xkj836+aHCKA4DC3/Ej4Y+eS/4ALsCXompmuOud0QaA1BiGMUELpqNuEAAE9Aa8V817RkI2WPOTwusmKc+iV9YIxccQUW9pvkwP/7pMoKEFi9GpGGGFS0EIMYRosAARUnFDIIYks0sgjkUxSySWZbNLJJ6GMUsopqazSyiuxzFLLLbns0ssvwQxTzDHJLNPMM9FMU8012WzTzTfhjFPOOems08478cxTzz357NPPPwENVNBBCS3U0EMRTVTRRRlt1NFHIY1U0kkprdTSSzHNVNNNN7VAgE9BDVXUUUkt1dRTUU1V1VVZbdXVV2GNVdZZaa3V1ltxzVXXXXnt1ddROeBU2GGJLdbYY5FNVtllmW3W2WehjVbaaamt1tprsc1W22257dbbb8ENV9xxyS3X3HPRTTfd8IZcYLk6SOLSI3XpBTMRvuYtYjfm/xLoao/d4r1rX24CzlciEtPjRgEXBeFRkoVvdJgRiF+UmBAGKmR3G4w30TgXji1sCYLtWgnykpE3Gbg7klX2JrhgakRooYgMHqLll8byjA+AS3rpZlQKjqabAgiwR0eT+SCgGfAQ0Pkz8rZrmhulof7RaU8GICAkFMPKJeutJ+saIa3rC/tBSRogwDMXWWIk7bWDapuQtwEUxCWija4QaUKSSIm4tIYBhrACZgxnjAKXaI/ksGoLioFENhGpY58OcOKABAxoZRTBbeLPt0k2ScBpLiBvpmMD4CJ8E6I7duzyoBKoUJgGMreEcBKv6JiT4kKuKUbcLMaDkiEG6/k8xP+Mv2R4IYpXzBbM5Najlssmiz6P6Tmr/uPVLOmQ+73xYOB7l38/xT9q1DGYo92ABKCAiNChIvOFXUFDDTbGksMBVR6wjiLLRYcF+A1DCIQjw+WAIwz0EIELVHDLKA6Qifa9jzeMEZ0UDsMFCEjBgZwwIEXgEDRylOVse5gOPAaINqDE4zEr9JcKeRKUFzLiQknRR02KckOd5FAolwhIIKgiiR8uJBdDDCJgUtiOJF5iLRTJhPrIsBvkHMAhdEnJW6AAjeNoDQHEMwAVpWGeyv2PebbgWQFdAbmUMVBoHLlGMMACxgoSYYxlaAZGAjCEBNhkFvEKGhhqtoddAMJuqFj/Hjq6dzx4gM8Oh2wHI+vgP40IbSj9CJ4dJAkA810Ce01pxSs6uYpP0sIgo+yOiXrhHt05CIpzLMDlrHOAJBDgi64ImElm476KOAEkRhhjHetosz8ELF4LWCIAtAESWl7hK6+cyxyJJ4dpDCMjtOEjGt03i2UEUg/gwMox92AOrryjEjMkhDjLeY9+lHAP79JkDyXhTh1eIiE2PCIf6unJe+4hn6LcJyO8SUhwEmJfUBhLjTiyR2QGcDiNcEAmttNBuCygfkncHxeuRkZg2kKh2cTmflKnCoy6z0FikIxxGAqHjtJRmneMQnTKMgBiuiIl9tgmJSWxlXTqZIXs1MNO/y4TFJ/mAaicEepRcvhPPTDFn7lg6i2IiJ9vXkWgVC2CVLQyExZqxkFDWKCP7nMbC7EsRvsBwzX2ATnjmKQ+HXPA/X7EGMvJIZgFtNBMmbeJ6AyBC0FpzwAmwx8tkNV9vStjGAlIu9V51KOY2R0gcRrP8mWSD4uho8cm1p/LiqiymiUeZucWmc7kYjNDGG1lRDuZjNJwNal5mlpYo5qYxLYbCbMrZR3FTTAhiEIL6k52IsqN8YQmuL/9TnFzQR/1sCdmklCufdyTHuhug0D78Sx+0GndS+KhugbyBm+XQB3c5jayZdIRYbabhxCBiGWcZWJ7RYYwSOoBRSWKL4tcdv+j5v5Cvy3qL84yVsN6DZjABTbwgRGcYAUvmMENdvCDIRxhCU+YwhW28IUxnGENb5jDHfbwh0EcYhGPmMQlzpKnfpViFa+YxS128YthHGMZz5jGNA6WiXGcYx3vmMc99vGPgRxkIQ+ZyEU28pGRnGQlL5nJTXbyk6EcZSlPmcpVlgRo50AXbmD5CHXFkm69grD9Poxh6FRYmdOLB4o1zBsg43JOAwyiOHsDZSUTGcvmm4c6/+xgMHPJvYTATT5/xJx3GMtQ57AbL3+3vOWQA5g9gbfwLlYiS4vaaiVBNeJabWqW5rTXyLbchSA6D18r26i3YWpRi00zaqub9fRAtwL/FZK0rp41rAkh6aMxOnaBbjQB7dBEQviNEYrG9XN+7Yk6QjrT5Uv2Hg7ZvOQibz7UBuXztHdt6tEaMNjmNhPH573ZJjJD4Z6as9Nsh751sQwdCyvr7lo42BDERxb5RMfI0ACEQSN0RFifWq/austlzt4KUGtpbvejK7AidPaoEOrUGFaEkawZwEAdSXHH8OKQzrCKWWIiBpqHBriwMiTXjMl/wUNSq1vlOLQhPBlhxCJiRal5kLnCPp4V6qIPmeVd3x8mmMIHnEEOKwWASdunR/P8ewtbreDl4GIAckzTmn1pzwOMxwYtHr0A6tMCKzJBQlZcAeskPSAclm0VEgoX/5XfZoQj253nI8AdEq+gO7klkclNksKSR+l7txWSPEKEEqqCr2wpDS+JQQb82HdoYgR7zo6fS6MJDtkjv1sHkBllwgBN8ExmhFlBlRn7sLrj9h8B0jopmAEurdTkFb7wlZzhNe2QTTcdAhrwkOPBzESgCSp6j8hCh1NAv/eEPGFOCOSvvA7LL4hCan6HfkI1+naYvhCc8orcR0Xndl9l0yUfxUU48y+zzzpSOkqAwRRA2P4WP7BDT0YyOn0IAVsLGsBAdfVPwfXHiL0wzA+bai/ysmqceCqGki9peqomFnApksqpHhCp7MmquG/3uGuqpKqqCnCncqGg0AKhyEChAP8LLhqKPLrILRbOOOwiEHRmDcCB3fTl/aCp6uRvjJDDHjStgNjtAJSg1xiADQrgrcrgAQ7KCHbD/zhh7CjClvrIFRaIAJlND2yrsMbreq6rN9xLeq6wMRRjC99M5FIL9C6htKRDtUgrDDEtaVqL+eogB03QtXRiDb1hCmNjGxqgqyZBCcDK/QqLMAhLHAiiQqIDctjj6FonNDbBOiZvBnFD/ejKCQaAEO9DdRYCDO5wIbSORPpjD+MPCcHA4lKnCUMjKFTQ9roBvBSkCukLuL5wFY+rFfWMFbMQ2qSLuaILPmxxPmpRPqYiu7yrF/XjF7ErGK/Qa/YqFSnlltjkvAT/TCvgq82esRvWi87k677sixrxSzb+SxtfZMwybRtbghlvT1CU0crM8RzRMR3VcR3ZsR3d8R3hMR7lcR7psR7t8R7xMR/1cR/5sR/98R+PAMVqbCAJsiAN8iARMiEVciEL8sYA8iEhMiIlciIpsiIt8iIxMiM1ciM5siM98iNBMiRFciRJsiRN8iRREg9g0UjcJZwaj0miEBD9rBvWLPhACc28oSbHkQ7cbBYvZs6kESiFC8/uLGXk7g727Ch/Ssz+LC0ETSmXhPQEBipxT5ueDTaKZtLwzjSqRmoqrSvTkG88zSvHBmxQDdTMktWwJtS4hg3rQNbYhhvgMm7k0tbi/7IldE1veI1mkm3QqkQqYcIvAcoqL4kA0G3aGMOUDMna7I4xAS973G5ivO0l54DwoGd7xo0qh0B8MhMzYWsrdeIwp2YBiC3i3I9zKDEcMC8NiI236g0MGuctZsQrSYaIIhGOWAqECG5zBA5zNGcJDo6NSkcgOiYsUpNz/G3iegcUMe5zdIfjuOyEKsEC7WDkEHD4Yg3lxlA7M63ldujl3JIXvFPZaG7mCKn67ODmtkE6iwDkukGheqmV2IcMKOgIxgICmsgBlGB/hGCP8scIeu1y7CF2XLAK7uOXAkjqYpB5EnTqmsHoGkg9cOpDgm4GseDrFkTsjqHsPgiBRKiw2P9p8biPMsOg+ECTD+5OM4/ORFVU764SD1x0J4cgRkkp8LTNhhJPehCvG0S0Kkh0Dh7viXxOBqfIIZKgY+DCCh4I8yyE2ATCR9BLaJTJ9Jzmlx5xQWvQCUxPpNqo66CUCooU/joR9jhB9t4Cr/6IAOdg+6qCOuvAJtsNO23OROWU9+hUnUIhAdtpnfCUHsKzCK6PONGTDgI1+xihUKOqITAwub5PPscPlvriQ4htDD6kHL+CC8ghABGxFtrGSg+LD7NUkwotmUamP6iO/Cz0CMk0awDwTEUxTblJp9qT/vimAX8CAf/0qmyVFCLQASdQAvWJAttUWB/CTevgiLBqY7T/qk71wAOLcEFFMKXoKBMY4Jkogj/aKgWdQQeXwAFOMBs+oYuw7hNtwVPlT+k+1QbDwg1HinCYgBx+8EKk1eiAzROVsCIYK15qCgqfjQ59yzAQwycNzQsF1g4s67MK9i3R8Ay3LSxjbWFfazNpKw5nCw65ErYs1jUmSy7x8Oj08HNCrxH/EPtCZ69Y0Kv0iueQKXP4IxMwgz+cwOBCJ0bM1csacaOQSRLZyK8WDnbwh7AaEVQ9EThSJhSxybFuymFQUbyESxab9hUT1g6GqzxusWx40e520RtpERevFhW6qxgHxBfBVhK+VkbnYGn/NU5EQ2vxIiabRByhMWWiNnyiW9EZ5dYaF0BFjaC+8hZv9faqwFFGutG/BhfAMk9OSCbphsRtU7JxHfdxITdyJXdyKbdyLfdyMTdzNXdzObdzPfdzQTd0RXd0Sbd0Tfd0UTd1VXd1Wbd1XVcIggAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31518=[""].join("\n");
var outline_f30_49_31518=null;
var title_f30_49_31519="Aspirin 10 yr risk levels";
var content_f30_49_31519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72074%7ECARD%2F62463%7ECARD%2F53748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72074%7ECARD%2F62463%7ECARD%2F53748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    10-year CHD risk levels at which the number of cardiovascular disease events prevented is closely balanced to the number of serious bleeding events",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-year CHD risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle2\">",
"        10-year stroke risk, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45-59 y",
"       </td>",
"       <td>",
"        &ge;4",
"       </td>",
"       <td>",
"        55-59 y",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-69 y",
"       </td>",
"       <td>",
"        &ge;9",
"       </td>",
"       <td>",
"        60-69 y",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70-79 y",
"       </td>",
"       <td>",
"        &ge;12",
"       </td>",
"       <td>",
"        70-79 y",
"       </td>",
"       <td>",
"        &ge;11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Shared decision making is strongly encouraged with persons whose risk is close to (either above or below) these estimates of 10-year risk levels. As the potential cardiovascular disease reduction benefit increases above harms, the recommendation to take aspirin should become stronger.",
"    <div class=\"footnotes\">",
"     CHD: coronary heart disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement. AHRQ Publication No. 09-05129-EF-2, March 2009. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated number of strokes prevented and estimated harms of using aspirin for 10 years in a hypothetical cohort of 1000 women on the basis of age and 10-year stroke risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Estimated strokes prevented (per 1000 women),",
"        <em>",
"         n",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        10-year stroke risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 55 to 59 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 60 to 69 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 70 to 79 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        <strong>",
"         1.7",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.7",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         1.7",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        <strong>",
"         3.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.4",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        <strong>",
"         5.1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         5.1",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"       <td>",
"        <strong>",
"         6.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.8",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        <strong>",
"         8.5",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         8.5",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        <strong>",
"         10.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         10.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7",
"       </td>",
"       <td>",
"        11.9",
"       </td>",
"       <td>",
"        <strong>",
"         11.9",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         11.9",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td>",
"        13.6",
"       </td>",
"       <td>",
"        13.6",
"       </td>",
"       <td>",
"        <strong>",
"         13.6",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9",
"       </td>",
"       <td>",
"        15.3",
"       </td>",
"       <td>",
"        15.3",
"       </td>",
"       <td>",
"        <strong>",
"         15.3",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        <strong>",
"         17",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11",
"       </td>",
"       <td>",
"        18.7",
"       </td>",
"       <td>",
"        18.7",
"       </td>",
"       <td>",
"        18.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12",
"       </td>",
"       <td>",
"        20.4",
"       </td>",
"       <td>",
"        20.4",
"       </td>",
"       <td>",
"        20.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13",
"       </td>",
"       <td>",
"        22.1",
"       </td>",
"       <td>",
"        22.1",
"       </td>",
"       <td>",
"        22.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14",
"       </td>",
"       <td>",
"        23.8",
"       </td>",
"       <td>",
"        23.8",
"       </td>",
"       <td>",
"        23.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15",
"       </td>",
"       <td>",
"        25.5",
"       </td>",
"       <td>",
"        25.5",
"       </td>",
"       <td>",
"        25.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        16",
"       </td>",
"       <td>",
"        27.2",
"       </td>",
"       <td>",
"        27.2",
"       </td>",
"       <td>",
"        27.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        17",
"       </td>",
"       <td>",
"        28.9",
"       </td>",
"       <td>",
"        28.9",
"       </td>",
"       <td>",
"        28.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        18",
"       </td>",
"       <td>",
"        30.6",
"       </td>",
"       <td>",
"        30.6",
"       </td>",
"       <td>",
"        30.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19",
"       </td>",
"       <td>",
"        32.3",
"       </td>",
"       <td>",
"        32.3",
"       </td>",
"       <td>",
"        32.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Type of event",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Estimated harms,",
"        <em>",
"         n",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GI bleeding",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    As indicated, the estimated number of strokes avoided varies with 10-year stroke risk. The estimated harms of using aspirin vary with age. Therefore, both 10-year stroke risk and age must be considered when determining whether the potential harms of aspirin use outweigh the potential benefit in terms of strokes prevented. The boldfaced numbers indicate the combinations of 10-year stroke risk and age for which the number of harms (GI bleeding) are greater than the number of strokes prevented.*",
"    <div class=\"footnotes\">",
"     GI: gastrointestinal.",
"     <br>",
"      * Calculations of estimated benefits and harms rely on assumptions and are by nature somewhat imprecise. Estimates of benefits and harms, especially at the borders of the boldfaced and non-boldfaced areas, should be considered in the full context of clinical decision making and used to stimulate shared decision making. The calculations in the table are based on the following assumptions: that there is a 17 percent risk reduction of strokes with regular aspirin use and that gastrointestinal bleeding includes serious hemorrhage, perforation, or other complications leading to hospitalization or death. Harm of GI bleeding in the table assumes that risk for GI bleeding increases with age and that the women are not taking nonsteroidal anti-inflammatory drugs, do not have upper GI pain, or do not have a history of GI ulcer. \"Strokes prevented\" is the net reduction of strokes, which includes a decrease in ischemic strokes and a small increase in hemorrhagic strokes.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement. AHRQ Publication No. 09-05129-EF-2, March 2009. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated myocardial infarctions (MIs) prevented and estimated harms of using aspirin for 10 years in a hypothetical cohort of 1000 men",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Estimated MIs prevented (per 1000 men),",
"        <em>",
"         n",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        10-year CHD risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 45 to 59 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 60 to 69 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age 70 to 79 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        <strong>",
"         3.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         3.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        <strong>",
"         6.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         6.4",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        <strong>",
"         9.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         9.6",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        <strong>",
"         12.8",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         12.8",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6",
"       </td>",
"       <td>",
"        19.2",
"       </td>",
"       <td>",
"        <strong>",
"         19.2",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         19.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7",
"       </td>",
"       <td>",
"        22.4",
"       </td>",
"       <td>",
"        <strong>",
"         22.4",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         22.4",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8",
"       </td>",
"       <td>",
"        25.6",
"       </td>",
"       <td>",
"        <strong>",
"         25.6",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         25.6",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9",
"       </td>",
"       <td>",
"        28.8",
"       </td>",
"       <td>",
"        28.8",
"       </td>",
"       <td>",
"        <strong>",
"         28.8",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        <strong>",
"         32",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        11",
"       </td>",
"       <td>",
"        35.2",
"       </td>",
"       <td>",
"        35.2",
"       </td>",
"       <td>",
"        <strong>",
"         35.2",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12",
"       </td>",
"       <td>",
"        38.4",
"       </td>",
"       <td>",
"        38.4",
"       </td>",
"       <td>",
"        38.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        13",
"       </td>",
"       <td>",
"        41.6",
"       </td>",
"       <td>",
"        41.6",
"       </td>",
"       <td>",
"        41.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        14",
"       </td>",
"       <td>",
"        44.8",
"       </td>",
"       <td>",
"        44.8",
"       </td>",
"       <td>",
"        44.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        16",
"       </td>",
"       <td>",
"        51.2",
"       </td>",
"       <td>",
"        51.2",
"       </td>",
"       <td>",
"        51.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        17",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"       <td>",
"        54.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        18",
"       </td>",
"       <td>",
"        57.6",
"       </td>",
"       <td>",
"        57.6",
"       </td>",
"       <td>",
"        57.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        19",
"       </td>",
"       <td>",
"        60.8",
"       </td>",
"       <td>",
"        60.8",
"       </td>",
"       <td>",
"        60.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Type of event",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Estimated harms,",
"        <em>",
"         n",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GI bleeding",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemorrhagic stroke",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    As indicated, the estimated number of MIs prevented varies with 10-year CHD risk. The estimated harms of using aspirin vary with age. Therefore, both 10-year CHD risk and age must be considered when determining whether the potential harms of aspirin use outweigh the potential benefit in terms of MIs prevented. The boldfaced numbers indicate the combinations of 10-year CHD risk and age for which the number of harms (GI bleeding and hemorrhagic stroke) are greater than or approximately equal to the number of MIs prevented.*",
"    <div class=\"footnotes\">",
"     CHD: coronary heart disease; GI: gastrointestinal; MI: myocardial infarction.",
"     <br>",
"      * Calculations of estimated benefits and harms rely on assumptions and are by nature somewhat imprecise. Estimates of benefits and harms, especially at the borders of the boldfaced and non-boldfaced areas, should be considered in the full context of clinical decision making and used to stimulate shared decision making. The calculations in the table are based on the following assumptions: that there is a 32 percent risk reduction of MIs with regular aspirin use and that gastrointestinal bleeding includes serious hemorrhage, perforation, or other complications leading to hospitalization or death. The harm of GI bleeding in the table assumes that the risk for GI bleeding increases with age and that the men are not taking nonsteroidal anti-inflammatory drugs, do not have upper GI pain, or do not have a history of GI ulcer. Estimates are based on age and 10-year CHD risk.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: Recommendation Statement. AHRQ Publication No. 09-05129-EF-2, March 2009. Agency for Healthcare Research and Quality, Rockville, MD. file://www.ahrq.gov/clinic/uspstf09/aspirincvd/aspcvdrs.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_49_31519=[""].join("\n");
var outline_f30_49_31519=null;
